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A survey of antibiotic resistance on Gram negative aerobic bacilli which had been
isolated from blood cultures during the period 1980-1991 from Edinburgh Royal
Infirmary was performed. All viable cultures were investigated for susceptibility to an
extensive range of antibiotics including the newer carbapenems, imipenem and
meropenem.
Gram negative, oxidase negative, aerobic bacilli (245) that were found to be resistant
to cefuroxime (>4.0 mg/1) were investigated further. As expected, the predominant
species present were: Enterobacter, Serratia and Acinetobacter. Isoelectric focusing
(IEF) and conjugation studies were performed. It was clear that most of these strains
possessed chromosomal cephalosporinases. None of the strains that transferred
ampicillin resistance to Escherichia coli J62-2 co-transferred resistance to any of the
later generation cephalosporins or to imipenem. It was apparent that inducible
chromosomal B-lactamases were the main cause of cefuroxime resistance in these
strains.
Amongst the cefuroxime resistant strains an isolate of Acinetobacter baumannii was
found to be resistant to all B-lactams, including imipenem and meropenem. Isoelectric
focusing revealed the presence of a chromosomal cephalosporinase and a novel B-
lactamase of pi 6.65. Despite the fact that the original clinical isolate could be cured
of its resistance to carbapenems and penicillins by growing in the presence of ethidium
bromide with the concurrent loss of the enzyme of pi 6.65, no resistance plasmid was
transferred. Plasmids were isolated but the physical loss of a plasmid in the cured
strain could not be demonstrated. The enzyme hydrolysed penicillin, ampicillin and
cephaloridine slowly during enzyme assay but inactivation of carbapenems could only
be demonstrated by microbiological means. The enzyme was thus designated ARI-1
(Acinetobacter resistant to imipenem). The molecular mass of the ARI-1 enzyme was
23 kDa. It was inhibited by BRL 42715 indicating that it was a serine active site B-
lactamase. It was not inhibited by EDTA.
The susceptibility profile and B-lactamase complement of 28 strains ofXanthomonas
maltophilia isolated from blood cultures were examined. Most strains were resistant
to a wide range of antimicrobials including carbapenems, although the level of




The B-lactamase complement of these strains was studied further. No discernible 13-
lactamase activity was present without prior induction of enzyme. Isoelectric focusing
revealed the heterogeneous nature of B-lactamase production amongst these isolates
with several B-lactamases identified by virtue of their isoelectric point. Contrary to a
previous report most strains appeared to code for two or more B-lactamases.
These results indicate the diversity of B-lactamases amongst this species.
Seven of the strains displayed identical B-lactamase profiles, designated XMCE type-1
(Xanthomoncis maltophilia chromosomal enzyme), these were studied further by
standard methodology with the aim of characterising them fully. On IEF, all seven
isolates demonstrated several bands commensurate with major B-lactamase activity of
between pi 5.2-6.8 when stained with nitrocephin. Strain 5B105 was chosen as
representative. It was found that these strains encoded for the production of at least
four B-lactamases. One was an inducible penicillinase of pi 6.8 with potent
carbapenemase activity. The approximate molecular mass (Mr) was 96kDa by
Sephadex gel filtration and 26kDa by SDS-PAGE, suggesting that this enzyme was a
tetramer consisting of four subunits of equal size. The enzyme was completely
inhibited by EDTA, but enzymatic activity was recovered by the addition of zinc
sulphate. It was not inhibited by BRL 42715. The other enzymes exhibited isoelectric
points ofpi 5.3, 5.55, and 6.2. The Mr of all bands of B-lactamase activity was 48kDa
by gel permeation and a single protein of Mr 24kDa was visualised by SDS-PAGE,
indicating dimeric enzymes in their native state. They were inhibited by BRL 42715
and partially inhibited by clavulanate suggesting they were serine active site B-
lactamases. Kinetic studies demonstrated that together they hydrolysed penicillins and
cephalosporins but not carbapenems or the monobactam, aztreonam.
The similarities of these serine active site B-lactamases with the ubiquitous TEM
plasmid-mediated enzymes did not go unnoticed. The hypothesis that the serine B-
lactamase present in the latter strains of Xanthomonas maltophilia may have an
ancestral relationship was investigated. Chromosomal DNA was prepared from X
maltophilia 5B105 and Polymerase Chain Reaction (PCR) was performed with
universal DNA primers for the TEM gene, to determine whether the structural gene
for TEM was present and could be amplified. The hypothesis was proven to be
unfounded.
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1.0. The Pre-antibiotic era: - Historical perspective
1.1. Introduction
What exactly is an antibiotic? Chambers Twentieth Century dictionary gives the
following definition:
"Inhibiting the growth of another organism, used especially of a substance produced
by micro-organisms which, in dilute solution, has the capacity to inhibit the growth of,
or to destroy, micro-organisms causing infectious diseases".
Selman Waksman is generally regarded as the instigator of the word antibiotic. In
1942, he was asked to suggest an appropriate term describing the plethora of
antimicrobial compounds that were appearing with increasing frequency in the
medical-scientific literature. It appeared in Index Medicns in 1943. Waksman's
original definition was very similar to the above:
"A compound produced by one micro-organism which is capable of killing or
inhibiting another".
These definitions are unsatisfactory. They do not include synthetic compounds such as
trimethoprim, sulphonamides and man-made modifications ofmicrobial products, e.g.
semi-synthetic penicillins and cephalosporins. Lietman, in 1986 [1], thought it more
appropriate to redefine an antibiotic as:
"Any chemical substance produced by various micro-organisms or by humans and
having the capacity, in dilute solutions, to inhibit the growth of or to destroy bacteria
and other microorganisms".
Paul Ehrlich is credited with the term "magic bullet", used to describe a compound
with a seemingly magical effect on bacterial infections, and targeted towards a specific
pathogen.
Salvarsan, the first of the "magic bullets", was discovered by Ehrlich and Hata in the
summer of 1907 [2], and caused great excitement, because of the potential ability to
cure syphilis, yaws and other Spirillum infections. Because of severe toxicity
associated with the drug, salvarsan was far from ideal, and unfortunately, was only
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effective against this single group of pathogens. The search was launched to find more
versatile (and safer) compounds. It was almost 25 years before the next breakthrough,
and physicians sought alternative approaches to the treatment ofbacterial infections.
Ample evidence exists that mould therapy was used from antiquity to relatively
modern times to treat bacterial infections. The remains of a Sudanese tribe from
around 350 AD, were found to contain traces of tetracycline (an antibiotic not
discovered until the mid-1940s). The most likely source was that tetracycline-
producing Streptomyces contaminating the food grains from which they made their
bread [3],
Plants were also a rich source of antimicrobial substances. Cinchona bark was used in
Peru to treat malaria, and ipecacuanha was found to be of use against amoebic
dysentery [3],
In the 1930s, maggot therapy was used in an attempt to cure osteomyelitis [4], It was
originally assumed that maggots removed wound debris, but William Baer a US
surgeon believed that maggots produced antibacterial, as well as wound healing
secretions [4], In 1935, S. W. Simmons demonstrated that maggot washings
contained substances that killed organisms [5], The nature of these substances has yet
to be elucidated.
In 1976, a 67 year old man suffering from mastoiditis, was treated with maggots
introduced into the mastoid cavity [6], The infection, caused by Pseudomoncis spp,
Proteus mirabilis and enterococci responded well. All conventional therapy had
failed. The authors concluded:
"The intractable nature of this man's infection makes it clear that, without maggot
therapy, healing would not have occurred. The authors recognise that this unusual
form of therapy is not part of the standard armamentarium against infections of the
temporal bone. We see no need to categorically discard successful techniques of the
past, however, because one never knows when they might be useful in the future. We
feel justified in using this otherwise antiquated technique in a situation in which
modern technology was inadequate".
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1.2. The dawn of antimicrobial chemotherapy
Penicillin, isolated originally from the fungus Penicillium notation, was discovered by
Fleming in 1928 [7], It was the first and arguably remains the most important of all
the antibiotics. Its discovery revolutionised the treatment of pneumonia, scarlet fever,
bacterial meningitis and septicaemia. The therapeutic power of penicillin was to
remain unrecognised until 1941 when it was "rediscovered" by Florey, Chain and
Heatley.
Although penicillin is generally regarded as the first antibiotic, it was in fact, preceded
by a compound isolated from, Bacillus brevis [8], This antibiotic, discovered by Rene
Dubois, was named tyrothricin. It was later split into two pure antibacterial
substances, which were named gramicidin and tyrocidin [9], These compounds were
too toxic for injection into the blood stream, but were found to be useful in the
control of local infections.
Garrod [10] argued that the modern era of antimicrobial therapy was initiated in 1932
when Domagk first reported the protective effect of prontosil (the forerunner of the
sulphonamides) against murine streptococcal infection. It was to be another three
years before prontosil was released for general use [11].
Soon after the discovery of penicillin, research into other antibiotic producing micro¬
organisms was initiated all over the world. The evolution of antimicrobial
chemotherapy is summarised in a table by Selwyn [12], updated by Hood [13] (see
figure 1).
It is noteworthy, that of the hundreds of compounds discovered capable of inhibiting
bacterial pathogens, very few were clinically useful. Fleming's discovery, although
unrealised at the time, would turn out to be very special indeed!
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1.3. The discovery of penicillin
When Alexander Fleming left his laboratory at the end of July 1928, he was unaware
he was due to make an historic discovery. In September, Fleming returned to his
laboratory. One of the dishes that he had inoculated previously, caught his eye.
Fleming observed that a contaminating mould was inhibiting the growth of colonies of
Staphylococcus aureus he had previously inoculated onto the plate. The colonies took
on a "ghost" like appearance, indicating that the mould was causing the bacteria to
lyse. The mould was originally misidentified as a strain ofPenicillium ruhrum by the
mycologist, C. J. La Touche, although he was later to apologise for his error. The
mould was subsequently correctly identified as Penicillium notatum.
Fleming realised that the mould was producing an antibacterial substance, which he
named, penicillin. He manufactured crude extracts of penicillin by fermenting
Penicillium notatum, and performed a number of early experiments on his "mould
juice", but lacked the knowledge or expertise to purify, concentrate or store penicillin.
In 1932, Fleming performed what was originally thought to be the first successful
therapeutic use of penicillin, on his laboratory assistant, K. B. Rogers, who had been
suffering from a pneumococcal eye infection.
In 1930, C. G. Paine, a hospital bacteriologist conducted some experiments on eye
infections due to staphylococci, gonococci and pneumococci. This work was never
submitted for publication. He was later to write (quoted by Wilson) [14]:
"The variability of the strain ofPenicillium and my transfer to a different line ofwork
led me to neglect further investigation of the possibilities of penicillin, an omission
which, as you may well imagine, I have often regretted since."
In 1986, the English microbiologist, Milton Wainwright and Dr H. T. Swan, an
ophthalmologist who had worked with Paine, discovered the original medical records
[15], There were two case notes, which confirmed that Paine used penicillin as early
as 1930. The first of the case notes refers to a 3-week old baby called Peter who was





R & L ophthalmia neonatorum
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Paine was to receive recognition, albeit 56 years later, of his early work, and he was
awarded an honorary degree ofDoctor ofMedicine by Sheffield University. No more
work of any note was performed on penicillin until 1940, when Howard Florey,
Ernest Chain and the other members of the "Oxford" team performed the first
therapeutic trials with partially purified penicillin. This led to their first publication on
the properties of penicillin in 1940 [16],
By the end of 1940, the Oxford group had produced enough penicillin to commence
clinical trials on a few patients. One of the first recipients was a 43 year old
policeman, Albert Alexander, who was infected with staphylococci and streptococci.
He was initially administered 200mg of partially purified penicillin, followed by
injections of half this dose every two hours. His condition improved until the supplies
of penicillin ran out. The setback of his subsequent death did not deter the British
pharmaceutical companies from becoming involved.
Large scale production of penicillin was attempted, although it soon became obvious
that the best hope for large scale production lay with the Americans. Scientists in
Peoria, Illinois, were to make two vital contributions. First the discovery that deep
fermentation techniques produced far greater yields than the shallow fermentation
used by British companies. Second the discovery of a new strain of Fleming's mould,
Penicillmm chrysogeimm. This strain was "mutated" by the Americans to produce
vast amounts of penicillin.
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The first therapeutic use of penicillin in a war zone by Major R. J. V. Pulvertaft took
place in 1942 [17], This was the final stimulus required for penicillin production. By
1944, supplies of penicillin to Allied troops were described as "unlimited".
1.4. The impact of 6-aminopenicilIanic acid (6-APA)
Work carried out on P. chrysogenum in the 1940s demonstrated that other forms of
naturally occurring penicillins were produced by fermenting P. chrysogenum. None of
these was superior to Penicillin G [18], although Penicillin V was more acid stable
and better absorbed when given orally.
In the late 1950s, Beecham Research Laboratories developed the production of large
quantities of 6-APA [19] (figure 2), the core structure of penicillin. This allowed the
addition of novel side chains, and development ofnew penicillins.
Benzylpenicillin still remains the first choice for a variety of bacterial infections,
particularly those caused by the pyogenic cocci [20], but resistance has eroded the
usefulness of penicillin. Ninety five per cent of hospital isolates of S. aureus and 85
per-cent of community isolates of S. aureus produced penicillinases that conferred
resistance to penicillin [21],
1.5. The semi-synthetic penicillins
Modification of the B-lactam nucleus to yield B-lactamase stable antibiotics takes
place on the acyl side chain attached to the Cg carbon (figure 2).
To combat penicillin resistant staphylococci the first of the semisynthetic penicillinase-
stable penicillins; methicillin and its derivatives, e.g. flucloxacillin were developed.
The addition of an acyl side chain prevented disruption of the B-lactam ring. These
drugs remain first choice therapy in most staphylococcal infections, although the re-
emergence ofmethicillin resistant S. aureus (MRSA) in the early 1980s has made in¬
roads into their usefulness. The need for penicillins with greater activity against Gram
negative bacilli prompted the development of the aminopenicillins, carboxypenicillins
and ureidopenicillins. Initially ampicillin was developed, followed by the extended-




8-lactam ring Thiazolidine ring
6-aminopenicillanic acid
Chemical structure of penicillins and 6-aminopenicillanic acid
The resulting large family can be conveniently divided into six groups [22] (figure 3).
The penicillins have one drawback; they possess only one site on the molecule
available for substitution (Cg), they have not, therefore, enjoyed the increased variety
and continued success of the cephalosporin antibiotics.
Figure3.FromLambertandO'Grady[22] Naturallyocu ringpenicillinsdpenicillinsderivefromN- yderiv tiv sf6-APA Groupl Benzylpenicillin anditslo gcting parenteralforms Benzylpenicillin Benethamine penicillin Benzathine penicillins Clemizole penicillins Procaine penicillinGroup2 Orallyabsorbed penicillins resembling benzylpenicillin Azidocillin Phenethicillin Phenoxy- methylpenicillin PropicillinGroup3 Penicillins resistantto staphylococcal B-lactamase Isoxazolyl- penicillins Cloxacillin Dicloxacillin Flucloxacillin Oxacillin Methicillin Nafcillin
Group4 Extended spectrum penicillins Ampicillin Ampicillin condensates Hetacillin Metampicillin Ampicillin esters Bacampicillin Lenampicillin Pivampicillin Talampicillin Amoxycillin Cyclacillin Epicillin Mecillinam Mecillinam ester Pivmecillinam
Group5 Penicillinsa tive against Pseudomonas aeruginosa Acylureido- penicillins Apalcillin Azlocillin Mezlocillin Piperacillin Carboxycillins Carbenicillin Carbenicillin ester Carfecillin Carindacillin Ticarcillin
Group6 B-lactamase resistantp nicillins Temocillin Foramidocillin
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2.0. The development of the cephalosporins
In 1945, Giuseppe Brotzu, Professor of Bacteriology at the University of Cagliari,
isolated a strain of Cephalosporium acremonium from a local sewage outfall. This
mould was found to exhibit antibacterial activity against a wide range of bacterial
species. His work is described in an obscure privately published pamphlet called the
'Works of the Institute of Hygiene of Cagliari'. In 1948, Brotzu sent a culture to
Howard Florey at Oxford. It was discovered that Brotzu's mould contained at least
two antibiotics; a narrow spectrum compound called cephalosporin P and a broad
spectrum agent, penicillin N. In 1955, Newton and Abraham published observations
on a third antibiotic derived from Cephalosporium acremonium, Cephalosporin C
[23], Despite its low antibacterial activity, its high resistance to staphylococcal
penicillinase was of great interest.
The cephalosporin nucleus, 7 amino-cephalosporanic acid (7-ACA) has served as the
parent structure for many thousands of different cephalosporins. It has the advantage
that chemical side groups can be added at two important sites on the molecule (figure
4). Modifications on or near the B-lactam ring affect antibacterial activity and stability
against B-lactamases, whilst modifications at position C3 are associated with
pharmacokinetic and metabolic parameters [24], allowing therapeutically important
modifications to be made.
2.1. Classification of the cephalosporins
The most widely accepted classification of the cephalosporins splits them into three
groups; early compounds (the first generation), compounds resistant to B-lactamases
(the second generation), and compounds resistant to B-lactamases and generally
exhibiting enhanced antibacterial activity (the third generation). Lambert and O' Grady
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Classification of the cephalosporins
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
Cefazaflur Cefaclor Cefamandole Cefepime Cefixime Cefoperazone
Cefazolin Cefadroxil Cefmetazole Cefetamet Ceftibuten Cefpimizole
Ceforanide Cefatrizine Cefodizime Cefmenoxime Cefpiramide
Ceftezole Cefroxadine Cefonicid Cefodizime Cefsulodin
Cephacetrile Cephalexin Cefotetan Cefotaxime
Cephaloridine Cephaloglycin Cefotiam Cefpirome







After Lambert and O'Grady [25],
Group 1: Parenteral compounds of moderate antimicrobial activity and resistance to
staphylococcal 13-lactamase, hydrolysed by a wide variety of enterobacterial 13-
lactamases.
Group 2: Oral compounds of moderate antimicrobial activity resistant to
staphylococcal 13-lactamase and moderately resistant to some enterobacterial 13-
lactamases.
Group 3: Parenteral compounds ofmoderate antibacterial activity resistant to a wide
range of 13-lactamases.
Group 4: Parenteral compounds with potent antimicrobial activity and resistance to a
wide range of 13-lactamases.
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Group 5: Oral compounds with potent antimicrobial activity and resistance to a wide
range of B-lactamases.
Group 6: Parenteral compounds with moderate activity against enterobacteria, but
active against Psendomonas aeruginosa with resistance to a wide range of 13-
lactamases.
3.0. Other B-lactam agents
The discovery of the penicillins and cephalosporins provided the incentive for research
into other 13-lactams. Naturally occurring 13-lactam structures have generally been
classified by a trivial nomenclature, the name of the compound usually relating to the
producing organism and chemical feature of the new compound [26], A more recent
classification, has been delineated on a defined parent B-lactam skeleton [26], (figure
5).
3.1. Monobactams: Aztreonam is the only monobactam currently in clinical
use, they are a family ofmonocyclic compounds derived from bacteria (Nocardia
spp).
3.2. Cephamycins: Cephamycins are derived from Streptomyces spp., and
therefore, are very similar in structure to the cephalosporins although different by
virtue of a methoxy group present in the seven position of the B-lactam ring. Removal
of the side chain allows modifications, for example cefoxitin.
3.3. Oxacephems: The sulphur atom of the cephem nucleus is replaced with an
oxygen atom. An example is latamoxef.
3.4. Penems: The penem nucleus is an unsaturated analogue of the penam ring.
3.5. Carbacephems: The carbacephems are a new class of B-lactam
antibiotics that are similar in structure to the cephalosporins, they differ however, in
the substitution of a sulphur atom in the dihydrothiazine ring [27], Loracarbef is the
first of these compounds undergoing clinical development. The development of the
carbacephem ring structure may lead to a proliferation of a new series of antibiotics,
similar to that experienced with the cephalosporins [27],
Introduction 15
Figure 5.
Skeletons of B-lactam antibiotics. The B-lactam ring (to the left of the dashed
line) is shared by all these compounds.
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3.6. Carbapenems: The carbapenems differ from penicillins by the substitution
of a carbon atom for a sulphur atom, and by the addition of a double bond to the
penicillin nucleus [28], The first two carbapenems (the olivanic acids and thienamycin)
were discovered in the mid 1970s. The olivanic acids were produced by Streptomyces
olivaceus, but are so unstable that they have not been employed clinically [29],
Imipenem is derived from thienamycin, a natural product of the soil organism
Streptomyces cattleya. It is the first of the carbapenems available for therapeutic use.
The jV-formimidoyl side chain of imipenem enhances the chemical stability of
imipenem. The hydroxyethyl side chain in the a or trans-configuration at Cg provides
remarkable resistance to B-lactamases [29], and, they exhibit the broadest antibacterial
activity of all antibiotics currently available for systemic use in humans [28],
Imipenem is not stable to human dehydropeptidases, it is thus administered with
cilastatin, a dehydropeptidase inhibitor. Other compounds, meropenem and biapenem
seem sure to join imipenem in the near future. Meropenem contains a unique side
chain at C2 that ensures a broad spectrum of activity. Its main advantage over
imipenem is the presence of a methyl group at Cj, that provides stability to human
renal dehydropeptidases, therefore, it does not require co-administration with
cilastatin.
4.0. B-Iactamase inhibitors
B-lactamase inhibitors were developed as another approach to find substances that can
protect against the problem of B-lactamases.
4.1. Clavams: Clavam is the parent ring nucleus found in the potent B-lactamase
inhibitor, clavulanic acid. It is a naturally occurring weak antimicrobial agent found
initially in strains of Streptomyces clavuligerus [30], The agent primarily acts as a
"suicide inhibitor" by forming an irreversible acyl enzyme complex with the B-
lactamase, leading to loss of activity of the enzyme. In clinical use it is combined with
amoxycillin, co- amoxyclav (augmentin).
4.2. Sulbactam: Sulbactam is a semisynthetic 6-desaminopenicillin sulphone
with weak antibacterial activity [31], For clinical use, it is combined with ampicillin.
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Sulbactam acts as an effective inhibitor of certain plasmid and chromosomally
mediated G-lactamases.
4.3. Tazobactam: Tazobactam is a penicillanic acid sulphone derivative that is
structurally related to sulbactam, it is combined with piperacillin (tazocin) for clinical
use.
4.4. BRL 42715: The penem BRL 42715 is a potent inhibitor of a broad range
of bacterial B-lactamases with a serine residue at their active site [32] but not against
metallo-B-lactamases [33], It is more effective against chromosomal
cephalosporinases than clavulanate, tazobactam or sulbactam [34], Unfortunately,
problems associated with stability of the compound have determined that it will not be
marketed [34],
5.0. Mode of action of B-lactams
B-lactam antibiotics inhibit bacterial cell wall synthesis [35], The bacterial cell wall is
constructed from alternating 7V-acetylglucosamine and ./V-acetylmuramic acid residues.
The final step of cell wall synthesis (transpeptidation) involves the transpeptidase-
catalysed cross-linking of peptidoglycan chains.
The targets for B-lactam antibiotics are the cell wall synthesising enzymes, the
penicillin binding proteins (PBPs), carboxypeptidases and transpeptidases [36,37],
PBP's are named for their ability to bind labelled penicillin [38], They are found in all
bacteria, but their number, size, amount and affinity for the B-lactam antibiotics vary
from species to species [38], PBPs are located on the outer face of the cytoplasmic
membrane, in Gram negative bacteria they are pseudoperiplasmic [39],
The action of B-lactams on the bacterial cell is not the only mechanism by which
bacterial cells are inhibited. Indirect inhibition of bacterial growth results from the
action ofmurein hydrolases, which are autolytic enzymes that cause nicks in the cell
wall to provide sites for new peptidoglycan synthesis during cell wall enlargement
[40], These enzymes are unaffected during inhibition of cell wall synthesis by B-lactam
antibiotics, and inhibition of PBPs and the unsuppressed activity ofmurein hydrolyses
procure autolysis of the bacterial cell.
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6.0. Genetics of antimicrobial resistance
Mayer et al. stated, "For microbial evolution to transpire, genetic variability is
essential" [41],
There are at least three mechanisms that bacteria utilise to ensure this variability:
Micro-evolutionary change: A point mutation may occur at a nucleotide base pair,
altering the target site of the antibiotic.
Macro-evolutionary change: This involves whole scale rearrangement of large
sections of the bacterial DNA, at a single event. Such rearrangements may include
inversions, duplications, insertions, deletions or transpositions of large sequences of
DNA, from one location of the bacterial chromosome to another. These arrangements
are usually mediated by insertion sequences or transposons.
A third mechanism is the acquisition of foreign DNA. These sequences are carried by
plasmids, bacteriophages or transposons. This mechanism is extremely important as it
endows bacteria with an almost limitless capacity to become resistance to
antimicrobial agents.
7.0. Mechanisms of bacterial resistance to B-lactam
antibiotics
Resistance to B-lactam antibiotics may occur at any of the steps involved in the action
of the antibiotic [42], and may be achieved through a combination of one or more
different mechanisms.
1. Alteration in outer membrane permeability.
2. Alteration in target enzymes (PBPs).
3. Enzymatic degradation of the drug either before or after it enters the bacterial
cell.
7.1. Alteration in outer membrane permeability
B-lactams must first penetrate the bacterial cell wall. This is easy in Gram positive
bacteria, which do not possess an outer membrane. The outer wall of Gram negative
organisms consists of lipids, proteins, and polysaccharides. The intrinsic susceptibility
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of Gram negative bacteria is greatly influenced by the nature of the outer membrane,
which can pose a formidable barrier to the entry of B-lactams [43-45],
The porin proteins of the outer membrane of Gram negative bacteria form channels
that facilitate the movement of nutrients and other substances between the
extracellular environment and the periplasmic space. Changes in outer membrane
permeability limit the inflow of drug [35], Two major proteins that have been
characterised in Escherichia coli are OmpF and OmpC [46], although three other
porins exist which have also been shown to affect antimicrobial susceptibility; LamD,
Phoe E and protein K [47], OmpF has the highest rate of permeability to the 13-
lactams [35], It has been shown that E. coli mutants deficient in OmpF and OmpC are
resistant to B-lactams as a consequence of reduced penetration [46], Alteration in
Gram negative outer membrane permeability plays an important role in resistance to
carbapenems. Pseudomonas aeruginosa mutants have been described which are
specifically resistant to imipenem and meropenem [48,49], Analysis of these isolates
showed markedly diminished amounts of outer membrane protein D2. It has been
suggested that protein D2 specifically facilitates the diffusion of carbapenems into the
bacterial cell of Ps. aeruginosa. [50,51], The imipenem resistant isolates remained
susceptible to most other antibiotics reported, suggesting that the protein D2 plays
only a small role in the diffusion of other antibiotics into the cell. Livermore [52],
demonstrated that imipenem resistance could only be mediated by the loss of the D2
porin when the chromosomal B-lactamase was also expressed. Carbapenem resistance
based on the interplay between the chromosomal B-lactamase and impermeability, has
likewise been described for Enterobacter cloacae [53,54] Enterobacter aerogenes
[55] and Proteus rettgeri [54], Clinical isolates resistant to imipenem have also been
reported in Proteus mirabilis [56], resulting from the loss of a 24 kDa OMP, no
concomitant B-lactamase was reported in these strains.
7.2. Alteration in target enzymes (PBPs)
Alterations in the binding characteristics of PBPs for B-lactam compounds may result
in the development of resistance [57], Any given organism can contain between four
to eight PBPs, and although only two to four are essential for cell survival, their
inhibition can lead to cell lysis, death or growth arrest.
This mechanism is more important in Gram positive bacteria, and the fastidious Gram
negative bacteria such as Haemophilus influenzae and Neisseria gonorrhoeae [58],
Introduction 20
Clinical resistance to B-lactams in Gram negative bacteria is not commonly associated
with altered PBPs [59], although a recent report describes Acinetobacter baumannii
isolates resistant to imipenem and ampicillin, as a result of decreased binding to all
PBPs [60], PBP associated resistance in clinically important bacteria is shown in table
2.
Table 2
PBP-associated resistance in clinically important bacteria
Organism Resistant to PBP (alteration) of
species affected
S. aureus Methicillin, most B-lactams 2a, 3.
S. epidermidis Methicillin, most B-lactams 2a
S. pneumoniae Ampicillin la, 2a, 2b.
Ent. faecalis Most B-lactams 1,3.
E. coli Mecillinam 2
Cephalexin 3
Ps. aeruginosa Piperacillin 3
Cefsulodinc
H. influenzae Ampicillinc 4
B-lactams 3, 4, 5.
A. calcoaceticus B-lactams 1,3.
N. gonorrhoeae B-lactams 1,2.
N. meningitidis B-lactams 2.




7.3. Enzymatic-mediated antibiotic degradation
The most common cause of resistance to B-lactam drugs is enzyme mediated





By far the most important of these mechanisms is B-lactamase production [35], the
others play a relatively minor role, if any, in antibiotic resistance [64], although
esterases are of clinical use when cleaving microbiologically inactive penicillin esters
e.g. talampicillin, releasing the active compound.
The first report of a penicillin hydrolysing enzyme was actually discovered before
penicillin G was widely used. Abraham and Chain [65] reported that they found an
organism, then called Bacillus coli, now Escherichia coli, that produced an enzyme
that inactivated penicillin.
Most early attention focused on staphylococcal B-lactamases, although by the 1960s,
the advent of the broader spectrum B-lactams, and the success of the anti-
staphylococcal drug, methicillin, shifted the focus of attention to the B-lactamases of
Gram negative bacilli.




8.1. The origin of B-Iactamases
It has long been postulated that B-lactamases might have evolved from the penicillin
sensitive D-alanyl-D-alanine-cleaving peptidases (DD-peptidase/PBPs), which are
involved in the synthesis of peptidoglycan, and are the target for B-lactam antibiotics.
Kelly et al. [66], compared the DD-peptidase from Streptomyces R61 with the B-
lactamase from B. licheniformis 749/C. Although the two strains were from different
species and lacked close homology in their primary structures (although they
contained several conserved residues in their active sites) the three dimensional
structures of the two enzymes were similar, implying a close relationship between the
two. Kelly went on to postulate that B-lactamases probably evolved from the soil
bacteria, like Streptomyces spp. Huletsky et al. [67], made significant progress in
explaining how the Class A B-lactamases evolved. They constructed a phylogenetic
tree, that split the B-lactamases into Gram negative and Gram positive subgroups and
demonstrated that B-lactamases from Gram positive bacteria probably evolved earlier
in evolution than those of the Gram negative bacteria. Kirby [68], elaborating on the
work ofHuletsky, examined the protein sequences of 18 Class A B-lactamases and 2
Class C B-lactamases and constructed a phylogenetic tree employing the DD-
peptidase of Streptomyces R61 as an outgroup. Kirby's work suggested that all the
Class A and C B-lactamases were evolved from an actinomycete B-lactamase, that had
previously evolved from the DD-peptidase gene.
The previous work does not take the Class B B-lactamases into consideration, and no
work of any note appears to address the evolutionary origin of these B-lactamases.
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8.2. Contribution of B-lactamase to B-lactam antibiotic
resistance
The level of antibiotic resistance mediated by any B-lactamase is governed by several
variables [41],
1. The efficiency of the G-lactamase in hydrolysing the antibiotic (Vmax) and its
affinity for the antibiotic (Xm).
2. The amount ofB-lactamase produced.
3. The susceptibility of the target protein (PBP).
4. The rate of entry of the antibiotic into the bacterial cell.
8.3. Action of B-lactamase
Most B-lactamases are members of a superfamily of serine proteases [69], which
hydrolyse the B-lactam ring (figure 6). The active sites of most B-lactamases
invariably contain the amino acid residue, serine, and a conserved lysine three residues
downstream from the serine [58], The serine at the enzyme's active site forms a non-
covalent complex with the fi-lactam (A). Acylation follows, yielding a covalent ester,
in which the carboxyl of the opened B-lactam ring is linked to the hydroxyl group on
the serine side chain (B). The ester is hydrolysed, liberating free enzyme and the
hydrolysed substrate (C) [70], The exception are the Class B B-lactamases, which
require a zinc co-factor for catalytic activity, and which are clearly different from the
other enzymes [71], The Class B B-lactamases will be discussed in depth in a later
section.
9.0. Chromosomal B-lactamases
Chromosomal B-lactamases are produced by virtually all Gram negative bacilli [62,72-
74], and the nature of B-lactamase produced is often species-specific [73], Most of
the chromosomally mediated B-lactamases preferentially hydrolyse cephalosporins,
although some organisms also produce a broad spectrum chromosomal B-lactamase,
that hydrolyses a wide range of fi-lactams [73], All of the chromosomal




Action of serine fi-lactamase
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9.1. Constitutive cephalosporinases
In certain species like E. coli, Shigellae and Proteus mirabilis, the enzyme is
produced constitutively, and manufactured in only basal amounts, insufficient to
protect the bacteria against drugs, such as ampicillin and cephradine, which are
rapidly hydrolysed by the enzymes [76,77], The gene responsible for production of
this chromosomal B-lactamase is known as ampQ. Overproduction of B-lactamase by
the ampC gene can cause resistance to B-lactams [78], although it is thought to be a
rare occurrence [76], It has been shown that two separate mutations are required for
this high level enzyme production, one increasing a promoter efficiency and the other
inactivating an attenuator [79],
9.2. Inducible cephalosporinases
Some species, including Ps. aeruginosa, Enterobacter spp., Citrobacter spp.,
Serratia spp., and indole positive Proteus, have inducible expression of chromosomal
cephalosporinase. This is simply a transient elevation in B-lactamase production that
occurs when a B-lactam substrate is present. There are thought to be at least four
other genes which are involved in control of B-lactamase expression; ampR, ampG,
ampD, and ampE [80] (table 3).
The amount of B-lactamase induced by a B-lactam compound depends on the
structure of the compound, on its concentration, and the period that the bacteria are
exposed to the substrate [81], Livermore describes four conditions for the interplay of
induction and drug inactivation [81],
1. An antibiotic may be labile to the B-lactamase and be a strong inducer.
2. It may be labile but a weak inducer.
3. It may be stable and a strong inducer.
4. It may be stable and a weak inducer.
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Table 3.
Elements involved in the expression of inducible B-lactamases in
Gram negative bacteria
Element Role or description
AmpR Transcriptional regulation
AmpQ Necessary for induction; integral
membrane protein responsible for
transmission of induction signal
AmpD Down-regulation of 13-lactamase
expression; maintenance of repressor
form of transcriptional regulation?
AmpE Enhancement of repression; dispensable
PBP2 13-lactam-interactive protein
Adapted from Bennett & Chopra [80]
The emergence of resistance during therapy with one of the newer generation of 13-
lactams was first described in 1978 [82], This resistance results from selection during
therapy of "stably derepressed mutations" (SDM) which produce very high levels of
chromosomal 13-lactamase, such mutations may be selected at a frequency of one in
106 to one in 107 cells [72], These stably derepressed mutations have seriously eroded
the efficacy of the third generation cephalosporins [58],
9.3. Broad-spectrum chromosomal B-lactamases
Klebsiella spp. produce a number of chromosomal penicillinases, which are normally
expressed at low level, however, it is sufficient to confer resistance to various 13-
lactam antibiotics [73,83], and accounts for the universal resistance to ampicillin for
this genus.
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10.0. The plasmid-mediated 15-lactamases
10.1. Broad-spectrum plasmid-mediated B-lactamases
Transferable ampicillin resistance from Salmonella typhimurium to recipient E. coli
was first reported by Anderson & Datta in 1965 [84], Subsequently, Datta &
Kontomichalou [85] reported the isolation of an ampicillin resistant strain of E. coli
from a Greek girl called, Temoniera. Both ampicillin resistance and B-lactamase
production could be transferred to a recipient E. coli by virtue of a resistance factor
(R-factor). The resistance to ampicillin was found to be mediated by a B-lactamase,
subsequently named, TEM-1, and is the most common mechanism of resistance to B-
lactam antibiotics in E. coli [86], Another enzyme, similar in substrate profile to
TEM-1, TEM-2, was described by Sykes & Richmond [87], These enzymes are often
carried on mobile genetic elements called transposons, which ensure their efficient
dispersal among the Enterobacteriaceae [88], TEM-1 is known to be commonly
carried on Tni. By 1974-76, these enzymes had also spread to Ps. aeruginosa, and by
1975 to H. influenzae and N. gonorrhoeae [62], In the late 1970s, Petrocheilou [89]
described another plasmid mediated enzyme, SHV-1, which was to become the
second most common plasmid mediated enzyme after TEM-1. TEM-1, TEM-2 and
SHV-1 enzymes are expressed constitutively [76], and are considered to be "broad-
spectrum" B-lactamases that effectively hydrolyse both penicillins and cephalosporins,
but not extended-spectrum B-lactams [90], Several studies during the 1980s and
1990s in Europe and India have shown that TEM-1, which is found in 70-95% of
ampicillin resistant strains of E. coli is predominant [91-95], There have also been a
number of other broad-spectrum B-lactamases reported, however these are rare, and
have only been reported on very few or single occasions [96], It was thought that
with the introduction of the third generation cephalosporins in the early 1980's,
resistance to these agents mediated by B-lactamases from Enterobacteriaceae would
not develop, however, reports of resistance to these drugs were beginning to emerge,
that could not be explained by hyperproduction of chromosomal B-lactamase or
permeability defects [90], Karen Bush was to quote from Democritus [90]:
"Your victory is in fact your defeat"
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10.2. The extended-spectrum B-Iactamases
The explosion of reports of new G-lactamases is most significant for the extended
broad-spectrum G-lactamases [97], which confer resistance to many of the newer G-
lactam antibiotics. The first of these reports appeared in 1983, Knothe el al. [98]
described transferable resistance to extended spectrum G-lactams in strains of
Klebsiella pneumoniae and Serratia marcescens. The resistance was subsequently
shown to result from a novel plasmid mediated G-lactamase, SHV-2 [99], These G-
lactamases are mostly derived from TEM-1, TEM-2 or SHV-1 (table 4). These
mutants differ from their parent enzymes by only one to four amino-acid residues, but
have substrate ranges that include not only most penicillins and cephalosporins, but
also aztreonam [100], In a recent report [101], Palzkill and Botstein found that TEM-
1 G-lactamase was very tolerant of amino acid substitutions. They screened 20
different residue positions for amino acid substitutions that increased enzyme activity
towards the extended-spectrum cephalosporin, cefotaxime. Substitutions at positions
104, 168, 238 in the TEM-1 G-lactamase resulted in increased activity toward
extended-spectrum cephalosporins. Also, small deletions in the loop containing
residues 166-170, increased hydrolytic activity towards the extended-spectrum
cephalosporins but drastically reduced the activity towards ampicillin.
A puzzling aspect of the epidemiology of ESBLs is the regularity with which they
arise in isolates of K. pneumoniae, rather than other members of the
Enterobacteriaceae. Katansis & Jacoby [102] demonstrated that neither a difference in
the efficiency of expression of G-lactamase, nor the frequency of G-lactamase
mutations could account for the frequency of ESBLs in K. pneumoniae and clearly
further study is required.
These ESBLs have been described as "chance mutations", and do not normally appear
to have the capacity to spread throughout the general bacterial population [103], The
most frequent reports have emerged from those countries where there has been
extensive use of third generation cephalosporins, notably France and North America




Molecular basis of extended-spectrum fi-lactamases
Amino acid at position1
B-lactamase 39 104 164 205 237 238 240 265
TEM-1 Gin Glu Arg Gin Ala Gly Glu Thr
TEM-2 Lys
TEM-3 Lys Lys Ser
TEM-4 Lys Ser Met
TEM-5 Ser Thr Lys
TEM-6 Lys His
TEM-7 Lys Ser
TEM-8 Lys Lys Ser Ser





TEM-14 Lys Lys Ser Met
TEM-15 Lys Ser




TEM-24 Ser Thr Lys
TEM-26 Lys Ser
SHV-1 Gin Asp Arg Arg Ala Gly Glu Leu
SHV-2 Ser
SHV-3 Leu Ser
SHV-4 Leu Ser Lys
SHV-5 Ser Lys
SHV-6
Amino acid residues are numbered as described by Ambler et al. [108], Abbreviations: Ala,
alanine; Arg. arginine; Gin, glutamine; Glu. Glutamic acid; Gly, glycine; Leu, leucine; Lys. lysine;
Ser, serine; Thr, threonine; met, methionine. Updated from Jacoby & Medeiros [100]
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10.3. TEM-type B-lactamases resistant to B-Iactam
inhibitors
Until recently, all the TEM and SHV enzymes were thought to be very sensitive to
the B-lactamase inhibitors, such as clavulanate, sulbactam and tazobactam. In a recent
review, Brumfitt and Hamilton-Miller stated [3]:
"Even the recent development of inhibitors of B-lactamases (such as clavulanic acid
and sulbactam) will probably only alleviate this decline".
They were to be proven correct, with recent reports of TEM enzymes found in
clinical isolates with resistance to B-lactamase inhibitors [109-111],These enzymes
have been designated TRC-1 (TEM resistant to clavulanate) and TRI (TEM resistant
to B-lactamase inhibitors). It has been shown that the increased resistance to inhibitors
results from a replacement of the methionine residue at position 67 by isoleucine and
of the methionine residue at position 180 by threonine [111]. A spontaneous
laboratory mutant of OHIO-1 B-lactamase, an SHV-1 family member, resistant to
inhibitors, has also been shown to have methionine at position 67 replaced by an
isoleucine residue, and it has been suggested that this residue is the critical residue for
resistance to suicide inhibitors for both TEM and SHV [112],
10.4. Plasmid-mediated extended-spectrum B-lactamases
encoded by ampC type genes
Recently, another group of extended-spectrum plasmid-mediated B-lactamases have
emerged. The structural gene of these enzymes is related to the ampC gene (table 5.).
They are all insensitive to clavulanate and have basic isoelectric points. Two of the
most extensively studied are MIR-1, which is 90% identical to the nucleotide
sequence of the ampC gene of E. cloacae, and BIL-1, which shows homology with
the ampC gene ofCitrobacterJreundii [113],
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Table 5.
Plasmid-mediated extended spectrum B-lactamases encoded by
ampC type genes
B-lactamase Pi Structural gene shares Reference
homology with ampC gene
of
MIR-1 8.4 Enterobacter cloacae [114]
BIL-1 8.8 Citrobacterfreundii [113,115]
CMY-1 8.0 Sequence not yet available [116]
MOX-1 8.9 Pseudomonas aeruginosa [117]
10.5. The future threat of plasmid-mediated ESBLs
Despite a steady increase in the use ofmore powerful B-lactams, especially the third
generation cephalosporins, over the last few years, TEM-1 and SHV-1 still
predominate. This may result from the carriage ofESBLs genes on large plasmids (80
to 300 kb), that do not appear to harbour transposable genetic elements to help in the
efficient dissemination of the resistance gene [88], However, reports of ESBLs are
becoming increasingly common in the scientific literature, and the continued efficacy
of later generation cephalosporins is often held to question. The introduction of the
newer oral third generation cephalosporins into community practice may change the
current situation, and continued diligence with respect to screening programmes is
required. Payne and Amyes [103] remarked that, ". ..these are still early days and our
controlled use of later generation cephalosporins will probably determine whether we




The carbapenems have the broadest antibacterial spectrum of any of the G-lactam
antibiotics currently available, and are stable against the inducible Class I
cephalosporinases, and serine active site ESBLs. These factors will probably
guarantee that use of carbapenems will increase in the future. It appears inevitable
that this usage will exert selective pressures for resistance to develop. Already there
have been reports of B-lactamase mediated resistance to these drugs. These enzymes
may be broadly divided into two groups, by virtue of their mechanism of action:
1. Metallo-B-lactamases.
2. Serine active site carbapenemases.
11.1. Metallo-B-lactamases
These enzymes form a small group of B-lactamases whose catalytic activity appears to
be dependant on a zinc ion at the active site, that participates directly in hydrolysis of
the B-lactam ring. They have recently been reviewed by Payne [118], (table 6).
Most of the early reports of metallo-B-lactamases were from species of little clinical
significance, e.g. Bacillus cereus [119], Flavobacterium odoratum [120], Legionella
gormanii [121], however, there have been several recent reports of metallo fi-
lactamases from more clinically relevant species, e.g. Aeromonas hydrophila [122],
Xanthomonas maltophilia [123,124], Bacteroides fragilis [125], and Ps. aeruginosa
[126], All these enzymes are chromosomally encoded with the exception of the B-
lactamases from single strains of Ps. aeruginosa GN17203 [126] and B. fragilis 10-
73 [127], which have been found to be carried on conjugative plasmids, that are
transferable only within the same species. It is generally thought that most of the





Bacterial Producer Enzyme Pi Mr Plasmid Country Ref.




CfiA 4.7 25249 USA [124]
[129]
B. fragilis GAI30144 4.7 33000 Japan [130]
B. fragilis G 237 4.8 26000 Japan [131]
B. fragilisa BFR81R CfiA-type 4.7 France [132]
B. fragilis 119 4.6 UK [133]
B. fragilis QMCN3 CfiA-type 25249 UK [134]
B. fragilis QMCN4 CfiA-type 25249 UK [134]
B. fragilis GAI30079 Japan [135]
B. fragilis KSB1468/90 4.5 31000 Sweden [136]
B. fragilis 10-73 YES Japan [127]
B. distasonis 4.6 160000 Sweden [137]
B. cereus 569/H/9 II 8.45 24932 UK [138]
B. cereus 5/B/6 II-type 9.1 22500 UK [139]
A. hydrophila 19 A-2 8.0 31500 USA [122]
A. hydrophila AE036 CphA 8.0 28000 Italy [140]
F. odoratum GN14053 5.8 26000 Japan [120]
L. gormanii ATCC33297 10.5 25000 Japan [121]
Ps. aeruginosa GN 17203 9.0 28000 YES Japan [126]
S. marcescens TN9106 IMP-1 >9.5 30000 Japan [141]
X. maltophilia GN12873 L-l 6.9 118000
26000*
Japan [123,124]
a One of four laboratory mutations
*Subunit size
Updated from Payne f 118]
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A recent report describes a metallo-B-lactamase (IMP-1) from S. marcescens TN9106
[141], This enzyme was chromosomally encoded with a pi >9.5. Analysis of its amino
acid sequence has shown the enzyme to have considerable homology with the
metallo-13-lactamases of B. cereus, B. fragilis and A. hydrophilci. The four zinc metal
ligands which form the active site of the B. cereus B-lactamase II were shown to be
conserved in the amino acid sequence of IMP-1. The G+C content of the blamv gene
was lower than the species average of S. marcescens, suggesting that the imipenem
resistance gene had been acquired through transfer of blamp from an external source.
To date, there have been reports of metallo-B-lactamases reported in ten strains of B.
fragilis, all have similar isoelectric points, and some may be identical. The nucleotide
sequence of the TAL3636 (CcrA) [142] B-lactamase and the TAL 2480 (CfiA) [143]
B-lactamase have been shown to be comparable, and a CcrA gene probe was shown
to hybridise with DNA from two of five strains of B. fragilis from the UK [134], A
recent report by Podglajen et a/., has shown that it is possible to select spontaneous
carbapenem-resistant mutants in vitro, following exposure to imipenem [132], The
carbapenemase genes in the carbapenem resistant strains selected in vitro and in vivo
were homologous, raising the possibility that the resistance results from a one-step
mutation, leading to the expression of a silent carbapenemase gene. Podglajen also
demonstrated that DNA from the imipenem resistant strains and some of the
imipenem sensitive strains, hybridised with a 720 bp DNA probe from the CfiA gene.
This raises an important epidemiological question. Is there a reservoir of B. fragilis
strains carrying the silent CfiA gene within the B. fragilis population? The possibility
of treatment failure, resulting from expression of a silent carbapenemase gene, after
treatment with a carbapenem, is a worrying concern. The only other species of
Bacteroides reported to produce a metallo-B-lactamase is from a strain ofBacteroides
distasonis [137], This enzyme appears distinct from the CfiA group of
carbapenemases, its isoelectric point is similar (4.8) but the isolate has a lower MIC to
imipenem (1 mg/1) than most of the other metallo-B-lactamases reported from
Bacteroides spp (>16 mg/1). The enzyme also has a molecular mass, as determined by
Sephadex gel filtration, of approximately 4 times that of any of the B. fragilis Group
carbapenemases. It would be interesting to determine the Mr, employing SDS-PAGE,
to ascertain whether the enzyme existed in subunit form, similar to that of the LI
enzyme from X. maltophilia.
The metallo-B-lactamase from A. hydrophila AE036 encoded by the CphA gene
possesses an unusual spectrum of activity compared with the other metallo-B-
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lactamases identified so far, being active on penems and carbapenems only [144],
whereas other metallo-B-lactamases are known to hydrolyse a variety of B-lactams,
other than carbapenems.
11.2. Mode of action of metallo-fi-Iactamases
As previously briefly alluded, the mode of action of metallo-13-lactamases is different
from that of the serine active site B-lactamases. The original and most extensively
studied metallo-B-lactamase is B-lactamase II, from B. cereus, 569/H/9 and 5/B/6
[138,145,146],
The hypothetical mechanism for B-lactamase II action was outlined by Little et al.
[147], and probably reflects the action of all the metallo-B-lactamases (figure 7). It
appears that three histidine residues serve as ligands to the Zn++ ion, a water
molecule bound to the catalytic Zn++, attacks the B-lactam carbonyl group, with
glutamate-37 acting as a general base, deprotonating the water molecule. The water
molecule is then donated to the nitrogen atom of the B-lactam ring. Subsequent X-
ray-crystallographic studies have confirmed that the binding site consists of a Zn++
ion surrounded by three histidine residues and one cysteine residue. However, it
appears that the distance of glutamic acid-37 is too far from the metal ion to act as a
general base, as suggested by Little [147], and that glutamic acid-212, which is
considerably closer to the metal ion, may be an alternative candidate.
11.3. Sequence homology between the metallo-B-lactamases
Table 7 shows the amino acid sequence comparison between the five Class B metallo-
B-lactamases that have been investigated to molecular level.
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Figure 7.














From Little et al. [147]
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Table 7.
Amino acid sequence homology between the metallo-fi-lactamases
Identity (%)
B. fragi/is CfiA B. cereus A. hydrophila
B. cereus 5/B/6 41.4 - -
A. hydrophila CphA 34.3 34.9 -
X. maltophilia. LI 22.7 21.4 21.0
S. marcescens IMP 1 35.9 38.9 22.1
Adapted from Felici et o/.f 148]. and Osano et «/.[ 1411
The sequence comparison of the above enzymes, indicates that the metallo-B-
lactamase LI from X maltophilia shares little homology with the other enzymes.
Collectively, all five enzymes share only 14 strictly conserved residues, but this
number is increased to 37 with the removal of the X maltophilia LI B-lactamase
[148], It has, therefore been proposed, that the LI enzyme be placed in a separate
subclass of the Class B B-lactamases [148,149], Massidda el al. [140], also argued
that the A. hydrophila metallo-B-lactamase CphA was also sufficiently dissimilar to
the original Class B metallo-B-lactamase, 5/B/6, to warrant its inclusion in a separate
molecular subclass from that of X maltophilia LI, although they noted that the
sequence homology of the CphA enzyme to the B. cereus B-lactamase II enzyme was
more pronounced in the regions known to encompass the active site. Surprisingly,
His-86, one of the histidine binding ligands in the B. cereus 5/B/6 B-lactamase was
replaced by an aspargine residue in the CphA gene, although this residue has been
shown to play only a minor role to the binding of the metal co-factor in B-lactamase II
from B. cereus 5/B/6.
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11.4. Serine active site carbapenemases
Serine active site carbapenemases, are probably the rarest of all the B-lactamases.
Class I chromosomal cephalosporinases have been shown to slowly hydrolyse
imipenem, but resistance to carbapenems is only conferred if the enzyme is produced
at high levels with a concomitant decrease in outer membrane permeability as
described for overproduction of chromosomal cephalosporinase in E. cloacae [53],
A carbapenemase, which when coupled with a permeability factor, confers resistance
to a wide range of fi-lactams, including imipenem (16.0 mg/1), has been described in a
single strain of B. distasonis TAL 7860 [150], although this enzyme has not been
shown to be inducible. This strain produces an enzyme with a pi of 6.9. Differences in
physicochemical properties and inhibition studies suggest that this B-lactamase is
different from the imipenem-inactivating metallo-B-lactamases previously described in
B.fragilis, its Vmax for imipenem is only 0.2% that for cephalothin. Livermore [151],
thought it questionable whether it should appear on a list of carbapenemases at all.
There are only two fully characterised serine carbapenemase reported to date, the
NMC-A enzyme from E. cloacae NOR-1, described by Nordmann et al. [152], and
the SME-1 B-lactamase from S. marcescens S6, recently reported by Naas et al.
[153], although there are partly characterised enzymes from Serratia and
Enterobacter spp, reported only in abstracts, that may belong to this category [154],
The NMC-A B-lactamase is chromosomally encoded with a molecular mass of 30 kDa
and a pi of 6.9. The strain of E. cloacae also encodes for a Class I cephalosporinase
of pi 9.2. The NMC-A enzyme was not inactivated by the metal ion chelator EDTA,
which indicated that it was not zinc dependant. A 1.2 kb DNA fragment of the NMC-
A structural gene from a recombinant plasmid failed to hybridise with ampC of E.
cloacae, with other known B-lactamase genes found commonly in the
Enterobacteriaceac and b/asHV_3 derivatives), and with carbapenemase genes
such as those from X. maltophilia, B. cereus, B. fragilis (CfiA), and A. hydrophila
(CphA). It has however, been shown to share 70% amino acid identity with SME-1, a
Class A B-lactamase [153], which would infer that NMC-A is also a Class A B-
lactamase.
The SME-1 B-lactamase from Serratia marcescens S6 [153], has a pi of 9.7. and a
molecular mass of 29.3 kDa. It shares similar hydrolytic properties with NMC-A.
SME-1 was initially inferred to be a metallo-B-lactamase on the basis of data
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suggesting inhibition by EDTA [155], however the blasme-1 gene shows no homology
with the Class B metallo-B-lactamases.
A recent report has described imipenem resistance in E. coli and the strain was also
resistant to most other agents tested. The mechanism of resistance has not yet been
ellucidated, although the patient had previously received imipenem and a decrease in
permeability is suspected, rather than production of a carbapenemase. We await with
interest the outcome of further investigations to determine the cause of the resistance
[156],
12.0. B-lactamase nomenclature
The penicillin destroying activity of extracts from E. coli, first described by Abraham
and Chain in 1940, was shown to be enzymatic and given the name "penicillinase". In
1965 the Enzyme commission gave penicillinase the official name, when it described
the enzyme as "penicillin-amide-B-lactam-hydrolase", EC 3.5.2.6. With the
introduction of new B-lactams in the 1960s, and the discovery of new B-lactamases,
the term "cephalosporinases" was widely utilised. In 1972, the Enzyme commission
introduced "cephalosporinase as EC 3.4.2.8. However, the situation was confused
rather that clarified, by the introduction of the term "B-lactamase I" for penicillinase
and "B-lactamase II" for cephalosporinase. The situation was clarified in 1984. The
Enzyme commission finally grouped all B-lactamases under the one heading, EC
3.5.2.6.
13.0. Classification schemes for B-lactamases
Classifying the B-lactamases has proven to be a difficult task [157], A number of
schemes have been proposed. Although most are based on substrate and inhibitor
profiles, a molecular classification scheme based on amino acid sequence around the
active site has also been proposed. Most of the classification schemes have essentially
disregarded the B-lactamases of Gram positive bacteria, and their attention has been
focused on the B-lactamases ofGram negative bacteria.
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13.1. Early classification schemes.
The first early attempts at classification were those by Sawai et al. [158] in 1968, and
Jack and Richmond [159] in 1970. Sawai listed three types of B-lactamases on the
basis of substrate profile:
Group 1: Inducible cephalosporinases.
Group 2: Cephalosporinases that had properties of penicillinases, or specifically,
broad spectrum B-lactamases identified from Proteus vulgaris.
Group 3: Penicillinases.
The classification scheme of Jack and Richmond was essentially similar, but they
divided the cephalosporin-hydrolysing enzymes into two categories. They proposed
four groups of B-lactamases.
Group 1: Broad spectrum enzymes.
Group 2: Penicillinases
Group 3: Cephalosporinases having little or no hydrolytic activity against
penicillins.
Group 4: Cephalosporinases
Using additional parameters of enzyme inhibition (p-CMB and cloxacillin) and
electrophoretic mobility they identified at least eight different B-lactamase types.
13.2. The Richmond and Sykes classification scheme
In 1973 Richmond and Sykes [160] proposed a classification scheme that is still
widely used today. In a recent article by R. C. Moellering Jr. [157], he describes their
system as "...the classic scheme".
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Richmond and Sykes outlined five broad classes of 13-lactamases from Gram negative
bacteria, on the basis of substrate profile and inhibition studies:
Class I: This class comprises enzymes that are predominantly active against
cephalosporins. These enzymes are chromosomally mediated by such strains as E.
coli, Enterobacter spp., Citrobacter spp., Indole positive Proteus, Pseudomonas spp.,
and Serratia spp, and are either produced constitutively or are inducible.
Class I enzymes have been subdivided into four types (table 8).
Table 8.
Classification of chromosomal cephalosporinases
R & S Class
and type
Expression Species Other names
la Inducible E. cloacae P99
lb Constitutive E. coli AmpC B-lactamase
lc Inducible P. vulgaris Cefuroximase,
cefotaximase
Id Inducible Ps. aeruginosa Sabath-Abraham enzyme
Taken from Sanders [161],
Class II: This class comprises enzymes that are predominantly active against
penicillins, these are uncommon and have been found in species ofProteus.
Class III: This class comprises enzymes that have approximately equal activity
against penicillins and cephalosporins but are sensitive to inhibition by cloxacillin and
resistant to inhibition by p-CMB. These enzymes are plasmid-mediated and
encompass the TEM and SHV B-lactamases.
Class IV: Class IV enzymes have a substrate profile similar to that of the Class III
enzymes but are resistant to inhibition by cloxacillin and sensitive to inhibition by p-
CMB. Enzymes of this class include the chromosomally encoded B-lactamases of
Klebsiella spp. They are produced constitutively.
Class V: Class V enzymes are all plasmid-mediated, and comprise a heterogeneous
group of enzymes. They all exhibit a "penicillinase" profile, including activity against
Introduction 42
cloxacillin. They are resistant to p-CMB. Included in this group are the oxacillin-
hydrolysing enzymes (OXAs) and the Pseudomonas specific enzymes (PSEs).
13.3. The Sykes and Matthews classification scheme
In 1976, Sykes and Matthew expanded on the R & S scheme [74], including, for the
first time, the use of isoelectric focusing as a major criterion for differentiating 13-
lactamases. They proposed two major groups, Classes A and B, which were further
subdivided into three subclasses:
Class A
These enzymes are all chromosomally mediated and are sub classified into:
(a) Penicillinases.
(b) Cephalosporinases.
(c) Broad spectrum 13-lactamases.
Class B
These enzymes are those determined by R-plasmids and are sub classified into:
(a) Enzymes that do not hydrolyse isoxazolyl 13-lactam substrates.
(b) Enzymes that hydrolyse methicillin and isoxazolyl 13-lactam substrates.
(c) Other enzymes specified by R-plasmids.
13.4. Early classification schemes for R-factor-mediated
enzymes
The increase of reports of R-plasmid mediated enzymes in the 1970s led to the
development of additional schemes to deal specifically with these enzymes. These
included the classification schemes of Mitsuhashi et al. [162] and Pitton [163],
Mitsuhashi grouped these enzymes into four types:
Type 1: Comprised of the TEM-type enzymes.
Type II: Comprised of the oxacillin-hydrolysing enzymes that also hydrolyse
methicillin.
Type III: Comprises the oxacillin-hydrolysing enzymes that do not hydrolyse
methicillin.
Type IV: Comprises the carbenicillin hydrolysing enzymes (PSEs).
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Pitton subdivided the TEM and SHV enzymes by isoelectric focusing and substrate
profile, into Pitton type 1 and 2. In this scheme he refers to SHV as TEM-1 type 2.
Neither of these schemes have been widely adopted.
13.5. The Ambler classification scheme
In the second half of the 1970s it began to be possible to classify B-lactamases
according to their molecular structures rather than their enzymatic activities and
isoelectric points. In 1980, Richard Ambler proposed a classification scheme based on
molecular structure [164], Ambler originally identified two classes of enzyme, A and
B:
Class A: This class was based on the amino acid sequences of Staphylococcus
aureus PCI, Bacillus licheniformis 749/C, B. cereus 569/H (B-lactamase I) and the
E. coli plasmid mediated B-lactamase Rtem- AH the Class A enzymes have a
molecular mass of ~30kDa and share considerable homology. Ambler concluded that
their similarity was so great that they had diverged from a single ancestral gene.
In 1991, Ambler [108] introduced a standard numbering scheme for Class A B-
lactamases, by aligning 20 Class A proteins and attaching numbers to the alignment.
In his scheme the active site serine residue has been given the number ABL 70. The
other scheme in general use, is that of Sutcliffe [165], This numbering system is
derived from the natural sequence of TEM-lpBR322- In this scheme the active site
serine residue is placed at number 68.
Class B: This class was created for the zinc requiring metallo-B-lactamase, B-
lactamase II from Bacillus cereus 5/B/6. In contrast, it shows no similarity in
sequence to the Class A enzymes.
As previously discussed, the other metallo-B-lactamases (table 7) for which we have
amino acid sequences, do not share extensive homology with B-lactamase II, although
the residues around the active site are highly conserved. Sanders [73] went as far to
suggest that a new Class, E, be created for the LI B-lactamase of X maltophilia
[123].
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Class C This class was first recognised in 1981 by Jaurin and Grundstrom [166],
Confirmation of this group was also shown by Knott-Hunziker el al. [167],
Subsequent experiments with DNA probes indicate that this class of enzyme is widely
spread through the chromosomes ofGram negative bacteria [75], These chromosomal
cephalosporinases also function with a serine residue at the active site, but are very
different in structure to those of the Class A enzymes [73],
Class D: This class was proposed by Huovinen et al. [168], who after having
deduced the amino acid sequence of the PSE-2 B-lactamase, found that it shared
extensive homology with the OXA-2 B-lactamase [169], Neither of these enzymes
share structural similarities with TEM or ampC B-lactamases, and were therefore
placed in a new Class, D.
13.6. The Bush classification scheme
In 1988, Bush [170], although acknowledging the versatility of the R & S, scheme
criticised it on a few salient points. She stated that NaCl should not be used as one of
the reference criteria as NaCl-B-lactamase interaction had not been correlated with
any specific structural or mechanistic characteristic. Another criticism was that Gram-
positive organisms were not included in the scheme.
Bush, therefore, thought it attractive to consider a revaluation of B-lactamase
classification schemes, though, perhaps from a biochemists viewpoint, she also
thought it premature to use the current molecular results to define a grand plan for B-
lactamases [170], She stated that:
"...it is possible to use much of the information now available to develop a
classification system that will be reasonably simple, accurate, and fairly rapid. This
scheme must be based upon principles and techniques easily accessible to the clinical
laboratory".
In making these comments, Bush had perhaps found an ally. Sykes [64], after his
comprehensive review of classification systems at the time, including the scheme of
Ambler [164], stated:
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"The scheme (Richmond & Sykes) is recommended for continued use on two counts:
(1) it has been cited extensively in previous literature, and (2) it can serve as a
common reference for future studies on new 13-lactamases".
Clearly Sykes was unhappy at the classification of (3-lactamase by purely molecular
means. With this common ground, Bush and Sykes published a much needed set of
guidelines [171], They recognised that the methodology in many studies had led to
insufficient and often inaccurate data, with wide variation between different workers,
and that these guidelines would bring about a more united approach to the study of 13-
lactamases.
The criteria in these guidelines led to the compilation of an updated classification
scheme (outlined in table 10), that utilises substrate and inhibitor profiles, in addition
to physical data for both plasmid-mediated and chromosomal enzymes [149,172],
In the Bush scheme, four classes of 13-lactamases are described:
Group 1: This class includes many of the inducible chromosomally mediated 13-
lactamases from Gram-negative bacteria.
Group 2: This class includes all the important plasmid-mediated 13-lactamases,
that are inhibited by clavulanate, sulbactam and tazobactam. All the
ESBLs fall into Class 2b'.
Group 3: Group 3 enzymes are metallo-13-lactamases, not inhibited by the
available 13-lactamase inhibitors, and are inhibited by EDTA.
Group 4: Group 4 contains unusual penicillinases not inhibited by clavulanic
acid.
The Bush classification scheme is the most versatile and comprehensive to date. It
satisfies the biochemist, clinician and to a certain extent, the molecular biologist, and
is now the most widely accepted scheme for the classification of 13-lactamases.
Although it was acknowledged that all major 13-lactamases would eventually be
sequenced, Bush went on to state:
"...the biological activity associated with the enzyme should be emphasised as the
most relevant attribute to a novel 13-lactamase".
This statement emphasises the continued requirement for biochemical characterisation
of all novel 13-lactamases. It can perhaps be exemplified by the TEM-3 plasmid -
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mediated fi-lactamase [173], which differs from TEM-2 by only two amino acid
substitutions. Based on molecular structure, they would both be placed in Ambler
Class A. This classification may be ofworth to the molecular biologist, but clinically it
has little value. TEM-3 can hydrolyse, and confer resistance to later generation
cephalosporins. This difference in hydrolytic activity has enormous clinical
significance.
Table 10.
Bush classification scheme for B-lactamases
Group Subtitle Preferred Inhibi ted by* Representative
substrate(s) Clav EDTA enzymefs)
1 CEP-N Cephalosporms No No Chromosomal enzymes
from Gram-negative
bacteria

















Yes No OXA-1,2,3 OXA-7, PSE-
2, B. fragilis
2e CEP-Y Cephalosporins Yes No P. vulgaris,
B. fragilis
3 MET-N Variable No Yes B. cereus II
X. maltophilia LI
4 PEN-N Penicillins No ? Ps. cepacia
B. fragilis
* EDTA = ethylencdiaminctetraacetic acid; Clav = Clavulanic acid
Adapted from Moellering [157|
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13.7. The Payne & Amyes classification scheme for
plasmid-mediated extended-spectrum ft-lactamases
Payne and Amyes also acknowledged that it would be a long time before all the 13-
lactamase genes would be sequenced, and all the important amino acid changes were
known. They recognised a need to classify the growing number of ESBLs, based on
biochemical properties. They proposed a classification system for the plasmid-
mediated ESBLs, by dividing them into four groups by virtue of their relative
hydrolytic efficiencies of cefotaxime and ceftazidime [103]:
Group 1: Those enzymes that hydrolyse cefotaxime and ceftazidime with poor
efficiency.
Group 2: Those enzymes that hydrolyse ceftazidime more efficiently than cefotaxime.
Group 3: These enzymes confer a greater resistance to ceftazidime, and have been
subdivided into three subgroups:
(a) All TEM derived B-lactamases.
(b) All SHV derived B-lactamases.
(c) B-lactamases of unknown derivation.
Group 4: This group consists ofB-lactamases that confer resistance to all generations
of cephalosporins and clavulanic acid.
Because of insufficient data, Payne and Amyes listed five enzymes that do not fit into
the classification scheme.
13.8. The Livermore classification scheme for
carbapenemases
Although these enzymes are rare, Livermore has proposed a classification scheme
[151], They have been categorised into three groups.
Group 1: Chromosomal enzymes that are ubiquitous in certain species.
Group II: Chromosomal enzymes that are rare.
Group III: Plasmid determined B-lactamases.
The carbapenem hydrolysing enzymes have already been discussed in some depth, and




A nosocomial infection, is an infection that is not present or incubating when a patient
is admitted into hospital [174], Nosocomial infections may be either endogenous or
exogenous [175], It has been estimated that between 5 and 10% of patients entering
U.S. hospitals acquire a nosocomial infection [176], There are a number of factors
that predispose patients to nosocomial infection. Intrinsic or host factors such as age,
sex, underlying disease, and immunosuppressive therapies, increase the risk of
infection at all sites [174], whereas the importance of extrinsic risk factors varies with
the type of infection (table 11).
Table 11
Important extrinsic risk factors for major nosocomial infections
Infection Risk factor














Presence of foreign body
Intravascular cannulas
Duration of cannulation
From Hughes and Jams [174J
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14.2. Nosocomial Infection - The early years
At the advent of the antibiotic era, organisms such as S. aureus, S. pneumoniae and
B-haemolytic streptococci were the major causes of hospital infection [177], The
1960s saw a subsidence in the importance of staphylococci as a result of the discovery
of the B-lactamase stable B-lactams. They were replaced by the enteric Gram negative
bacilli [177], During the 1980s, there has been a noticeable change in the pattern of
hospital infection, partly due to the selective pressures exerted with the use (and
abuse) of more powerful broad spectrum antibiotics, such as the third generation
cephalosporins and the carbapenems. Recently there has been a resurgence in the
Gram positive bacteria in hospital nosocomial infections, with such species as
enterococci and multi-resistant staphylococci [177], Species of glucose non-
fermenting Gram negative bacilli, which previously posed few clinical problems, have
also begun to emerge as important nosocomial pathogens. These organisms are often
multi-resistant to antimicrobials, and have been responsible for outbreaks of hospital
infection or colonisation [178], Two species that have recently been well publicised
are Acinetobacter spp. and Xanthomonas maltophilia.
15.0. Acinetobacter
The genus Acinetobacter has emerged as one of the more significant opportunistic
pathogens within the hospital environment during the last decade.
These organisms have undergone extensive taxonomic changes, and many different
names have been used, such as Bacterium anitratum, Herellea vaginicola and Mima
polymorpha. In 1986, the taxonomy of this species was extensively altered by Bouvet
and Grimont [179], who delineated 12 species by DNA-DNA-hybridisation. Most A.
baumannii strains were formerly classified as A. calcoaceticus subspp. anitratus. This
species has been described as the predominant entity in nosocomial infections [178],
and is also the species that exhibits the highest level of resistance among the
Acinetobacter [180],
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15.1. Infections caused by Acinetobacter baumannii
Acinetobacter spp are not thought to carry any formal virulence factors, and in
general are opportunistic pathogens. Despite this, recent literature is replete with
reports of infections caused by A. baumcmnii. The organism has been found to be
capable of causing life-threatening infections such as pneumonia, meningitis,
endocarditis and septicaemia [181-183],
15.2. Treatment ofAcinetobacter
Treatment of infections caused by Acinetobacter can pose serious problems for the
clinician. They are often resistant to multiple antimicrobials. This resistance results
from the production of aminoglycoside-modifying enzymes, B-lactamase production,
and/or reduced outer membrane permeability [184-186], Table 12 shows the results
of two recent surveys on the activity of antimicrobial agents against A. baumannii
[180,186], Despite wide differences between the susceptibility of different
antimicrobials within the two studies, it is apparent that no single agent, with the
exception of the carbapenem, imipenem, is effective against all the strains tested.
These results clearly show the efficacy of this drug against A. baumannii.
15.3. Imipenem resistance in Acinetobacter baumannii
In 1992, Neu, stated [187]:
"...Acinetobacter will probably become resistant to these agents (carbapenems) as
have many other organisms".
This statement, was in fact, preceded by several years. In 1991, Bergogne-Berezin
and Joly-Guillou, [188] reported two strains of Acinetobacter spp. resistant to
imipenem, (MICs 4-8 mg/1) that had been isolated as early as 1987, although these
levels probably indicate a diminished susceptibility rather than high level resistance.
Since then, the same group have isolated 20 more resistant strains. None of these
strains exhibited any G-lactamase activity against imipenem, and a decrease in
permeability is suspected as the mechanism of resistance.
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Table 12.
Percentage of isolates ofAcinetobacter bciumannii susceptible to
various antimicrobials
















a, adapted from Vila et al. [186]
b. adapted from Seifert et al. [ 180]
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There have been other reports of resistance to imipenem, Gehrlein et cil, reported
strains with MICs of 4 mg/1, as a result of altered PBPs, rather than a decrease in
permeability, again there was no evidence of B-lactamase involvement [60],
The increasing number of reports of imipenem resistance in this species is of great
clinical concern as in many cases, imipenem may be the only antibiotic available for
treatment. It is perhaps exemplified by an outbreak of imipenem resistant strains ofA.
baumannii (MICs 8-16 mg/1) between 1988-89, in a surgical intensive care unit in
Booth Memorial Medical Centre, Flushing, New York. Extensive use of ceftazidime
and imipenem resulted in the selection of strains resistant to all classes of
antimicrobials, including imipenem. The organism was eradicated with the use of
ampicillin/sulbactam (8/4 ratio), although the results of in vitro tests indicated that
sulbactam was the sole agent responsible for the killing of these organisms. No
attempt was made to determine the mechanism of resistance in these strains [189],
16.0. Xcinthomonas maltophilia
Another organism that is gaining in prominence is X. maltophilia. It is a glucose non-
fermenting, Gram negative bacillus. X. maltophilia is a free-living ubiquitous
organism, with a wide geographic distribution. It was originally named Bacterium
bookerii [190], and was subsequently classified as Pseudomonas maltophilia by Hugh
and Ryschenkow in 1961 [191], It was found to be marginally related to
Xanthomonas species, a family of plant pathogens, and was subsequently included in
the genus Xanthomonas by Swings et al. in 1983 [190], The significant differences in
the two taxa have been outlined on several occasions, and Van Zyl and Steyn [192]
proposed that a new genus should be created for X. maltophilia, which could be
placed together with the genus Xanthomonas in a separate natural group. A recent
article has proposed the name Stenotrophomonas (a unit feeding on few substrates)
maltophilia [193], In this thesis the name, Xanthomonas maltophilia, will be used.
16.1. Infections caused byX maltophilia
This organism is increasingly recognised as an important opportunistic pathogen.
Severe infections, including septicaemia, peritonitis, meningitis and endocarditis, may
be caused by this organism in seriously ill and immunocompromised patients [194-
197],
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16.2. Mechanisms of resistance in X. maltophilia
The emergence of X maltophilia as a pathogen has been attributed to selective
pressure by the use of broad spectrum antibiotics [198], Extensive use of imipenem is
a primary cause of this selection. It is one of the few clinically relevant Gram negative
bacilli that is resistant to this antimicrobial. Recent studies have shown that the
species is commonly resistant to a wide range of B-lactams as well as other classes of
antimicrobials [199-201], This resistance has been attributed to the interplay between
outer membrane impermeability [202] and the production of two potent chromosomal
13-lactamases. LI, a metallo-B-lactamase [123] and L2, described as an unusual
cephalosporinase [203] which between them hydrolyse virtually the entire spectra of
B-lactams. It has been assumed that all strains produce the LI and L2 enzymes.
However, two recent studies have shown an unexpected heterogenicity amongst B-
lactamases produced by the species [204,205], Both studies reported that there were
several B-lactamases which could be differentiated by their isoelectric points. In the
study by Cullmann [205], none of the strains examined produced more than one B-
lactamase.
16.3. Treatment ofX. maltophilia infections
The control ofX maltophilia infections remains a particular problem to clinicians. A
recent study by Garcia-Rodriguez et al. of in vitro susceptibilities to 42 strains of X.
maltophilia, found that no single antibiotic was effective for all strains tested [200],
B-lactams fared particularly badly, with the exception of ceftazidime (30.9%
resistance). The trimethoprim-sulphamethoxazole combination appeared to be the
most efficacious, with 74% of strains sensitive. Another survey by Elting and Bodey
[195] reported similar findings, with 89% of strains sensitive to these drugs. Other
classes of antibiotics also fare less well in the treatment ofX maltophilia, although
ciprofloxacin appears reasonably effective. In the survey of Garcia-Rodriguez et al.,
40.5% of strains were sensitive, compared with 92% of strains sensitive in the Elting
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1.0. Bacterial Strains
All bacterial strains investigated in this thesis were collected from the blood of
patients in the Royal Infirmary ofEdinburgh (RIE) during the period 1980-1991.
All strains were stored initially as lyophilised cultures, and reconstituted by adding
200pl of sterile distilled water, allowed to stand for 15 minutes, plated out onto both
Colombia agar supplemented with 5% horse blood and MacConkey agar and
incubated overnight at 37°C in air. The purity and integrity of the strains was verified
at this point. The strains were then sub-cultured onto nutrient agar slopes and
incubated overnight at 37°C, before storage at room temperature in darkness, until
required.
Strains that were subjected to further investigations were also stored at -70°C in
nutrient broth with sterile glycerol to a final concentration of 10% v/v.
All strains were identified at the time of isolation by either the API20E or API20NE
system (API System, S. A. France). This work was performed by staff of the blood
culture laboratory, Clinical Bacteriology, Dept. of Medical Microbiology, Edinburgh
University.
Details of individual strains are held on a separate document, in the Clinical
Bacteriology laboratory, Dept. ofMedical Microbiology, Edinburgh University.
Details of the cefiiroxime-resistant strains and their fi-lactamase content are listed in
the appendix.
Tables 11-13, list the standard bacterial strains, standard bacterial plasmids and the
standard B-lactamase producing strains used in this thesis.
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Table 11.
Standard bacterial strains
Strain Genotype Source* Original
Reference
NCTC 6571 S. aureus










pro~, his', trp~, lac~^ Riffi DP55 [206]
Table 12.
Standard Bacterial plasmids
Plasmid Markers Size (kb) Source* Original
Reference
R1 Ap Cm Km Su incYW 90 DP 6 [207]
RP4 Ap Km Tc />/cP-l 52 DP42 [208]
R1010-6 Ap (tra~) incN 54 DP38 [89]
* CPHL, Central Public Health Laboratories. Colindale, London; DP denotes Dr D. Payne culture
collection; SGBA denotes Professor S.G.B. Ainyes culture collection.
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Table 13.
Standard fi-lactamase producing strains
Bacterial strain ^lactamase Plasmid Source* Original
produced (pi) reference
E. coli K12 J62-2 TEM-1 (5.4) R1 DP6 [207]
E. coli 7604 TLE-1 (5.55) pMG204b DP37 [209]
E. coli J53-2 2141E SHV-1 (7.6) R1010-6 DP38 [89]
E.coli J53-2 OXA-1 (7.4) R455 SGBA1336 [210]
E.coli J53-2 OXA-4 (7.5) pMG204 SGBA1337 [210]
*DP denotes Dr D. Payne culture collection
SGBA denotes Professor S.G.B. Amyes culture collection
1.1. Information storage and retrieval of survey strains
All blood cultures isolates collected were suffixed with a number ranging from 1-13
indicating the year of isolation (1=1980, 2=1981 etc.), and the letter "B".
Data concerning blood culture isolates from Edinburgh Royal infirmary was stored in
the database program, dBASE III+ (Ashton-Tate, Milton Keynes). All information
regarding aerobic Gram negative bacilli was retrieved with this system.
2.0. Materials
2.1. Media
Unless otherwise stated, all growth media used was sterilised by autoclaving at 15
lbs/in2 at 121°C for 15 minutes.
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2.1.1. Complex media
The following complex media were used: Isosensitest Agar (ISTA) (CM471),
Nutrient broth No 2 (CM 67), MacConkey agar (CM7), Mueller Hinton agar (MHA)
(CM 337), Diagnostic Sensitivity Test Agar (DSTA) (CM261), Colombia Agar
(CM331) with 5% added horse blood (Equine Bovine Products, Bonnybridge,
Stirlingshire). All materials were supplied by Oxoid, Unipath (Basingstoke, Hants.)
unless otherwise stated.
2.1.2. Minimal Media (DM agar)
Minimal media was prepared as described by Davis and Mingioli [211] (table 14).
Fifty ml of double strength DM was then supplemented with the appropriate amount
of the required amino acid stock solution to achieve the final concentrations shown in
table 15. After the appropriate antibiotics were added, 2.5ml of a 20% solution ofD-
glucose was added and the volume made up to 60ml with sterile distilled water
(SDW). This solution was mixed and added to 40ml of molten Bacteriological Agar
No 1 (lg of agar/40 ml of SDW). The solution was mixed well and 20ml of the agar
solution added to each plate.
A single strength salts medium was prepared by dilution of double strength DM with
an equal volume of SDW. This was used for dilution ofbacterial cell suspensions.
Table 14.
Preparation of double strength Davis and Mingioli basal medium
Ingredient Chemical formula Quantity dissolved
in 1L (g)
d/'-Potassium hydrogen phosphate k2hpo4 14.0
Potassium z/z'-hydrogen phosphate kh2po4 6.0
tri-Sodium citrate Na3C6H507 1.0
Magnesium sulphate MgS047H20 0.2
Ammonium sulphate (NH4)2S04 2.0




















All buffer solutions used in this thesis were prepared as described in Data for
Biomedical Research (Oxford University Press, 1974), unless otherwise stated.
2.1.4. Antimicrobial agents
The antimicrobial agents used and their suppliers are listed in Table 16.
Antibiotic discs
All antibiotic discs were obtained from Mast Laboratories Ltd, Liverpool, UK.
3.0. Methods
3.1. Antibacterial susceptibility testing
3.1.1 Minimum Inhibitory concentrations (MICs)
All minimum inhibitory concentrations were performed on ISTA or MHA agar, unless
otherwise stated, following the guidelines established by the British Society for
Antimicrobial Chemotherapy (BSAC) [212], Bacterial strains to be tested were grown
overnight in nutrient broth and diluted in single strength DM to give approximately
106 cfii/ml. A lpl volume of this suspension was inoculated onto the surface of the
plate, employing a Denley multipoint inoculator (Denley, Surrey) to
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give a final inoculum of 104 cfii/spot. E. coli NCTC 10418, Ps. aeruginosa NCTC
10662 and S. aureus 6571 were incorporated as control organisms. A plate with no
added antibiotic was established as a positive control. The plates were incubated in air





Ampicillin Sigma Chemical Co. Ltd
Aztreonam E. R. Squibb and Sons
Benzylpenicillin Sigma Chemical Co. Ltd
BRL 42715 SmithKline Beecham Pharmaceuticals
Carbenicillin SmithKline Beecham Pharmaceuticals
Cefotaxime Roussel Laboratories Ltd
Ceftazidime Glaxo Group Research Ltd
Cefuroxime Sigma Chemical Co. Ltd
Cephaloradine Glaxo Group Research Ltd
Ciprofloxacin Bayer UK Ltd
Clavulanic acid SmithKline Beecham Pharmaceuticals
Gentamicin Nicholas Laboratories
Imipenem Merck Sharp and Dohme Ltd
Meropenem Zeneca Pharmaceuticals
Netilmicin Schering Plough Ltd
Nitrocephin Glaxo Group Research Ltd
Rifampicin Le Petite
Tobramycin Lilly
3.1.2. Disc sensitivity testing
Disc sensitivity testing was performed and interpreted as sensitive, intermediate or
resistant by Stoke's method as described by Holt and Brown [213],
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3.2. Conjugation experiments
The conjugation experiments were performed as described previously by Amyes and
Gould [214], Broth cultures of donor and recipient strains were incubated overnight
in nutrient broth, then 4.5 ml of fresh pre-warmed, nutrient broth was inoculated with
0.1 ml of the donor strain and 1.0 ml of the recipient strain and gently mixed. This
mixture was then incubated at either 30°C or 37°C for 6 hours. The bacterial cells
were harvested, and resuspended in 5.6 ml of single-strength DM and a series of ten¬
fold dilutions prepared. A 0.1ml volume of each dilution was spread onto minimal
media plates containing the appropriate auxotrophic supplements and selective
antibiotics. The plates were then incubated for 48 hours at 37°C.
All colonies selected were verified by checking the auxotrophic requirements and
resistance markers.
E. coli recipients:
To select ampicillin or imipenem resistant E. coli K12 J62-2 transconjugants, minimal
media containing the auxotrophic requirements of this strain, histidine (50mg/l),
tryptophan (50mg/l) and proline (50mg/l), plus 25 mg/1 rifampicin and 50 mg/1
ampicillin or 1 mg/1 imipenem, as appropriate for selection, was used.
Ps. aeruginosa recipients:
Ps.aeruginosa PA08 was mutated to rifampicin resistance by inoculating an ISTA
plate containing 25mg/l rifampicin with a lOOpl aliquot of an overnight nutrient broth
culture grown at 37°C, and incubated at 37°C for 48 hours. Mutant colonies were
selected and mated withA baumannii 6B92. Transconjugants were selected on ISTA
plates containing lmg/1 imipenem and 25mg/l rifampicin.
Acinetobacter recipients:
A clinical isolate of A. baumannii (lab no 5255/3/91) resistant to gentamicin (MIC
128mg/l) was mated with A. baumannii 6B92 and transconjugants selected with
gentamicin (10mg/l) and imipenem (lmg/1) on ISTA.
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3.2.1. Plasmid mobilisation
A 0.1 ml volume of an overnight broth culture of the donor strain harbouring the
?>?cP-l plasmid, RP4, was added to 1ml of recipient culture in 4.5ml of pre-warmed
nutrient broth. The mixture was incubated at 37°C for 18 hours. A 0.1ml volume of
this mixture was added to 4.5 ml pre-warmed nutrient broth along with 1 ml of an
overnight broth culture of recipient E. coli K12 J62-2. The mixture was incubated for
6 hours at 37°C. The selection procedure was performed as described above.
3.2.2. Transformation of plasmid DNA from A. baumannii
6B92 to Escherichia coli C600
3.2.2a. Preparation of competent E. coli C600 cells
Five ml of an overnight nutrient broth culture of E. coli C600 was grown with
shaking at 37°C and added to 200ml of prewarmed nutrient broth. The culture was
grown with shaking at 37°C until the OD540 (Spectronic 20, Bausch and Lomb, UK)
was between 0.3 and 0.4 so that the cells were in the mid-exponential phase of
growth. The cells were immediately cooled in an ice-bath and harvested by
centrifugation (10000 x g, 8 minutes, 4°C, Sorvall RC-5B Refrigerated Superspeed
Centrifuge, Du Pont Instruments, Stevenage, Herts.). The cells were resuspended in
10ml of ice-cold 0.1M MgCl2 and incubated on ice for 20 minutes, then harvested by
centrifugation as before. The cells were then resuspended in 10ml of ice-cold CaCl2
and dispensed into 200pl aliquots into pre-chilled eppendorf tubes for 2-4 hours prior
to use.
3.2.2b. Transformation ofE. coli C600
The plasmid preparation from A. baumannii 6B92 (prepared as described in section
3.8.1.) was dissolved in lOOpl of TE buffer (lOmM Tris-acetic acid (pH8.0), 2mM
EDTA). Five pi of this mixture was added to one tube of competent cells and 50pl to
another and left on ice for 30 minutes. The tubes were then transferred to a 37°C
waterbath for 10 minutes and then 200pl of nutrient broth added to each tube. The
cells were then incubated for 1 hour at 37°C and spread onto 1STA plates containing
lmg/1 of imipenem. The plates were incubated at 37°C for 48 hours.
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3.3. B-lactamase preparation
3.3.1. Small scale preparation of crude cell free extracts
The strain under test was inoculated onto the surface of a nutrient agar slope and
incubated overnight at 37°C. Cells were then washed off the agar surface with 1.0ml
of 50 mM sodium phosphate (pH 7.0.) buffer and transferred to a separate container.
The cells were then disrupted by ultrasonication (8pM, 30s, MSE Soniprep 150, MSE
Instruments, Crawley). The cell lysate was cleared by centrifugation (11600 x g, 10
min, 4°C, MSE Microcentaur centrifuge). The resultant cell free supernatant was
stored at -20°C until required [264],
3.3.2. Large scale preparation of crude cell free extracts
The bacterial strain under investigation was grown with shaking (200 osc/min) at
37°C in 9ml of nutrient broth. This was used to inoculate a 1L culture of pre-warmed
nutrient broth. The cells were grown with shaking at 37°C overnight and harvested
by centrifugation at 6000 x g for 15 min at 4°C (Sorvall RC-5B). The pellet was
resuspended and washed in 20ml of 50mM sodium phosphate buffer (pH 7.0), unless
otherwise stated, and recentrifuged at 2500 x g for 15 minutes (Heraeus Christ,
Bactifuge). The pellet was resuspended in 4ml of the same buffer and disrupted by
ultrasonication with constant cooling (8pM, 1 min x 3, Soniprep). The cell debris was
removed by centrifugation at 11600 x g, lOmin, at 4°C. The crude 13-lactamase
preparation (supernatant) was stored at -20°C until required.
3.3.3. Induction of small scale B-lactamase preparations
from X. maltophilia
A 20ml volume ofMueller Hinton broth (MHB) was inoculated with the strain under
test and grown overnight at 37°C with continuous shaking. This was added to 180ml
ofpre-warmed MHB and incubated for a further 90 minutes. For induction, imipenem
or cefotaxime was then added at lA the MIC. After incubation for a further 3 hours
the cells were harvested, washed in 50 mM Tris CI buffer (pH 8.0), and the 6-
lactamase released as previously described for small-scale preparation of crude
enzyme extract.
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3.3.4. Induction of large-scale B-lactamase preparations
from X. maltophilia
The technique was essentially that described for small-scale B-lactamase induction of
B-lactamase, except a five-fold increase in the volume of broth was used. The B-
lactamase enzymes were extracted as previously described for large-scale preparation
of crude enzyme extracts.
3.4. Assessment of B-lactamase activity of B-lactamase
preparations (Nitrocephin spot test)
The time in seconds for a 30pi volume of the B-lactamase preparation to change
lOOpl of a solution of nitrocephin (50mg/l) from yellow to red was taken as an
indication of the B-lactamase activity of the enzyme preparation.
3.5. Analytical isoelectric focusing
B-lactamases were identified by analytical IEF as described by Matthew et a/.[215],
The B-lactamase extracts were focused on a thin layer polyacrylamide gel containing
broad range ampholines (pH 3.5-10.6), or a mixture of broad range and narrow range
(pH 4-6) carrier ampholines (ratio 1:1). The composition of the gel is shown in table
17.
Focusing was usually performed on an apparatus comprised of two glass plates 1mm
apart. One plate was siliconised with Sigmacote siliconising solution, whilst the other
was coated with a binding solution (0.5%w/v gelatine and 0.5%w/v chromium
potassium sulphate dodecahydrate (both Aldrich Chemical Co. Ltd, Gillingham,
Dorset.) dissolved in sterile distilled water, and allowed to dry in air for 1 hour prior
to use) to promote adhesion of the gel to the glass plates prior to use.
Occasionally focusing was performed with an LKB 2217 Ultraphor Electrofocusing
unit (Pharmacia, Uppsala, Sweden), with a pre-poured polyacrylamide gel containing
broad range ampholines, pH range 3.5-9.5 (PAGplate, Pharmacia).
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Samples of B-lactamase preparations were applied close to the anode on the surface
of the gel. The time taken (in sees) for the nitrocephin spot test to show a positive
reaction was equivalent to the amount of B-lactamase preparation (in pi) applied to
the gel. A maximum of 60pl of enzyme preparation was added to any one lane.
3.5.1. Running conditions
Isoelectric focusing was performed at 4°C at 1W (constant), 550V (limiting) and
20mA (limiting) for 18 hours. Five pi of wide-range isoelectric point markers, pi
range 4.7-10.6 (BDH, Poole, England) were loaded onto the gel in order to quantify
the gradient.
Table 17.




5% v/v TEMED* in distilled water Sigma 0.2 0.25 mg/1
40% w/v ampholines
pH 3.5-10
pH 3.5-10/pH 4-6 (Ratio 1:1)
Sigma 2.0 2.0%w/v
Acrylamide (lOOg) plus methylene
bisacrylamide (2.7g) in 300 ml
distilled water
BDH 9.0 acrylamide: 75g/l
bisacrylamide: 2g/l
Distilled water 25
Riboflavin (20mg/l) Sigma 4.0 2mg/l
*TEMED: Tetramethyl-ethylenediamine
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3.5.2. Staining
13-lactamase activity was visualised by repeatedly overlaying the surface of the gel
with filter paper (Whatman No 54, BDH), previously dipped in nitrocephin solution
(500mg/l). B-lactamase activity appeared red on a yellow background.
3.5.3 Photography
Photographs of focused 13-lactamases were taken with a Polaroid camera (settings;
B4, F8) with a green filter system.
3.6. Partial Purification of 15-lactamases by Sephadex gel
filtration
3.6.1. Preparation of Sephadex G-75 and G-150 gel
filtration columns
The media (Sephadex G-75 or G-150, Pharmacia) was swollen with the appropriate
volume of buffer (50mM sodium phosphate buffer (pH7.0) for G-75, 50mM Tris CI
(pH 8.0) plus 0.1 mM zinc sulphate (Sigma) for G-150) at 100°C for 1 hour. The
slurry was allowed to cool to 4°C and poured into a 2cm2 x 90cm acrylic column
(Amicon Ltd, Stonehouse, Glos.) until packing was complete. When fully packed the
top was connected and a flow rate of 2ml/10min established in an ascending direction
with an LKB 10200 peristaltic pump (Pharmacia). The gel was allowed to equilibrate
for 48 hours with the appropriate buffer before use. After each run, the column was
flushed with two volumes ofbuffer (180ml).
3.6.2. Calibration of Sephadex G-75 and G-150 gel
filtration columns
The Sephadex columns were calibrated according to the method of Andrews [216],
Three proteins of known molecular weight were applied to the column (see table 18)
in a 1ml aliquot and eluted at a rate of 2ml/10mins in the appropriate buffer.
After application of the standard proteins the eluted fractions were collected in 2ml
volumes with an LKB 2070 Ultrorac II fraction collector (Pharmacia). The elution of
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Table 18.
Protein standards (lOmg in 1 mi buffer) applied to Sephadex column
Column Protein Standards (Sigma) Molecular size (daltons)
Sephadex G-75 ovalbumin 45000
chymotrypsinogen 25500
cytochrome-C 12384
Sephadex G-150 alcohol dehydrogenase 150000
bovine serum albumin 66000
cytochrome-C 12384
the standard proteins was determined by measuring absorbance (k = 280nm) of the
fractions with a Perkin-Elmer UV/Vis Lambda 2 Spectrophotometer (Beaconsfield,
Bucks.). The position of the protein markers was then established by plotting the
absorbance of each fraction against the fraction number. A standard curve of Mr
versus fraction number could then be drawn.
The void volume of the column was established by the application of a 1ml volume in
buffer of 10mg/l blue dextran (Mr >2000kDa) (Sigma), to the column.
3.6.3. Determination of the Mr of B-Iactamases
One ml of the crude large-scale B-lactamase preparation, prepared as described
previously, was applied to the column. The flow rate of the column and the settings of
the fraction collector were those employed for the calibration procedure.
B-lactamase activity in any of the eluted fractions was established primarily with the
nitrocephin spot test described previously. These fractions were then assayed by the
spectrophometric method of O'Callaghan et al. [217],
Fractions containing significant activity were pooled and used for further
spectrophotometric assays described in the following section and also to load IEF
gels.
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3.7. Kinetic studies on B-lactamases
3.7.1. Measurement of B-lactamase activity
All spectrophotometric studies of 13-lactamases were performed on either a Perkin-
Elmer UV/Vis Lambda 2 Spectrophotometer or a Perkin-Elmer UV/Vis 554
Spectrophotometer. All assays were performed at 37°C in either 50mM sodium
phosphate buffer (pH7.0) or 50mM Tris CI (pH8.0). Substrate solutions were freshly
prepared in 50mM sodium phosphate buffer (pH7.0). Penicillin substrates were
prepared at 10"2M, monobactams, cephalosporins and carbapenems were prepared at
10"3M. Nitrocephin was prepared at K)-4M.
Assays were performed at the wavelength (X) ofmaximal absorbance for the B-lactam
ring of each drug (Table 19).
Table 19.
Maximal wavelengths for the measurement of B-lactam hydrolysis













A 0.1ml aliquot of B-lactamase preparation was added to a test cuvette containing
0.3ml of substrate and 2.6ml of the appropriate buffer. Control cuvettes were
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established with no added substrate. Monitoring of the decrease in absorbance over
time (in minutes) was begun immediately. The initial linear part of the reaction curve
was used to obtain the rate of hydrolysis.








AA x n x d
A0 x t
pM of substrate hydrolysed/ minute/ ml of enzyme solution
change in absorbance
pM substrate in cuvette (0.3 for cephalosporins, 3.0 for
penicillins, 0.03 for nitrocephin)
enzyme dilution adjusted to 1 ml
absorbance of intact substrate
time (in minutes)
3.7.2. Specific activities
All measurements were performed on a Perkin-Elmer UV/Vis Lambda 2
Spectrophotometer. Nitrocephin (10"4M) was employed as the test substrate. The rate
of hydrolysis was calculated as described above.
Protein concentration was calculated as described by Waddell [218], The B-lactamase
preparation was diluted in distilled water 1:100, prior to measurement of absorbance
at 215nm and 225nm. The difference in absorbance between the two measurements
was multiplied by the correction factor for the spectrophotometer (165). The specific
activity of the B-lactamase was expressed as nanomoles of nitrocephin hydrolysed
min/ mg of protein.
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3.7.3 Determination of Michaelis Menton kinetics
Values of Vmax and Km were derived by linear regression analysis of Lineweaver-
Burk plots of initial velocity data at different substrate concentrations [219], The
Relative Vmax values were normalised with respect to the value (%) of that for
penicillin.
Vm(iX substrate
Relative Vmax ~ x
Vmax penicillin
3.7.4. Measurement of fi-Iactamase inhibition values
The ID50 value is defined as the amount of inhibitor required to reduce the enzymatic
activity of the B-lactamase by 50%. The test substrate employed was as stated in the
appropriate results section. The initial rate of hydrolysis was determined as described
previously, in the absence of inhibitor. This procedure was then repeated in the
presence of 10"8M of inhibitor and repeated with increasing ten-fold concentrations of
inhibitor until inhibition approached 100%.
The B-lactamase inhibitors clavulanic acid and BRL 42715 were pre-incubated with
the enzyme solution for 5 minutes at 37°C prior to addition of test substrate.
Percentage inhibition was then plotted against log[0 concentration of inhibitor. The
concentration of the inhibitor which gave 50% inhibition was calculated from the
graph.
Some inhibitor studies were performed with a fixed concentration of inhibitor. These
results were expressed as % inhibition of rate of reaction compared to a control
reaction with no added inhibitor.
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3.8. Isolation and purification of DNA
3.8.1. Isolation of plasmid DNA
Three methods were employed for the isolation of plasmid DNA from A. baumannii
6B92; these were the methods of, l)Takahashi and Nagano [220], 2) Hansen and
Olsen [221] and 3) Gerner-Smidt [222]
For all methods, cells were grown overnight with shaking in 4.5ml of nutrient broth
and harvested by centrifugation (2500 x g, 20 minutes, Heraeus Christ, Bactifuge).
The methods suggested by the authors were then followed exactly.
3.8.2. Isolation of total genomic DNA
Cells were harvested from 1.2ml of an overnight nutrient broth culture, centrifuged
(12500 x g for 10 minutes in an MSE Micro Centaur centrifuge), and resuspended in
0.31ml ofHTE buffer (50mM Tris CI, pH 8.0, 20 mM EDTA). Two per cent sarcosyl
(0.35ml) in HTE buffer was added and mixed well by inversion. Five pi of RNase was
added to remove RNA and the mixture incubated at 37°C for 15 minutes. Thirty five
pi of pronase was added and the mixture heated at 50°C until lysis was complete (30-
90 minutes). The sample was extracted (to remove lipids and denature proteins) with
an equal volume (0.7ml) of phenol chloroform (ratio 1:1) and briefly mixed,
centrifuged as before for three minutes to separate the phases. The top layer was
carefully removed and transferred to a new microfuge tube. The aqueous DNA layer
was extracted a further two times. The sample was then extracted with an equal
volume of ether (0.7ml) to remove traces of phenol and chloroform from the aqueous
layer. The sample was mixed by inversion and the top layer discarded. Residual ether
was evaporated at 60°C for 15 minutes. The DNA was precipitated by the addition of
sodium acetate to 0.3M (70pl), mixed well and an equal volume of isopropanol added
(0.7ml). After addition of the isopropanol the sample was inverted six times. The
sample was then frozen at -70°C for 10 minutes, centrifuged for five minutes and the
supernatant discarded. The DNA pellet was washed with ~ 1.0ml of 70% ethanol,
vortexed briefly and centrifuged for five minutes to remove residual salts as well as
remaining phenol. The pellet was dried under vacuum for 10-20 minutes and
resuspended in 50pl ofTE buffer (lOmM Tris CI pH 8.0, 0.1 mM EDTA).
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The purity of DNA extracted was measured by adding 20pi of DNA preparation to
0.98 ml of TNE buffer (lOmM Tris CI, pH8.0, lOmM NaCl, O.lmM EDTA). After
mixing, the sample was added to a 1 ml quartz cuvette, absorbance was measured at
both 260nm and 280nm with a Perkin-Elmer UV/Vis Lambda 2 Spectrophotometer.
The ratio of ^260/A280 was calculated. The purity of the DNA preparation should fall
between 1.65 and 1.85. A higher or lower value suggests contamination by phenol or
proteins respectively.
The sample was stored at -20°C until required.
3.8.3. Amplification of DNA with the Polymerase Chain
Reaction (PCR)
PCR amplification of the TEM structural gene was based on the method described by
Du Bois [223],The reaction components are listed in table 20. PCR reaction was
performed in a total volume of lOOpl prepared in a 0.5ml microfuge tube with a
Techne PHC-2 Dri-block Cycler (Cambridge, Cambs.). The mixture was overlaid
with mineral oil, the tube was lightly smeared with vacuum grease to ensure efficient
heat exchange between the tube contents and the heating block of the thermal cycler.
The amplification program was as described in table 21. The sequences of the
oligonucleotide primers are shown in Figure 8.
Figure 8.
The sequences of the oligonucleotides, Blab' and BlaV
Bla3':
5-CTC TCT AGA AAA AGG AAG AGT ATG AGT ATT-3'
Bla4':
5-CTC GCA TGC GTA AAC TTG GTC TGA CAG TTA-3'
After the amplification procedure was complete the samples were placed on ice to
terminate any further reaction. PCR reactions were then ethanol precipitated before
verification ofDNA amplification by agarose gel electrophoresis and stored at -20°C
until required.




\0xTaq reaction buffer (Mg2+ free) lOpl Promega (Southampton, Hants.)
25mM magnesium chloride lOpl Promega
4mM dNTP stock solution* 5pi Boehringer Mannheim, UK.
Bla 3' PCR primer 1 Opmoles Oswel laboratory, Dept. of
Chemistry, Edinburgh University
Bla 4' PCR primer lOpmoles Oswel laboratory
Genomic DNA preparation 2pl
Taq DNA Polymerase 1 unit Promega
Deionised distilled water (Milli-Q) to lOOpl
* 50 mM Tris CI (pH8.0), 76pi Milli-Q-H20. lpl lOOmM dATP, lpl lOOrnM dCTP, lpl lOOmM
dTTP. 1 pi lOOmMdGTP.
Table 21.
The PCR heating cycle protocol



















3 72°C 5 min _ Final extension
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3.8.4. Agarose electrophoresis of DNA
Intact plasmid DNA or PCR-amplified DNA were electrophoresed in 0.7-1.0% w/v
agarose gels (Sigma) in TAE buffer (40mM Tris-acetate pH 7.9, 2 mM EDTA). The
samples were loaded near the cathode. Electrophoresis was performed on either large
(14cm x 25cm x 0.5 cm) or small (Bio-rad Mini Sub Cell) horizontal slab gels
submerged in TAE buffer at 70V overnight for the large gels and at 100V for 2 hours
for the mini-gels. Each sample was mixed with loading buffer (0.01% w/v
bromophenol blue, 50% v/v glycerol) to a ratio of loading buffer to sample of 1: 5,
prior to loading onto the gel.
X phage-DNA digested with Hind III (Sigma) was run alongside samples during
electrophoresis.
DNA was visualised after electrophoresis by staining for one hour in a 50mg/l
solution of ethidium bromide solution and viewed on a UV transilluminator (UV
Products, Cambridge).
Photographs of the stained gel were taken with a Polaroid camera system (setting; F8)
for 3 minutes with an orange filter.
The distance travelled by DNA through the gel is inversely proportional to the
logarithm of its molecular size. Thus, the unknown sizes were calculated from a graph





Resistance ofbacterial pathogens to antimicrobial agents remains a serious problem in
spite of the synthesis or discovery of new and novel antimicrobial agents. Traditional
methods ofmonitoring trends in bacterial resistance rely largely on the data of pooled
nation-wide statistics detailing the antibiotic susceptibility of pathogens isolated from
hospitals over the whole country. These surveys provide general guidelines for
treating infections [224] but their value is limited by their inability to detect specific
trends within a single hospital.
By analysing susceptibility data over several years, changes can readily be observed in
the prevalence of the infecting organisms and the susceptibility to antimicrobials used
clinically. Bloodstream monitoring of pathogens has been shown to be an effective
means ofmonitoring the activity of antibiotics and has been used as a primary monitor
of pathogenic isolates to detect normal resistance patterns [225],
The Royal Infirmary of Edinburgh is a large teaching hospital and over the past
decade, as in other hospitals, there has been a steady increase in the use of more
powerful antibiotics for prophylaxis as well as first line drugs in the battle against
infection. This is particularly apparent with the use of the third generation
cephalosporins and, latterly, imipenem. As a result of the universal increase in use of
these agents, there have been many reports of extended-spectrum B-lactamases
produced by Gram negative aerobic bacilli. Recently, there have been reports of these
strains isolated in Scotland (Dr C. Thompson, personal communication).
Laboratory policy in the Medical Microbiology Department of Edinburgh University
has been to collect and store all significant bacterial isolates from blood cultures from
patients in Edinburgh Royal Infirmary. This has given us a unique opportunity to
study the incidence of resistance among Gram negative aerobic bacilli over a 12 year
period. These strains have been collected from the introduction of extended-spectrum
B-lactams, right through to the present day use of the powerful carbapenems. This
information can be of considerable assistance in selecting antimicrobial agents for
empiric treatment of sepsis of unclear aetiology.
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1.1. The initial aims of the study:
• To study the prevalence of the various species of Gram negative aerobic bacilli
responsible for septicaemia over a 12 year study period.
• To determine the in vitro susceptibility of these strains to various classes of
antibiotics, with particular attention to the B-lactams.
• To study the role of B-lactamases in those strains which are resistant to
cefuroxime (excluding Pseudomoncis spp., and X. maltophilia, which are normally
intrinsically resistant to cefuroxime).
• To determine whether there was any resistance to the newer carbapenem
antibiotics; meropenem and imipenem, and to investigate the mechanism of this
resistance.
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2.0. The antibiotic sensitivity of Gram negative aerobic
bacilli isolated from the blood of patients in Edinburgh
Royal Infirmary during 1980-1991
Figure 9 shows the percentage of individual species collected during the twelve year
study period. As expected E. coli was the predominant isolate amongst all Gram
negative bacilli examined (53%) with Klebsiella spp and Psendomonas spp. the next
most prevalent (10%).
Figure 9.
Percentage distribution ofGram negative aerobic bacilli isolated
from blood cultures during 1980-91 from Edinburgh Royal
Infirmary
Esche^hi/1 ^ 2 f\os.
/ \ h X-. maltophilia 2.0%
Acinetobacter spp. 6.0%- /■ \ X/ —Enterobacter spp. 7.0%
Cilrobacter spp. 2.0%— M Serratiaspp. 3.0%
Klebsiella spp. 10.0%Pseudomonas spp. 10.0%
Proteus/Morganella spp. 7.0%-
Total number of organisms = 1453
The study strains were further examined to determine whether there had been any
change in the incidence of isolation of various species during the study period.
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2.1. Prevalence of individual species collected annually,
over the twelve year study period.
Figures 10 to 12 show the distribution of each species isolated over the twelve years
in both graphical and tabular forms.
Figure 10.
Prevalence ofE. coli, Enterobacter spp., and Klebsiella spp. isolated




Prevalence of Proteus/Morganella spp., Acinetobacter spp., and





Percentage of species isolated —Proteus/Morganella spp.
—Acinetobacter spp.
—Serratia spp.
0 _2 L L k _1_
CD CD CD CD CD CD CD CD CD CD CD CD
oo OO OO OO OO 00 00 00 00 00 CD CD
O k N> OO 01 a> 00 CD O —k
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Figure 12.
Prevalence of Citrobacter spp., Pseudomonas spp., X. maltophilia and
other miscellaneous Gram negative bacilli isolated over 12 years
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Citrobacter spp. 0 0 1.2 0 1.6 1.75 1.2 2.1 2.1 3 2.5 0.5
Pseudomonas spp. 2.2 5.7 21.7 2.4 6.2 4.6 10.7 12.2 17.4 4.3 3.3 16.5
Xanth. maltophilia 0 0 0 0 0.5 1.7 4.4 5.3 3 2.4 0 2.7
Others 4.5 0 0 2.4 0.5 2.3 1.2 0.5 8.3 3.7 2.5 6.9
Year isolated
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The following conclusions were made:
In parallel with the overall incidence of isolation, E. coli remained the most frequently
isolated pathogen during the study period, followed by Klebsiella spp. There was a
general decrease in the percentage ofE. coli isolated throughout the first six years of
the study period, although this percentage levelled out over the final six years of the
study, with an average frequency of isolation of 50%. The incidence ofPsendomonas
spp. isolated, fluctuates greatly over the years, peaking in 1982, with an isolation rate
of 21.7%, in contrast with only 3.3% in 1990. Despite the increase in use of later
generation cephalosporins over the last decade, there appears to be no obvious trend
to the regularity of isolation of any of the other species.
2.2. Minimum inhibitory concentrations of survey strains
MICs were performed on all isolates of Gram negative aerobic bacilli, usually at the
time of isolation, to monitor the incidence of resistance to a variety of antimicrobials
(the number of antibiotics increasing as newer drugs became available) on either DST
or 1ST agar. It should be noted that for most of the antibiotics used here there is no
difference for MIC values between the two media. The exception are MICs performed
for X. maltophilia. This shall be further discussed in a later section.
Some of the early MIC work was performed by various members of staff from the
clinical bacteriology section of the department.
Although recently introduced into the UK, the carbapenems; imipenem and
meropenem (not yet licensed for use) and the quinolone ciprofloxacin were added to
the survey in 1991. It is expected that the use of these agents will increase in the
future. They were therefore included to determine whether there was any underlying
resistance to these drugs amongst the survey strains. All strains that were successfully
reconstituted from lyophilised cultures were tested against these agents.
The numbers ofmost of the different species isolated annually were too small to attain
statistical significance, and invalidated any attempt to evaluate trends in the incidence
of resistance to different antimicrobials over the twelve year period for each species.
The incidence of resistance of each species to various antimicrobials was therefore
calculated en bloc. The minimum inhibitory concentration for 50% and 90% of strains
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of strains respectively, against a particular antibiotic (MIC50, MIC90 values) and
MIC range for all the isolates collectively were determined. Sensitivity breakpoints
were as recommended by the British Society for Antimicrobial Chemotherapy
Working Party (BSAC) [212],
2.3. Overall resistance of the survey strains to various
antimicrobials
Table 22 lists overall MIC data for all species investigated. The highest incidence of
resistance to all strains was for ampicillin (63%). Overall resistance to aminoglyosides
was surprisingly high (gentamicin 12%, tobramycin 15% and netilmicin 21%)
although this may be explained by the number of resistant strains that fell close to the
breakpoint. Cumulative MICs for aminoglycosides to all species are shown in figure
13. Ceftazidime was the most effective cephalosporin with 16% resistance,
cefotaxime resistance was 21% and as expected, the second generation cephalosporin,
cefuroxime was the least effective cephalosporin with 32% resistance. The efficacy of
ciprofloxacin was similar to that of imipenem and meropenem.
Figure 13.















Minimum inhibitory concentration (mg/l)
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Table 22.
Sensitivity of Gram negative aerobic bacilli isolated during 1980-








Ampicillin 1431 32 >256 <0.12->256 63 8
Gentamicin 1402 0.5 2 <0.12 ->256 12 1
Tobramycin 1027 1 2 <0.12 ->256 15 1
Netilmicin 1016 0.5 2 <0.12 ->256 21 1
Piperacillin 735 2 32 <0.12->256 21 16
Cefuroxime 1434 4 256 <0.12 ->256 32 4
Cefotaxime 1441 <0.12 8 <0.12 ->256 21 1
Ceftazidime 737 0.25 4 <0.12 ->256 16 2
Imipenem 1178 0.12 2 <0.008 - >256 4 4
Meropenem 1178 0.016 0.12 <0.018 ->256 2 4
Ciprofloxacin 1176 0.5 0.5 <0.12->256 3 1
BP = breakpoint (mg/1)
%R = percentage resistant
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2.4. Breakdown of bacterial genera or species and the
incidence of resistance within each genus
It is well known that intrinsic resistance within various bacterial species may produce
a bias, therefore, for a more informative and complete evaluation of resistance
patterns, the incidence of resistance within each genus/species was determined (tables
23-31).
Table 23.
Sensitivity of Escherichia coli isolated during 1980-1991 from blood






Ampicillin 724 8 >256 0.12 ->256 49 8
Gentamicin 718 0.5 1 0.12-256 5 1
Tobramycin 535 1 1 0.12- 16 10 1
Netilmicin 533 0.5 1 0.12- 16 7 1
Piperacillin 333 2 128 0.12->256 25 16
Cefuroxime 723 2 4 0.12->256 9 4
Cefotaxime 728 <0.12 0.12 <0.12->256 4 1
Ceftazidime 334 <0.12 1 <0.12-64 3 2
Imipenem 585 0.03 0.5 <0.008 - 1 0 4
Meropenem 589 0.016 0.016 <0.008 - 0.5 0 4







Sensitivity of Klebsiella spp. isolated during 1980-1991 from blood








Ampicillin 143 64 >256 2 - >256 83* 8
Gentamicin 137 0.5 1 0.12 >256 5 1
Tobramycin 75 0.5 1 0.12-64 5 1
Netilmicin 70 0.5 1 0.12 - 128 4 1
Piperacillin 79 2 8 0.12 ->256 10 16
Cefuroxime 143 2 8 0.12 ->256 9 4
Cefotaxime 143 <0.12 0.12 <0.12-2 3 1
Ceftazidime 79 0.12 2 <0.12-2 8 2
Imipenem 114 0.25 1 <0.008 - 2 0 4
Meropenem 114 0.016 0.03 <0.008 - 1 0 4
Ciprofloxacin 120 <0.12 0.25 <0.12-0.25 0 1
BP = breakpoint (mg/1)
%R = percentage resistant
* See section 2.4.2 p 93
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Table 25.
Sensitivity of Proteus!Morganella spp isolated during 1980-1991 from
blood cultures to 11 antimicrobial agents
Antibiotic Number (mg/1) Range %R BP
tested MIC™ MICon
Ampicillin 89 4 >256 0.25 - >256 42 8
Gentamicin 86 0.5 2 0.25 - 2 10 1
Tobramycin 66 0.5 2 0.12-4 9 1
Netilmicin 67 0.5 2 <0.12-64 15 1
Piperacillin 50 0.5 16 <0.12-64 6 16
Cefuroxime 91 2 32 <0.12- 128 19 4
Cefotaxime 91 <0.12 0.12 <0.12-8 4 1
Ceftazidime 50 <0.12 1 <0.12-4 4 2
Imipenem 72 1 >4 0.03 - >4 10 4
Meropenem 72 0.06 0.25 <0.008 ->4 2.8 4







Sensitivity of Enterobacter spp. isolated during 1980-1991 from blood








Ampicillin 97 64 >256 0.25 - >256 87 8
Gentamicin 95 0.5 64 <0.12- 128 14 1
Tobramycin 63 1 8 <0.12- 16 25 1
Netilmicin 61 0.5 16 1 - >256 21 1
Piperacillin 54 2 >256 1 - >256 15 16
Cefuroxime 97 8 >256 0.25 - >256 70 4
Cefotaxime 98 0.25 8 <0.12- 128 24 1
Ceftazidime 54 0.5 16 <0.12 - 128 22 2
Imipenem 83 0.5 1 0.016-2 0 4
Meropenem 83 0.03 0.06 <0.008 - 0.25 0 4
Ciprofloxacin 83 <0.12 0.25 <0.12-2 4 1
BP = breakpoint (mg/1)
%R = percentage resistant
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Table 27.
Sensitivity ofAcinetobacter spp. isolated during 1980-1991 from
blood cultures to 11 antimicrobial agents
Antibiotic Number (mg/1) Range %R BP
tested MICsn MICQO
Ampicillin 86 32 128 <0.12->256 74 8
Gentamicin 84 1 2 <0.12 - 128 18 1
Tobramycin 67 1 8 <0.12-32 30 1
Netilmicin 66 2 32 <0.12-256 55 1
Piperacillin 42 16 64 0.5 ->256 48 16
Cefuroxime 87 16 64 <0.12 - 128 77 4
Cefotaxime 88 8 16 <0.12- 128 84 1
Ceftazidime 42 4 32 <0.12- 128 71 2
Imipenem 73 0.06 0.25 0.008 - >4 0.7 4
Meropenem 75 0.25 0.5 <0.008 - >4 0.7 4
Ciprofloxacin 74 0.25 1 <0.12-4 5 1
BP = breakpoint (mg/1)
%R = percentage resistant
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Table 28.
Sensitivity of Citrobacter spp. isolated during 1980-1991 from blood
cultures to 11 antimicrobial agents
Antibiotic Number (mg/1) Range %R BP
tested MIC™ MIC90
Ampicillin 25 256 >256 1 - >256 76 8
Gentamicin 24 0.5 64 0.25 - 128 17 1
Tobramycin 20 1 8 0.25 ■- 8 30 1
Netilmicin 20 0.5 8 0.12- 16 25 1
Piperacillin 17 4 64 1 - >256 18 16
Cefuroxime 25 8 64 0.25 - >256 56 4
Cefotaxime 25 0.25 2 <0.12--32 28 1
Ceftazidime 17 2 16 <0.12-■64 29 2
Imipenem 20 0.25 1 0.016 -2 0 4
Meropenem 20 0.03 0.25 <0.008 -2 0 4
Ciprofloxacin 20 0.06 0.5 <0.12 - 1 0 1
BP = breakpoint (mg/1)
%R = percentage resistant
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Table 29.
Sensitivity of Serratia spp. isolated during 1980-1991 from blood
cultures to 11 antimicrobial agents
Antibiotic Number (mg/1) Range %R BP
tested MlCsn MICon
Ampicillin 64 16 >256 0.25 - >256 69 8
Gentamicin 59 0.5 1 0.25 - 4 3.4 1
Tobramycin 57 1 2 <0.12-4 19 1
Netilmicin 54 0.5 2 <0.12-4 30 1
Piperacillin 25 2 4 <0.12 - 8 0 16
Cefiiroxime 64 32 256 1 - >256 89 4
Cefotaxime 64 0.12 2 <0.12-8 9 1
Ceftazidime 25 0.25 2 <0.12-4 12 2
Imipenem 44 0.25 1 0.016-2 0 4
Meropenem 44 0.03 0.06 <0.008 -2 0 4







Sensitivity of Pseudomonas spp. isolated during 1980-1991 from
blood cultures to 11 antimicrobial agents
Antibiotic Number (mg/1) Range %R BP
tested MIC™ MICQO
Ampicillin 129 >256 >256 <0.12 ->256 95 8
Gentamicin 125 1 4 0.5 ->256 44 1
Tobramycin 92 0.5 1 <0.12-256 8 1
Netilmicin 93 2 8 0.25-32 66 1
Piperacillin 81 4 64 <0.12-64 15 16
Cefuroxime 129 256 >256 <0.12->256 88 4
Cefotaxime 129 4 8 <0.12->256 88 1
Ceftazidime 82 2 32 <0.12 - 128 42 2
Imipenem 114 2 >4 <0.008 - >4 10 4
Meropenem 114 0.25 1 <0.008 - >4 3.5 4
Ciprofloxacin 113 0.25 1 <0.12-8 6 1
BP = breakpoint (mg/1)
%R = percentage resistant
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Table 31.
Sensitivity ofXanthomonas maltophilia isolated during 1980-1991
from blood cultures to 11 antimicrobial agents
Antibiotic Number
tested
(m<?/l) Range %R BP
MIC50 MICqo
Ampicillin 31 64 >256 1 - >256 97 8
Gentamicin 30 16 64 0.5 - 128 83 1
Tobramycin 25 8 32 0.25 - 64 72 1
Netilmicin 26 8 128 <0.12-256 81 1
Piperacillin 23 16 64 4 - 64 26 16
Cefuroxime 31 >256 >256 >256 100 4
Cefotaxime 31 16 64 1 - 128 87 1
Ceftazidime 23 4 16 0.5 - 16 50 2
Imipenem 24 >4 >4 100 4
Meropenem 24 >4 >4 100 4
Ciprofloxacin 24 8 64 0.5 - 64 87.5 1
BP = breakpoint (mg/1)
%R = percentage resistant
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In brief, the results of individual species are as follows:
2.4.1. Escherichia coli
E. coli comprised the largest proportion of species tested. The penicillins, ampicillin
and piperacillin (49% and 25% resistance respectively) proved to be the least effective
antimicrobial against this pathogen. In general, the aminoglycosides exhibited a
slightly higher level of resistance than the second and third generation cephalosporins
tested. The newer antibiotics, meropenem and imipenem (carbapenems) and the
quinolone, ciprofloxacin were extremely active against this species, with no resistance
to these drugs from any of the strains ofE.coli tested.
2.4.2. Klebsiella spp.
Apart from ampicillin (83% resistance, although it is generally accepted that all
Klebsiella spp. are intrinsically resistant to ampicillin), the incidence of resistance to
all other antimicrobials was similar to that of E. coli, although resistance to
piperacillin was 15% less than that to E. coli. Again, there was no resistance to the
carbapenems or to ciprofloxacin.
2.4.3. Proteus/Morganella spp.
Proteus/Morganella spp.were more resistant to cefuroxime (19% resistance) than
either E. coli or Klebsiella spp. Three strains were resistant to ciprofloxacin, although
the MIC values for all three isolates were only one doubling dilution higher than the
breakpoint value. The Proteeae were the only members of the Enterobacteriaceae to
demonstrate any resistance to the carbapenems, with 10% resistance to imipenem and
2.8% resistance to meropenem respectively.
2.4.4. Species that produce a Class I cephalosporinase
In general, all these species were much more resistant to almost all classes of
antimicrobials tested, than were the other genera, particularly to the cephalosporins,
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aminoglycosides and penicillins. There was virtually no resistance to the two
carbapenems. One strain of Acinetobacter baumannii exhibited resistance to these
drugs. Ciprofloxacin was again a very useful agent, highly effective against all strains
examined.
2.4.5. Pseudomonas spp.
Pseudomonas spp. as expected, were resistant to most classes of antimicrobials.
Tobramycin was the most effective aminoglycoside of the three examined. The
carbapenems and ciprofloxacin remained active for most strains.
2.4.6. Xanthomonas maltophilia
X. maltophilia proved to be resistant to most of the antimicrobials tested. Piperacillin
proved to be the most useful with only 26% of strains resistant. It has been recently
reported that the type of media used, can affect the susceptibility ofX maltophilia to
various compounds [226-228], These results may not truly reflect the level of
resistance. The susceptibility of this species shall be examined in more depth in a later
section (5.2.).
In conclusion:
The survey demonstrated that there was a higher than expected level of resistance to
almost all classes of antimicrobials, including later generation cephalosporins and
aminoglycosides. Only the carbapenems and ciprofloxacin showed excellent activity
against most isolates.
One of the original aims of this thesis was to establish the resistance mechanism of
these strains to later generation cephalosporins and 245 cefuroxime resistant strains




Strains from the main survey, that were resistant to cefuroxime (>4 mg/1, as
recommended by BSAC guidelines) were selected to examine their B-lactamase
complement. All strains ofPseudomonas spp. and X. maltophilia were excluded. The
distribution of species is shown in table 32. Their sensitivity values and percentage
resistance to a range of antimicrobials is shown in table 33.
Table 32.











The cefuroxime-resistant population demonstrated the presence of a large proportion
of organisms such as Enterobacter spp. and Serratia spp. that are known to produce
an inducible Class 1 cephalosporinase. There are also a large number ofAcinetobacter
spp. present (59), although it is of some debate whether these organisms produce a
typical inducible cephalosporinase. There was a surprising number of E. coli isolates
resistant to cefuroxime (44). On closer scrutiny of the MIC data, it was seen that 24
of these strains fell only one dilution above the breakpoint value (data not shown).
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Table 33.
Sensitivity values for the 245 cefuroxime resistant strains to other
antimicrobials
Antibiotic Number tested % Resistant Break point
(mg/1)
Ampicillin 245 93 8
Gentamicin 242 15 1
Tobramycin 152 29 1
Netilmicin 151 39 1
Piperacillin 150 27 16
Cefuroxime 245 100 4
Cefotaxime 245 46 1
Ceftazidime 150 36 2
Imipenem 225 0.8 4
Meropenem 225 0.4 4
Ciprofloxacin 226 2.2 1
As expected almost all the cefuroxime-resistant strains were also resistant to
ampicillin. Gentamicin was the most effective of the aminoglycosides, with an overall
resistance of 15%. Resistance to ciprofloxacin was 2.2%. The carbapenems
demonstrated the highest level of activity against all species, with <1.0% resistance
for both drugs.
These results demonstrate that the cefuroxime-resistant population displays cross
resistance to other classes of antimicrobials. Only one strain was resistant to both
carbapenems. This was a strain ofA. baumannii 6B92.
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3.1. Analytical isoelectric focusing of the B-lactamases
produced by the cefuroxime-resistant population
The B-lactamase complement of all the cefuroxime-resistant strains was determined by
analytical isoelectric focusing of small-scale crude B-lactamase extracts. The plasmid
mediated B-lactamases, TEM-1 and SHV-1 were used as standard B-lactamases. The
gels were also quantified with the use of standard isoelectric point marker enzymes.
This allowed for the presumptive identification of the B-lactamases present as to
whether they were of plasmid or chromosomal origin. A representative gel is shown
(see figure 14). The distribution of the presumptive B-lactamases present in the 245
cefuroxime-resistant isolates is shown in table 34. No attempt was made to distinguish
between chromosomal B-lactamase types e.g. E. cloacae P99 B-lactamase, and these
B-lactamases are simply referred to as chromosomal B-lactamases.
Table 34.
Distribution of B-lactamases present in the 245 cefuroxime isolates
examined
Bacterial Chromosomal Chromosomal Plasmid None Uncertain
species B-lactamase and plasmid B-lactamase identification
alone B-lactamases alone
Enterobacter 49 10 (TEM-1) 1 (SHV-1) 1
spp.
Acinetobacter 56 1 (TEM-1) 1 1 (pi 6.65)
spp.
Serratia 36 1 (TEM-1)
spp.
Escherichia 22 14 (TEM-1) 4 (TEM-1) 1
coli 3 (SHV-1)
Klebsiella, spp. 8 1 (SHV-1) 2 (SHV-1)







Total 198 28 (TEM-1) 4 (TEM-1) 7 1
1 (SHV-l) 6 (SHV-1)
Results
Figure 14.
Analytical isoelectric focusing of B-lactamases from cefuroxime-
resistant strains
1 2 3 4 5 6 7 8 9 10 11 12
IEF gel contained ampholines pH range 3.5-10.6.
Lane 1 Achromobacter xylosoxidans 9B49
Lane 2 Acinetobctcter anitratus 9B138
Lane 3 Acinetobacter anitratus 9B208
Lane 4 Citrobacter freundii 9B219
Lane 5 Acinetobacter anitratus 9B322
Lane 6 TEM-1 6-lactamase (pl 5.4)
Lane 7 SHV-1 6-lactamase (pi 7.6)
Lane 8 Acinetobacter anitratus 9B330
Lane 9 Serratia marcescens 9B337
Lane 10: Serattia marcescens 9B364
Lane 11: Knterobacter spp. 10B38
Lane 12: Serratia spp. 10B53
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In summary, of 245 cefuroxime resistant strains examined; 198 produced a
chromosomal enzyme alone, 28 produced a chromosomal enzyme plus the TEM-1 13-
lactamase, 1 produced a chromosomal 13-lactamase plus the SHV-1 G-lactamase, 6
produced the SHV-1 B-lactamase alone. Four produced the TEM-1 13-lactamase
alone. Seven strains failed to produce a detectable B-lactamase. One strain of A.
baumannii 6B92 produced a chromosomal enzyme and an unknown B-lactamase, that
focused with a pi of 6.65.
These findings would suggest that the cefuroxime resistance in most of these strains
would result from the production of a 'typical' chromosomal B-lactamase. No strain
appeared to produce any of the extended-spectrum plasmid-mediated enzymes,
derived from the common plasmid-mediated B-lactamases, TEM-1 and SHV-1. To
attempt to confirm this statement, conjugation experiments were performed on the
245 cefuroxime strains. It should be noted, however, that other mechanisms of
resistance such as permeability and change in affinity for PBPs should not be
discounted.
3.2. Conjugation experiments
Conjugation experiments were carried out with E. coli J62-2. E. coli J62-2
transconjugants were selected on suitably supplemented DM agar containing
ampicillin (10mg/l) and rifampicin (25mg/l). Resistance patterns of the
transconjugants were determined by Stokes' disc sensitivity testing on 1ST agar.
The results of the conjugation experiments are shown in table 35. Twenty
transconjugants were obtained, and of these, 18 produced the TEM-1 B-lactamase
while 2 produced SHV-1. It was concluded that the other presumed plasmid-mediated
B-lactamases in the survey strains that were not transferred, were either carried on
non-transmissible plasmids, or that they had integrated into the host cell chromosome.
There was no evidence for production of plasmid-mediated, extended-spectrum B-
lactamases in these strains. Only the well known TEM-1 and SHV-1 B-lactamases
were encoded by the transconjugants. These results further substantiated the
statement that production of chromosomal cephalosporinases are largely responsible
for cefuroxime resistance in the survey strains.
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Table 35.








E. coli 1B4 TEM-1 Ap, Tp
E. coli 1B7 TEM-1 Ap, Tp
E. coli 1B51 TEM-1 Ap, Tp
E. coli 1B39 TEM-1 Ap, Tp
E. coli 1B104 TEM-1 Ap, Tp, Te
K. pneumoniae 2B64 SHV-1 Ap, Tp
E. coli 3B28 TEM-1 Ap, Tp
E. coli 3B91 TEM-1 Ap
E. coli 4B115 SHV-1 Ap
E. coli 5B90 TEM-1 Ap, Sm, Te
E. coli 5B101 TEM-1 Ap, Te
E. cloacae 6B242 TEM-1 Ap
E. cloacae 8B491 TEM-1 Ap
E. cloacae 9B230 TEM-1 Ap
E. coli 11B46 TEM-1 Ap, Te
E. coli 11B75 TEM-1 Ap, Sm, Te
E. coli 11B218 TEM-1 Ap, Te
E. coli 11B351 TEM-1 Ap, Sm
E.coli 12B453 TEM-1 Ap
E. coli 12B458 TEM-1 Ap
Abbreviations: Ap, ampicillin; Sm, streptomycin; Te, tetracycline, Tp, trimethoprim.
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4.0. Carbapenem resistance among the cefuroxime-
resistant survey strains
Another aim of this thesis was to examine any strain in the survey of cefuroxime
resistant strains that exhibited resistance to carbapenems. As previously mentioned,
one strain, Acinetobacter baumannii 6B92, was resistant to both carbapenems
(MIC>4 mg/1). This strain was isolated in 1985 from a 55 year old male from a
surgical ward in Edinburgh Royal Infirmary. Resistance to carbapenems in clinical
isolates of Acinetobacter spp. is very rare, and is usually the result of a presumed
permeability mutation, or altered PBPs, as a consequence of the heavy use of
imipenem. In this particular instance, imipenem was not available for clinical use at the
time.
The resistance mechanism to carbapenems in this strain was studied further.
4.1. Acinetobacter baumannii 6B92: Investigation of the
resistance mechanism to carbapenems
The mechanism of this resistance was investigated to determine whether it might be 13-
lactamase-mediated. The biochemical characterisation of the B-lactamases studied,
essentially follows the recommendations for the evaluation of novel B-lactamases as
proposed by Bush and Sykes [171],
4.2. Susceptibility testing
Stokes' disc sensitivity and MIC determinations are shown in Table 36. A baumannii
6B92 was resistant to all penicillins tested and resistant or of intermediate sensitivity
to all classes of cephalosporins. It was resistant to both the carbapenems, with MIC
values of 16.0 and 32.0 mg/1 for imipenem and meropenem respectively. Only
ciprofloxacin (0.25 mg/1) and gentamicin (0.5 mg/1) were effective against this strain.
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Table 36.






Ampicillin 10 Resistant >256
Piperacillin 75 Resistant -
Azlocillin 75 Resistant 128
Amp/Clavulanate* 30 Resistant >128
Cephaloridine 30 Resistant -
Cephalexin 30 Resistant -
Cefuroxime 30 Resistant 32
Cefotaxime 10 Intermediate 16
Ceftazidime 10 Intermediate 4
Cefoxitin 10 Resistant -
Trimethoprim 2.5 Resistant -
Gentamicin 10 Sensitive 0.5
Imipenem 10 Resistant 16
Meropenem - - 32
Aztreonam 30 Resistant -
Ciprofloxacin 1 Sensitive 0.25




A large-scale 13-lactamase preparation was prepared from 1L of nutrient broth.
Isoelectric focusing of the preparation, employing a broad range of ampholines (pH
3.5-10.6), revealed the presence of two B-lactamases. One enzyme produced several
satellite bands with a main band focusing at pi 6.65. The other enzyme focused poorly
and spread up the gel towards the cathode, with a pi of> 9.0 (figure 15).
It is known that all strains of Acinetobacter spp. produce a chromosomal
cephalosporinase of high pi, whereas the other B-lactamase present of pi 6.65 differs
from any other B-lactamase found in Acinetobacter spp.
This was a significant finding, and the enzymes were partially purified in order to
study their properties in more detail.
4.4. Molecular mass determination (Mr)
Both these enzymes were partially purified and their Mr determined by gel filtration
using a pre-calibrated Sephadex G-75 gel filtration column as described in Materials
and Methods. The samples were eluted with 50mM sodium phosphate buffer (pH
7.0). The elution of the standard proteins and B-lactamase activity from the G-75
column are shown in figure 16.
A standard curve of logjo molecular mass versus fraction number was drawn (data
not shown), and the Mr of the B-lactamases determined.




Isoelectric focusing ofAcinetobacter baumannii 6B92 B-lactamases
pi
1 2 3 4
IEF gel contained ampholines pH range 3.5 -10.6
Lane 1: TEM-1 B-lactamasc (pi 5.4)
Lane 2: TLE-1 B-lactamase (pi 5.55)
Lane 3: wide range pi markers 4.7-10.6
Lane 4: Acinetobacter baumannii 6B92
Lane 5: OXA-1 ft-lactamase (pi 7.4)
Lane 6: OXA-4 ft-lactamase (pi 7.5)
Lane 7: SHV-1 ft-lactamase (pi 7.6)
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Figure 16.
Relative rate of hydrolysis of nitrocephin by B-lactamases from
Acinetobacter baumannii 6B92 eluted from G-75 Sephadex column
-210 ~ p.M nitrocephin hydrolysed/min/ ml enzyme Absorbance
Fraction number
ofnitrocephin hydrolysed/ min/ ml ofenzyme solution Absorbancej
The isoelectric points and Mr determinations of the two B-lactamases suggested that
the enzyme of high pi was indeed a 'typical' chromosomal cephalosporinase of the
type described by Hood and Amyes [229], They are enzymes of high molecular mass,
and have been shown to focus poorly in conventional systems [229], These
chromosomal B-lactamases have been shown to have no activity against carbapenems
[188], Attention was therefore centred on the enzyme that focused sharply at pi 6.65,
and enzyme kinetic experiments were performed to determine whether this B-
lactamase was capable of hydrolysing carbapenems.
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4.5. Hydrolysis of B-lactam antibiotics by the B-lactamase
of pi 6.65 from Acinetobacter baumannii 6B92
The enzyme preparation was concentrated before use in a centriprep® 10
concentrator (Amicon, Danvers, USA). The Michaelis constant (Km) and the
maximum rate of hydrolysis (Vmax) of the pi 6.65 enzyme were determined by
assaying the enzyme in decreasing substrate concentrations. The results are shown in
table 37. The values are expressed as a percentage of the value for penicillin.
Table 37.
Hydrolysis of B-lactam antibiotics by the B-lactamase of pi 6.65 from
Acinetobacter baumannii 6B92
Substrate I maxh Relative Vmi ixa K/rf
Penicillin 0.128 100 0.048
Ampicillin 0.196 153 0.139
Cephaloridine 0.07 35.7 0.083
a Relative to penicillin 100%
^ pmol of substrate hydrolysed/min /ml of enzyme solution
c mmol of substrate
Penicillin and ampicillin were hydrolysed weakly. The first generation cephalosporin,
cephaloridine was hydrolysed at about a third the rate of penicillin. Azlocillin was also
hydrolysed, but so slowly that it was impossible to calculate Vmax and Km values.
Hydrolysis of imipenem, meropenem, cefuroxime, cefotaxime and ceftazidime could
not be demonstrated by spectrophotometric methods even after prolonged assay
times.
These results do not show any evidence for carbapenemase activity; however, the




Although convenient, it is known that spectrophotometry is not suitable for assay of
all 13-lactamases. It was therefore decided to employ a microbiological assay.
Although time consuming, microbiological assays have been shown to be extremely
sensitive [230], The protocol was essentially that described by Masuda et al. [230],
The indicator organism employed was S. aureus NCTC 6571. Filter paper pads
containing 15pl of enzyme preparation neat or diluted 1:2, 1:4 or 1:8 in 50mM
phosphate buffer (pH 7.0) were placed at the periphery at the expected zone of
inhibition to the antibiotic discs.
4.6.1. Result
Any inactivation of substrate by the enzyme preparation was indicated by growth of
the indicator strain within the pre-determined zone of inhibition of the antibiotic. The
more dilute the enzyme preparation, the weaker the inhibition. This technique clearly
confirmed inactivation of imipenem (figure 17) and azlocillin (figure 18) by the B-
lactamase of pi 6.65. The zones of inhibition to the indicator strain by cefuroxime,
ceftazidime and cefotaxime were unaffected, confirming that these substrates were
not inactivated by the enzyme (figure 18).
This enzyme was thus designated ARI-1 (Acinetobacter resistant to imipenem).
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Figure 17.
Microbiological assay plate showing inactivation of imipenem by
Acinetobacter baumannii 6B92 ARI-1 b-lactamase
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Figure 18.
Microbiological assay plate showing action ofAcinetobacter








The effects of inhibitors, expressed as the concentration required for 50% inhibition of
enzyme activity (ID50) are shown in table 38. TEM-1 was included as a reference 13-
lactamase.
The ARI-1 enzyme required much higher amounts of clavulanate for inhibition than
TEM-1. P-chloromercuribenzoic acid (p-CMB) and EDTA did not inhibit the ARI-1
enzyme. Non-inhibition by EDTA would imply that metal ions play no part in the
catalytic activity of the enzyme, suggesting that ARI-1 functions by virtue of a serine
residue at the active site. ARI-1 was inhibited by BRL 42715, again suggesting the
presence of a catalytically active serine residue at the active site. TEM-1 was much
less susceptible to inhibition with imipenem and meropenem than the ARI-1 13-
lactamase. This indicates that the ARI-1 B-lactamase binds carbapenems.
Table 38.













Isolation of any plasmid DNA was unsuccessful despite the utilisation of three
differing plasmid DNA isolation techniques [220-222], All these methods are
essentially based on alkaline denaturation of chromosomal DNA but with differing
procedures for extraction and purification of plasmid DNA. One method has been
shown to be especially suitable for isolation of plasmid DNA from Acinetobacter spp.
[222],
Several of the gels confirmed the presence of a small plasmid (6.5kb), however the
physical loss of this plasmid could not be demonstrated in the cured strain. The small
size of this plasmid and its continued presence in the cured strain would make it
unlikely that it harboured the gene responsible for carbapenem resistance. The failure
to demonstrate physically the presence of a plasmid would therefore suggest the gene
is located on a large plasmid, which has broken up during the extraction procedure.
Transfer of resistance was attempted by conjugation to E. coli J62-2, Ps. aeruginosa
PA08 and a wild strain of A. baumannii. No transfer was obtained, suggesting the
possibility of a small plasmid unable to code for its own transfer. Mobilisation of
resistance was then attempted with the incV plasmid RP4. No transfer of resistance
was obtained, despite varying the incubation temperature (30°C and 37°C) and times
of incubation of the donor and recipient.
No transfer of plasmid DNA was detected by transformation to E. coli C600, it is
known that small pieces of DNA are transferred more efficiently by transformation
than large molecules, which would suggest again the possibility of a large plasmid.
It was concluded from the results of the genetic experiments that the gene that
encodes for ARI-1 was either located on the host cell chromosome or more probably
on a large plasmid, which has not been visualised or transferred.
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4.9. Plasmid curing experiments
In a final attempt to assert the extrachromosomal location of the genetic determinant
responsible for carbapenem resistance it was decided to employ plasmid 'curing'
experiments. Initial attempts involved the use of acridine orange as the curing agent.
Acridine orange preferentially inhibits plasmid replication [231], The method used
was that outlined by Caro et a/.[231],
4.9.1. Plasmid curing with acridine orange
Ten ml doubling dilutions of acridine orange (0.12 mg/1 - 1024 mg/1) were prepared in
nutrient broth, and 20pl of an overnight broth culture ofA. baumannii 6B92, grown
at 37°C was added. After overnight incubation at 37°C it was observed that A.
baumannii 6B92 was resistant to high concentrations of acridine orange (>1024
mg/1), and this dye was therefore unsuitable for plasmid curing for this particular
isolate. Another agent was required.
4.9.2. Plasmid curing with ethidium bromide
Ethidium bromide, a trypanocidal drug affecting nucleic acid was chosen. This agent
has been shown to eliminate some antibiotic resistance in bacteria, including
staphylococci and enterobacteria. Like acridine orange, ethidium bromide is
intercalated between base-pairs of DNA. It has previously been shown that ethidium
bromide eliminates antibiotic resistance at a higher frequency than acridine dyes [232],
The method chosen was that described by Bouanchaud et al. [232], which is
essentially similar to that for plasmid curing by acridine orange.
The experiment was performed as before. The growth of A. baumannii 6B92 was
visibly inhibited by 64 mg/1 of ethidium bromide. lOOpl of nutrient broth was
subcultured from this dilution onto antibiotic free medium (1ST agar). Forty distinct
colonies were tested for elimination of carbapenem resistance by subculturing onto
1ST agar and testing for imipenem resistance with a filter paper disc containing lOpg
of imipenem. The percentage rate of cure was 10%.
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Figure 19 presents a sensitivity plate inoculated with an imipenem resistant and
sensitive colony of A. baumannii 6B92. A four fold increase in size of the zone of
inhibition to imipenem, from 10 mm to 40 mm diameter was observed.
Figure 19.
Sensitivity plate inoculated with an imipenem resistant (right side)
and sensitive (left side) colony ofA. baumannii 6B92
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4.10. API profile of the cured strain
To ensure the integrity of the cured strain, an API 20NE identification strip was set
up. The API identification profile for both strains was identical.
4.11. Stability of loss of resistance to imipenem for the
cured strain
To determine whether the loss of resistance to imipenem was permanent. The cured
strain was grown overnight at 37°C in 10 ml of nutrient broth containing a sub-MIC
amount of imipenem (0.06mg/l). A 20pl amount of this dilution was sub-cultured into
the same imipenem containing broth over a 10 day period. A sensitivity plate was set
up each day from the inoculated broth and an imipenem disc placed onto the agar. No
resistant colonies were seen growing into the zone of inhibition of the imipenem disc
This suggests that the loss of resistance to imipenem was permanent.
The following conclusions may be made:
1. The genetic determinant of carbapenem resistance is located on a plasmid
which is not possible to visualise or isolate.
or
2. The genetic determinant is chromosomally based and the curing experiments
have effected a mutation in the host chromosome.
Either of these two statements are feasible, although the latter statement is unlikely
and the genetic location of the resistance gene is probably on a plasmid.
To determine the extent of loss of resistance to imipenem, and to other antimicrobials,
MICs and disc sensitivities were performed on the 'cured' strain.
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4.12. Susceptibility testing of the imipenem sensitive (cured)
strain ofA baumannii 6B92
Table 39 shows the MICs and disc sensitivities of the cured strain. The disc sensitivity
tests demonstrated loss of resistance to all penicillins and carbapenems. This was
further confirmed by MIC data, as MICs of penicillins were reduced by a factor of at
least 8. The loss of resistance to the carbapenems was most marked, with the MIC of
imipenem and meropenem reduced by a factor of 128. The MICs of second and third
generation cephalosporins were not significantly reduced.
4.13. Isoelectric focusing of the cured strain ofA. baumannii 6B92
The loss of resistance markers to penicillins and carbapenems but not to other classes
of antimicrobials would strongly suggest that this resistance had been mediated by a
G-lactamase. To confirm whether there was any loss of 13-lactamase production by the
cured strain, it was subjected to isoelectric focusing as before.
It can be clearly seen that the cured strain contained only the diffuse (presumed




Disc susceptibility results and MICs of various antibiotics to both the










Ampicillin (10) R >256 I 16 16
Piperacillin (75) R - I -
Azlocillin (75) R 128 I 16 8
Amp/Clav* (30) R >128 I 8 8
Cephaloridine (30) R - R -
Cephalexin (30) R - R -
Cefuroxime (30) R 32 R 32 1
Cefotaxime (10) I 16 I 8 2
Ceftazidime (10) I 4 I 4 1
Cefoxitin (10) R - R -
Trimethoprim (2.5) R - R -
Gentamicin (10) S 0.5 S 0.5 1
Ciprofloxacin (1) S 0.25 s 0.25 1
Imipenem (10) R 16 s 0.12 128
Meropenem - 32 - 0.25 128
Aztreonam (30) R - R -
Abbreviations: R, resistant; I, intermediate; S, sensitive.
*2:1 ratio. The results are expressed in terms of ampicillin.
Not tested; +, MIC expressed as mg/1.
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Figure 20.
Isoelectric focusing ofAcinetobacter baumannii 6B92 R-lactamases
after curing experiments with ethidium bromide
1 2 3 4 5
IEF gel contained ampholines pH range 3.5-10.6
Lane 1: TEM-1 B-lactamase (pi 5.4)
Lane 2: SHV-1 B-lactamase (pi 7.6)
Lane 3: Acinetobacter baumannii 6B92 (parent strain)
Lane 4: Acinetobacter baumannii 6B92 (cured strain, B-lactamase activity of the enzyme of
pl>9.0 was stronger in other preparations)
Lane 5: Acinetobacter baumanni 6B92 (purified through G-75 sephadex column)
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In conclusion:
This result corroborates the findings from the other experiments. Once cured of
imipenem resistance with the subsequent loss of the ARI-1 B-lactamase the strain
displayed loss of resistance to penicillins and carbapenems. The loss of resistance was
most apparent for carbapenems. The MICs of second and third generation
cephalosporins were not significantly reduced suggesting that resistance to these 13-
lactams came from the chromosomal B-lactamase of high pi. There was still some
residual resistance to the penicillins, and this may be as a result of hydrolysis by the
chromosomal cephalosporinase. Carbapenems are not hydrolysed by Acinetobacter
chromosomal B-lactamases, and this would explain the more impressive loss of
resistance to these compounds.
The microbiological assay was also consistent with the sensitivity data. The cured
strain only displayed loss of resistance to those compounds that were inactivated by
the ARI-1 B-lactamase but not to those compounds to which inactivation or
hydrolysis could not be demonstrated.
The evidence for carbapenemase activity by the ARI-1 B-lactamase was almost
complete. One nagging concern, however, was that the genetic determinant of
carbapenem resistance could not be transferred to other species, that would allow the
expression of the ARI-1 B-lactamase to be examined in a well-characterised host. It
could still be argued therefore, that changes in outer membrane permeability or
alterations in PBPs could not be discounted and could contribute to carbapenem
resistance.
The recent availability ofBRL 42715, a suicide inhibitor of serine active site enzymes
has provided us with a simple method for this purpose. A recent publication has
successfully used this compound for evaluating the role of cephalosporinase activity in
Ps. aeruginosa resistant to imipenem [233],
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4.14. Sensitivity of A. baumannii 6B92 to the carbapenem/BRL
42715 combination
An MIC determination on both the cured and parent strain to imipenem and
meropenem was performed, with the addition of a fixed concentration ofBRL 42715
(4 mg/1) to all dilutions. An inoculum of 104 clu/spot was applied to 1ST agar and the
plates incubated overnight in air at 37°C.
The results are shown in table 40.
Table 40.
MIC values ofAcinetobacter baumannii 6B92 to carbapenems,
combined with the li-lactamase inhibitor BRL 42715
Antibiotic
MIC (mg/1)
6B92 (parent strain) 6B92 cured strain)
Imipenem 16.0 0.12
Imipenem + 4 mg/1 BRL 42715 0.12 0.06
Meropenem 32.0 0.25
Meropenem + 4 mg/1 BRL 42715 0.5 0.25
The results show that resistance to carbapenems by the parent strain has been
eliminated by the addition ofBRL 42715, the MICs have been reduced to almost the
same level as the MICs of the cured strain.
This final piece of evidence confirms the role of the ARI-1 B-lactamase to carbapenem
resistance in A. baumannii 6B92.
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5.0. The B-lactamases of the species Xanthomonas
maltophilia
5.1. Introduction
The species X maltophilia was excluded from the initial survey of cefuroxime-
resistant blood culture isolates because of its intrinsic resistance to this compound and
many other antimicrobials. As mentioned in the introduction, this resistance has been
attributed to the interplay between the production of a serine active site
cephalosporinase (L2), a metallo-B-lactamase (LI) and the impermeability of the
outer membrane.
There has been contrasting information concerning the production of (3-lactamases in
X maltophilia. Two recent studies have shown an unexpected heterogeneity among
B-lactamases produced by the species. Cullmann and Dick [205] examined 20
different strains and identified 6 distinct B-lactamases by virtue of their isoelectric
point. None of these strains produced more than one B-lactamase. They all
demonstrated the ability to hydrolyse carbapenems. None of these enzymes was
inhibited by EDTA, which suggests this carbapenem hydrolysing ability may not be
conferred by a metallo-B-lactamase. Mattionni et al. [204] reported similar data, with
the demonstration of 5 B-lactamases which also hydrolysed carbapenems and were
again differentiated solely by virtue of their isoelectric points. None of these two latter
surveys included strains which encoded for the production of the two chromosomal B-
lactamases (LI and L2), described originally by Saino et al. [123,203],
Recent studies have also shown that MICs of B-lactam antibiotics for X. maltophilia
isolates vary with the test medium employed [226-228],
The MIC determinations of the X. maltophilia isolates from the blood culture
susceptibility survey strains were originally performed on either DST or 1ST agar,
dependant on when they were isolated, and to what B-lactams they were tested
against. This generates a degree of uncertainty as to the validity of the previous MIC
work. For this reason, it was decided to re-examine these strains to determine any
difference in susceptibility to various antimicrobials on differing media. 1ST and
Mueller-Hinton agar are two of the most commonly used sensitivity test media, and
were therefore selected for use in this study. Some of these isolates were from the
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same patients but isolated at differing time intervals and were probably different
strains and not repeat isolates, they were therefore included in the survey. Strains
isolated in 1992, were also included to allow a larger population ofX. maltophilia to
be examined.
The aim of this part of the study was therefore twofold:
• To investigate the incidence and level of antimicrobial resistance of the species on
differing susceptibility test media. This would provide a clearer insight into the
susceptibility of these strains, and hopefully provide a guidance as to which
medium was the more suitable for susceptibility testing of this species.
• To attempt to clarify the production of B-lactamases in this species, which at best
can presently be described as confused, with particular attention to their role in
carbapenem resistance.
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5.2. Antimicrobial susceptibilities of AT. maltophilia isolates
The MIC determinations of the test strains were performed as described in Materials
and Methods. The test media employed were 1ST agar and MH agar. The results are
shown in tables 41 to 42.
In general, most strains were resistant to all antimicrobials tested, although there were
major differences in the MICs of many strains, dependant on the media employed.
Generally, the isolates were more sensitive to the B-lactams when MICs were
performed on 1ST agar, in many cases a four-fold decrease in resistance was observed
when compared to the values obtained for those on MH agar. The only B-lactam to
exhibit similar susceptibility values on both media was cefuroxime. All strains tested
exhibited MIC levels of >256mg/l to this compound. On the other hand, MIC values
for other classes of antimicrobials, such as gentamicin and ciprofloxacin on the two
media were more in agreement, although some significant discrepancies to these
agents were also observed on the different media. Strains 8B368, 8B376, 8B379 and
8B404, were all isolated from the same patient over approximately a one month
duration. The MIC values for each of these strains were different. Specifically, 8B376
was less resistant to most of the antimicrobials tested, particularly to gentamicin and
ciprofloxacin.
This result has serious implications for the clinical laboratory. If breakpoint values
were to be used, in some cases, strains tested on 1ST agar would have been reported
as sensitive to certain B-lactams, whereas on MH agar these strains would have been
designated as resistant. The nature of this anomaly has been investigated by other
workers, and will not be examined further in this thesis.
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Table 41.
MICs (mg/I) of the X. maltophilia isolates against various antibiotics
Ampicillin Piperacillin Azlocillin Cefuroxime Cefotaxime Ceftazidime
Strain 1ST MH 1ST MH 1ST MH 1ST MH 1ST MH 1ST MH
5B105 64 >256 16 >256 16 >256 >256 >256 16 128 8 >256
6B52 64 >256 16 128 4 16 >256 >256 16 128 8 >256
6B133 128 >256 32 >256 16 >256 >256 >256 16 128 8 >256
6B295 64 >256 16 >256 32 >256 >256 >256 16 128 16 >256
7B78 16 >256 8 64 4 16 >256 >256 1 64 4 128
8B368 128 >256 32 >256 16 64 >256 >256 16 16 4 8
8B376 16 64 16 16 2 16 >256 >256 1 8 1 8
8B379 64 128 64 >256 16 32 >256 >256 16 16 2 8
8B404 16 32 16 64 16 16 >256 >256 4 8 1 4
8B405 32 >256 16 128 16 32 >256 >256 32 128 4 64
9B123 64 256 4 64 4 16 >256 >256 8 32 1 8
9B266 128 >256 4 64 4 64 >256 >256 8 32 2 8
10B6 128 >256 32 128 16 32 >256 >256 32 64 4 64
10B44 32 >256 32 >256 16 64 >256 >256 4 32 1 16
10B411 32 >256 8 64 8 32 >256 >256 2 16 4 32
11B4 32 >256 16 128 8 32 >256 >256 4 32 2 16
11B29 128 >256 32 128 16 32 >256 >256 32 64 4 64
12B286 128 >256 16 128 4 32 >256 >256 16 128 8 128
12B346 64 >256 16 256 16 256 >256 >256 32 256 4 >256
12B457 1 >256 16 64 4 16 >256 >256 8 64 2 16
12B507 128 >256 16 >256 16 256 >256 >256 128 256 8 >256
13B35 128 >256 32 128 16 64 >256 >256 16 64 4 16
13B318 4 4 16 64 2 4 >256 >256 4 16 1 2
13B275 >256 >256 16 128 4 32 >256 >256 16 64 2 8
13B289 >256 >256 16 128 4 16 >256 >256 16 64 2 8
13B344 >256 >256 16 128 4 16 >256 >256 16 128 8 64
13B357 >256 >256 16 128 8 16 >256 >256 16 128 8 64
13B366 >256 >256 16 128 4 16 >256 >256 16 128 8 64
1ST; Isosensitest agar, MH Mueller Hinton agar.
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Table 42.
MICs (mg/1) of theX maltophilia isolates against various antibiotics
Ciprofloxacin Mcropenem Imipenera Gcntamicin Aztreonam
Strain ist mh ist mh ist mh ist mh ist mh
5B105 4 4 32 128 16 256 64 64 16 >256
6B52 8 8 32 128 64 128 64 128 64 >256
6B133 8 8 32 256 64 >256 64 128 64 >256
6B295 4 4 32 128 16 256 64 64 16 >256
7B78 4 4 4 64 4 256 2 4 64 256
8B368 32 32 64 64 16 256 4 16 64 >256
8B376 2 0.5 4 64 4 64 0.5 2 8 16
8B379 64 64 8 16 32 256 2 16 32 32
8B404 64 32 4 8 4 16 1 16 16 16
8B405 32 32 64 256 32 256 16 2 32 >256
9B123 8 4 32 128 16 256 64 64 32 >256
9B266 8 2 32 128 64 256 64 128 128 256
10B6 32 8 64 256 128 256 64 128 32 256
10B44 32 16 2 16 8 128 16 64 32 >256
10B411 4 2 16 128 16 256 16 4 16 32
11B4 16 8 2 32 4 128 16 2 64 256
11B29 32 8 64 256 128 256 64 2 32 >256
12B286 8 4 32 256 64 64 64 64 16 >256
12B346 8 2 32 256 16 128 64 32 32 >256
12B457 16 8 8 32 16 256 16 16 32 >256
12B507 4 2 32 256 32 >256 16 4 128 >256
13B35 32 16 16 128 16 256 64 64 32 64
13B318 8 4 4 8 64 64 64 32 32 128
13B275 8 16 2 8 32 64 16 32 32 >256
13B289 8 4 2 8 64 64 16 32 32 >256
13B344 16 16 64 128 64 256 64 256 128 >256
13B357 8 4 64 256 32 256 64 256 128 >256
13B366 8 16 64 128 64 256 64 256 128 256
1ST; Isosensitest agar. MH; Mueller Hinton agar
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6.0. Characterisation of% maltophilia B-lactamases
Initially, to investigate the B-lactamases from X maltophilia it was decided to employ
isoelectric focusing. This is an easy technique to perform, and would primarily allow
the detection of any obvious differences in the B-lactamase complement of this
species.
6.1. Preparation of B-lactamases
All 28 isolates ofX maltophilia were examined. Initial studies on the B-lactamases
from this species were performed on small scale B-lactamase preparations. The
activity of these preparations, as measured by the nitrocephin spot test, was found to
be very poor, with reaction times of greater than 30s. Subsequent analytical EEF of
these preparations was disappointing, with few strains exhibiting any detectable B-
lactamase activity (data not shown). Therefore, in an attempt to increase the yield of
B-lactamase produced, the isolates were subjected to induction of B-lactamase prior to
extraction of the enzyme.
6.2. Induction of small scale B-lactamase preparations
Induction of B-lactamase was as described in Materials and Methods. Cefotaxime,
which has previously been shown to be a potent inducer of X maltophilia B-
lactamases [228] was added at Va the MIC to the broth.
After induction of the strains under test, B-lactamase activity was found to be greatly
enhanced with the nitrocephin spot test reaction times for all isolates reduced to
between 1 and 5 seconds.
This result indicates that all B-lactamase production in these strains was inducible.
6.3. Analytical isoelectric focusing




Figures 21 to 23 show the result of the isoelectric focusing. Initial staining of the gel
with nitrocephin appeared to show the production of a single B-lactamase, usually of
basic pi, from each strain. The exception to this was a B-lactamase(s) that focused as
a series of bands of activity ranging from pi 5.2-6.8. This focusing pattern was the
most common among the survey strains and was present in seven of the 28 strains
examined (5B105; 6B52; 6B133; 6B295; 7B78; 12B286; 12B346).
These results would have been consistent with the findings of Cullmann et al. [205],
who also recognised a single B-lactamase in all of their strains. However, in this study,
it was observed that following prolonged staining, other bands of B-lactamase activity
were visualised in most strains, generally at lower pis than the initial B-lactamase. The
pi values are listed in Table 43. It was assumed that the increased time for these
enzymes to be visualised was as a result of their lower hydrolytic activity against
nitrocephin.
Strains 13B275 and 13B289 exhibited identical IEF patterns. These were isolated
from the same patient, but at different times. Strains 13B344, 13B357 and 13B366
also shared identical isoelectric focusing patterns as one another, 13B344 and 13B366
were from the same patient, 13B357 was isolated from another source. The strains
8B368, 8B376, 8B379 and 8B404 that were from a single patient, shared a common
B-lactamase profile, aside from 8B376 which only harboured the B-lactamase of pi
9.7, but not the two other bands of pi 5.4 and 4.95 seen in the other three strains.
Strain 8B376 was less resistant to many of the antibiotics examined than the other
isolates from this patient, which may in part be as a result of the loss of these
particular B-lactamases, although it should be noted that both gentamicin and
ciprofloxacin resistance was also diminished in this strain, indicating the inclusion of
other resistance mechanisms. The B-lactamase profile of strains 10B6 and 11B29
were identical, these were from different patients.
These results not only indicate a high level ofheterogeneity of B-lactamase production
in different isolates ofX. maltophilia, but also the presence of multiple B-lactamases
in these strains. The most common B-lactamase profile focused as a series of bands of
activity ranging from pi 5.2-6.8. This pattern was displayed by seven of the study
strains (table 43). All these strains were isolated from different patients over the entire
study period, and were therefore unlikely to be duplicate isolates.
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Figure 21.









1 2 3 4 5 6
IEF gel contained ampholines pH range 3.5-10.6
Lane 1: X maltophilia 5B105
Lane 2: X. maltophilia 6B52
Lane 3: X maltophilia 6B13 3
Lane 4: X maltophilia 6B295
Lane 5: X. maltophilia 7B78
Lane 6: X maltophilia 12B286
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Figure 22.
Isoelectric focusing of B-lactamases from X. maltophilia blood culture
isolates
pi
IEF contained ampholines pH range 3.5-10.6
Lane 1: X. maltophilia 8B368 Lane 2: X. maltophilia 8B376
Lane 3: X. maltophilia 8B379 Lane 4: X. maltophilia 8B404
Lane 5: TEM-1 (pi 5.4) Lane 6: SHV-1 (pi 7.6)
Lane 7: X. maltophilia 8B405 Lane 8: X. maltophilia 9B123
Lane 9: X. maltophilia 9B266 Lane 10: X. maltophilia 10B6
Lane 11: X. maltophilia 13B275 Lane 12: X. maltophilia 13B289
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Figure 23.
Isoelectric focusing of B-lactamases from X. maltophilia blood culture
isolates
1 2 3 4 5 6 7 8 9 10 11 12
IEF contained ampholines pH range 3.5-10.6
Lane 1: X. maltophilia 10B44 Lane 2: X. maltophilia 10B411
Lane 3: X. maltophilia 11B4 Lane 4: X. maltophilia 11B29
Lane 5: X. maltophilia 12B346 Lane 6: X. maltophilia 12B457
Lane 7: X. maltophilia 12B507 Lane 8: X. maltophilia 13B35
Lane 9: X. maltophilia 13B318 Lane 10: X. maltophilia 13B344
Lane 11: X. maltophilia 13B357 Lane 12: X. maltophilia 13B366
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Table 43.
Isoelectric points of fi-lactamases from
X. maltophilia
Strain number Isoelectric points of
fi-lactamases
5B105 6.8, 6.2, 5.55, 5.3
6B52 6.8, 6.2, 5.55, 5.3
6B133 6.8, 6.2, 5.55, 5.3
6B295 6.8, 6.2, 5.55, 5.3













12B286 6.8,6.2, 5.55, 5.3




13B318 10.0, 6.9, 5.4
13B275 9.0,6.2, 5.3






Conjugation experiments were performed on all strains. These conjugation
experiments were unsuccessful. Despite varying the incubation times and temperature
of the conjugations, no transconjugants were detected.
As discussed previously, it would appear that all B-lactamase production in this
species was inducible, and hence unlikely to be plasmid-mediated. These enzymes
were therefore assumed to be of chromosomal origin.
From these results, it was possible to portray at least twelve differing isoelectric
focusing patterns on IEF gels. These were thus designated as Xanthomonas
maltophilia chromosomal enzymes (XMCEs), and a tentative classification scheme
is shown in table 44, based upon the pi values of these enzymes.
6.5. Conclusions
This study has shown the wide diversity of chromosomal B-lactamases produced by X.
maltophilia, with some strains demonstrating multiple bands of activity.
The methodology employed in this study differentiated these enzymes solely on the
basis of their isoelectric point. Categorising B-lactamases by isoelectric point alone,
yields no information regarding substrate and inhibitor profiles, and therefore provides
insufficient criteria to determine whether these enzymes have diverse biochemical
properties.
Detailed biochemical investigations are essential to elucidate the full nature of these
enzymes.
XMCE type-1 was the most universal enzyme type detected, and may be a common
B-lactamase pattern among isolates ofX. maltophilia. Strain 5B105 was selected as
representative of the XMCE type-1 group, for detailed biochemical investigations.
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Table 44.
Classification scheme for X. maltophilia chromosomal B-lactamases
XMCE* type Strain (s) pl(s)
1 6B105, 6B52, 6B133, 6.8, 6.2, 5.55, 5.3
6B295, 7B78, 12B286,
12B346
2 8B368, 8B379, 8B404 9.7, 5.4,4.95
2a 12B457 9.7, 8.2
2b 8B376, 9B266 9.7
3 8B405 9.3, 6.2
4 9B123 7.8, 6.9
5 10B6, 11B29 6.7, 6.3
6 10B44 9.2, 5.9
7 10B411 9.4,6.3
8 13B318 10.0, 6.9, 5.4
8b 11B4 10.0, 5.5
9 12B507 10.1
10 13B35 9.3,6.1
11 13B275, 13B289 9.0, 6.2, 5.3
12 13B344, 13B 357 9.6,6.2
13B366
XMCE*, Xanthomonasmaltophilia chromosomal enzyme.
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7.0. Purification and biochemical characterisation of the
XMCE type-1 X. maltophilia B-lactamase 5B105
The biochemical characterisation was carried out as recommended by Bush and Sykes
[171].
7.1. Assessment of inducibility of B-Iactamase
Either cefotaxime or imipenem was employed as inducer, previous studies have
shown both these compounds to be strong inducers of X maltophilia B-lactamases
[204,226], They were added at lA the MIC. Nitrocephin (50mg/l) was used as the
reporter substrate. Protein estimation was measured by the method ofWaddell [218],
The kinetics of B-lactamase induction for strain 5B105 are shown in figure 24. When
imipenem or cefotaxime was added as inducer, B-lactamase activity increased sharply
after less than one hour. Imipenem was a more potent inducer of B-lactamase than
cefotaxime. No discernible B-lactamase activity was detected in disrupted cells
without the prior addition of inducer.
This result confirms that all B-lactamase activity was inducible. No enzyme activity










a, Log to nanomoles nitrocephin hydrolysed/min/mg of protein.
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7.2. Large scale preparation of B-lactamases
Imipenem was used as the inducer for all large scale preparations.
7.3. Isoelectric focusing
We have previously shown the presence of at least four main bands commensurate
with major B-lactamase activity (pi 6.8, 6.2, 5.55, 5.3) with two minor bands (5.2,
6.6) produced by strain 5B105.
In their guidelines for the evaluations of novel B-lactamases [171], Bush and Sykes
recommended that characterisation be performed with a homogeneous enzyme
preparation, or a minimum requirement would be the demonstration of a single B-
lactamase activity on isoelectric focusing. X. maltophilia 5B105 presents several
bands of activity, clearly the next stage was to determine whether these bands were
satellite bands produced by a single enzyme, or several discrete B-lactamases.
7.3.1. Isoelectric focusing with B-lactamase inhibitor
overlays
To further elucidate the nature of these B-lactamases it was decided to employ a
technique originally described by Bakken el a/. [234] for the tentative characterisation
of B-lactamases from Aeromoncis spp. This procedure involved overlaying an IEF gel
with filter paper strips soaked with various B-lactamase inhibitors; this easy to apply
technique might allow an initial distinction between these B-lactamases.
To allow the effect of the B-lactamase inhibitors on the bands of B-lactamase activity
to be studied with greater clarity, we endeavoured to improve the resolution of these
enzymes. A customised gel was prepared. This gel contained a 1:1 ratio of ampholines
with a pH range of 3.5-10.6 and 4-6. This would create a non-linear pH gradient, but
would increase the resolution of the B-lactamase bands in the pi 4-6 range.
The inhibitors were chosen for their selective action on specific classes of B-
lactamases.
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The inhibitors and concentrations used were:
1 ImM EDTA, metal ion chelator, known to inhibit metallo-13-lactamases.
2 ImM potassium clavulanate, an inhibitor of penicillinases and broad spectrum 13-
lactamases.
3 ImM aztreonam, an inhibitor of cephalosporinases.
4 lOOpM BRL 42715, an inhibitor of all serine active site (3-lactamases, but not
metallo-13-lactamases.
5 Cloxacillin, an inhibitor of cephalosporinases.
Isoelectric focusing was performed as before, the gels were stained with nitrocephin
after a 30 second overlay with the various inhibitors soaked in filter paper. A control
lane was established with no prior overlay of inhibitor. The results are shown in figure
25.
The 13-lactamase band of pi 6.8 was partially inhibited by the overlay ofEDTA prior
to staining, whereas all other bands were unaffected. Conversely, the other 13-
lactamase bands were completely inhibited by the overlay ofBRL 42715 and partially
inhibited by potassium clavulanate. Aztreonam and cloxacillin overlays appeared to
have no significant effect on any of the 13-lactamase bands.
The inhibitor overlays proved to be a useful tool, although it should be noted that the
results are qualitative, and no substitute for formal quantitative inhibitor profiles. The
following assumptions could be drawn: The band of activity of pi 6.8 was partially
inhibited by EDTA and may be a metallo-B-lactamase.The other three main bands
(6.2, 5.55, 5.3) were inhibited by BRL 42715 and potassium clavulanate. This result
would intimate that they were serine active site penicillinases or broad-spectrum 13-
lactamases, non inhibition by cloxacillin or aztreonam would infer that they were
unlikely to be cephalosporinases.
We have therefore demonstrated by a simple technique that X. maltophilia 5B105
encoding for XMCE type-1 produces at least 2 and possibly more 13-lactamases. The
Results
Figure 25.
Isoelectric focusing patterns ofX maltophilia 5B105
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IEF gel contained a 1:1 ratio of ampholines pH range 4-6 / 3.5-10.6
Lane 1: control
Lane 2: overlaid with lOOgM BRL 42715
Lane 3: overlaid with lniM aztreonam
Lane 4: overlaid with ImM cloxacillin
Lane 5: overlaid with linM clavulanate
Lane 6: overlaid with 1 mM EDTA.
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next stage was to purify these enzymes to enable their individual substrate and
inhibitor profiles to be examined in more detail.
7.4. Purification of fi-Iactamases by low pressure Sephadex
G-75 gel filtration chromatography
Two ml of a large scale cell-free extract prepared from 1L of MH broth, previously
induced with imipenem at lA the MIC, was applied to a Sephadex G-75 gel filtration
column, previously equilibrated with 50 mM Tris CI buffer (pH 8.0) containing 0.1
mM zinc sulphate. The sample was eluted with the same buffer with a flow rate of 12
ml/hour. B-lactamase activity was detected with nitrocephin as before.
7.4.1. Results
Most of the B-lactamase activity was detected in the fractions containing the void
volume. The G-75 gel matrix has a useful fractionation range of 1 x 10^ - 5 x 10^
daltons. This result demonstrates that these enzymes are of large Mr (>50kDa).
The apparent large molecular weight of these enzymes, might indicate these B-
lactamases exist in sub-unit form. This would not be unexpected, for previous B-
lactamases from these species have been shown to exist in sub-unit form [124,203],
7.5. Gel filtration on Sephadex G-150 gel column
The next stage was to attempt purification by employing a gel matrix with a wider
fractionation range. The G-150 Sephadex gel matrix was chosen. This gel has a Mr
fractionation range of up to 1.5 x 10^ daltons.
The column was calibrated with the molecular weight standards alcohol
dehydrogenase (150000), bovine serum albumin (66000) and cytochrome C (12384).
The samples were eluted at the same rate of flow and with the same buffer used for
the G-75 column. Any B-lactamase activity present was initially identified with the
nitrocephin spot test. Fractions displaying B-lactamase activity were then assayed
spectrophotometrically employing either nitrocephin (lOOpM) or imipenem (ImM) as
reporter substrates. This would provide the following information:
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Nitrocephin hydrolysis would indicate total fi-lactamase activity (assuming all 13-
lactamases present hydrolysed this compound). Imipenem hydrolysis would indicate
the presence of any carbapenemase activity.
7.5.1. Results
All 13-lactamase activity was confined within the molecular weight fractionation range
of the column. Spectrophotometric analysis of the fractions eluted from the G-150
column (figure 26) and subsequent isoelectric focusing (figure 27), confirmed the
presence of at least two distinct enzymes. The B-lactamase with a pi of 6.8 eluted first
from the column and hydrolysed imipenem as well as nitrocephin, the other fi-
lactamase bands eluted from the column at the same rate, and hydrolysed nitrocephin
but not imipenem.
Figure 26
Relative rate of hydrolysis of imipenem and nitrocephin by B-





Isoelectric focusing patterns of ft-lactamases from X. maltophilia
5B105 eluted from Sephadex G-150 column
IEF gel contained ampholines pH range 3.5-9.5
Lanes 1-19:
Lane 20:
Fifteen pils of every second fraction eluted from G-150 Sephadex
column (fractions 52-88) applied to the gel.
Concentrated B-lactamase preparation ofX maltophilia 5B105.
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7.5.2. Molecular mass of B-lactamases
By comparison of peak activity with the standard proteins [216],The Mr of the B-
lactamase of pi 6.8 was calculated as 96 kDa, whereas the Mr of the B-lactamases of
pi <6.8 was 48kDa.
7.5.3. Conclusions
The previous result affirms the presence of at least two B-lactamases, both of high
Mr. This suggests that these enzymes may have aggregated and exist in sub-unit form.
We have also ascertained that the B-lactamase of pi 6.8 is a carbapenem hydrolysing
B-lactamase, and is probably a metallo-B-lactamase as a result of its inhibition by
EDTA. The other B-lactamase(s) present a more difficult problem. They appear to
share a similar inhibitor profile and elute from the gel filtration column at the same
rate, suggesting similar Mr.
Proteins can generally be separated by two components; their Mr and by their charge.
We have shown that in their native form, the B-lactamases of pi <6.8 have similar Mr.
Therefore, it would seem logical to attempt to separate these enzymes by their charge
(isoelectric point). Before we could do this we had to ascertain whether these multiple
bands of fi-lactamase activity were satellite bands emanating from a single enzyme, or
whether they were distinct B-lactamases.
7.6. Purification of B-lactamases by electrodialysis
Payne [235], demonstrated that when a B-lactamase satellite band was excised from a
gel, re-purified by electrodialysis and applied to an LEF gel and re-separated, the
satellite band migrated to the original pi of the B-lactamase, and not to the pi from
which it was excised.
This technique was applied to the B-lactamases of pi <6.8. The technique used was
that described by Payne et al. [236], The results are shown in figure 28.
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Figure 28.









1 2 3 4
IEF gel contained a 1:1 ratio of ampholines pH range 4-6 / 3.5-10.6
Lane 1: Original B-lactamase preparation from 5B105
Lanes 2-4: fi-lactamases bands (5.3, 5.55, 6.2) purified by electrodialysis.
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7.6.1. Results
After separation by IEF and subsequent staining with nitrocephin, each preparation
focused as a single band at exactly the same pi it had originally migrated to, indicating
that each B-lactamase was a discrete B-lactamase rather than satellite banding.
The small yield of enzyme made this technique unsuitable for purification of enzyme
for further studies.
This work has confirmed that the XMCE type-1 B-lactamase profile from X.
maltophilia 5B105 is comprised of several discrete B-lactamases. Therefore, the next
stage was to obtain enough pure enzyme solution of individual B-lactamases to allow
further studies on their properties.
Initially, it was decided to use the following technique:
High performance ion exchange chromatography employing the Fast Protein
liquid Chromatography (FPLC®) (Pharmacia) system.
Hopefully this would provide us with enough pure B-lactamase solution of each
enzyme to perform detailed Mr experiments, substrate and inhibitor profiles.
7.7. FPLC of the B-lactamases from X. maltophilia 5B105
7.7.1. Methodology
The fractions eluted from the G-150 column containing significant B-lactamase
activity were pooled (80ml) and concentrated to 5 ml in a Centriprep® 10
concentrator with a nominal molecular mass limit of lOkDa. One ml of the extract
(5.44 mg protein) was applied to a Mono Q (HR 5/5) prepacked anion exchange
column, previously equilibrated with 20 mM Tris CI (pH 8.0) buffer containing 0.1
mM zinc sulphate. After washing, the elution was carried out with a continuous linear
gradient ofNaCl (1.0M) with a flow rate of 1 ml/min. Thirty-four 1ml fractions were




The trace of the FPLC separation of protein fractions is shown in figure 29.
Figure 29.
FPLC® trace of high performance anion exchange (Mono Q) of the























(—Protein peaks —NaCI concentration)
B-lactamase activity was detected within fractions 4-12, although very small or no
protein peaks were visible on the trace at these areas. Biological activity of all
fractions was weak with nitrocephin spot test times of>30 seconds.
The fractions were applied to an IEF gel as before to determine whether the different
B-lactamase bands were successfully separated. The IEF is shown in figure 30. The
pis of the B-lactamase(s), and protein concentrations contained in those fractions are
shown in table 45.
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Figure 30.
Isoelectric focusing of R-lactamases from X. maltophilia
5B105 eluted from anion exchange step
1 2 3 4 5 6 7 8 9 10 11 12
IEF gel contained ampholines pH range 3.5-10.6
Lane 1: Original B-lactamase preparation
Lane 2: TEM-1 andSHV-1 B-lactamases
Lane 3: fraction 2 Lane 4: fraction 3
Lane 6: fraction 5 Lane 7: fraction 6
Lane 9: fraction 8 Lane 10: fraction 9
Lane 12: fraction 12
Lane 5: fraction 4
Lane 8: fraction 7
Lane 11: fraction 10
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Table 45.
Isoelectric points of B-lactamases eluted from anion exchange step
Fraction number Isoelectric point of Protein








10 5.3, 5.55, 6.2, 6.8 -
11 5.3, 5.55, 6.2, 6.8 0.297
12 5.3 0.067
not determined
The IEF gel shows that the G-lactamase of pi 6.2 eluted first from the column
between fractions 5 and 9 with peak activity (as ascertained by the intensity of
staining on IEF) present in fraction 6. Fractions 10 and 11 contained all fi-lactamases




The anion exchange step has succeeded in separating two of the four B-lactamase
bands. It should be noted, however, that the B-lactamase of pi 6.2 that eluted first
from the column may have comprised part of the initial void volume, as the salt
gradient was not initiated until fraction 7. This would indicate that the enzyme has
failed to bind to the column and has passed straight through along with other
contaminating protein. Secondly, the B-lactamase of pi 6.8 might have been expected
to have eluted first as it holds the weakest net negative charge.
A concern at this stage was poor recovery and the weak activity of the purified B-
lactamases. Although the fractions remained stable when stored at -20°C. The weak
activity was either as a result of binding to the column matrix or removal and dilution
of the proteins from their normal cellular environment.
7.8. Attempts to improve biological activity
To attempt to increase the activity of the eluted fractions, bovine serum albumin was
added (to a final concentration of 1%) to each fraction after elution. This failed to
enhance the biological activity of the enzyme.
We thought that the buffer system used may not be suitable and a Mono S cation
exchange column equilibrated with 50 mM sodium acetate (pH 5.0) buffer was
employed but this was found to have an even greater detrimental effect on the B-
lactamase activity and was not pursued any further.
Despite repeated attempts, the separations obtained with the Mono Q (HR 5/5) were
the best that could be obtained. These fractions were used for further study of the
properties of these B-lactamases.
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7.9. Native polyacrylamide gel electrophoresis (PAGE) on
the PhastSystem®
Native PAGE separates proteins on the basis of their size, net charge and
conformation. This technique, however, would be unsuitable for determination of
subunit size estimation of aggregated proteins as these proteins are held together in a
complex, which must be destroyed by denaturing agents such as detergents and
reducing agents prior to Mr estimation.
The previous results have suggested that the B-lactamases of pl<6.8 all share similar,
if not, identical Mr. The rationale is, therefore, that native PAGE would be unable to
separate these enzymes by their Mr but could separate them by their charge. The
enzymes would also be arranged in their native state, with their biological activity
intact and could be detected with nitrocephin.
7.9.1. Methodology
The separations were run on a Phastgel Homogeneous 12.5 mini-gel (Pharmacia).
The buffer system in the Native gel buffer strips was 0.88 M L-alanine and 0.25 M
Tris, pH 8.8. The buffer strips were made of 2% agarose IEF.
The fractions from the previous anion exchange step that showed greatest 13-
lactamase activity (6, 11, 12) were concentrated to 200pl in a Centricon®
concentrator prior to separation. These fractions and the partially purified enzyme
preparation that was originally applied to the Mono Q column were applied to the gel.
Four pi of each enzyme preparation was loaded at the cathode. The gel was run as
recommended by the manufacturer. 13-lactamase activity was visualised by emersing
the gel in nitrocephin solution (500mg/l) for up to 5 minutes.
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7.9.2. Results
The result of the Native PAGE gel is shown in figure 31. The original sample that had
not been passed through the anion exchange column revealed the presence of four
distinct bands of B-lactamase activity, compatible with the concept of four 13-
lactamases (Lane 1). After prolonged staining, each sample that had previously been
through the anion exchange step (fractions 6, 11 and 12) (lanes 2-4) revealed the
presence of 2-3 B-lactamase bands, although this is not clear in the figure. These
fractions (Lanes 2-4) stained weakly but did demonstrate that the enzymes with the
lower isoelectric point migrated to the anode at a faster rate than the enzymes of
lower pi. It might be assumed that the enzyme of pi 6.8 was responsible for the B-
lactamase activity closer to the cathode, not only because of its lower density of
negative charge but also because of its high Mr, and the other three bands closer to
the anode portion of the gel were the B-lactamases of pl<6.8.
7.9.3. Conclusions
Although electrophoresis, under nondenaturing conditions, can provide useful
information concerning the physical characteristics of proteins, it cannot be assumed
that the proteins are all in the shape of linear molecules and in this instance is probably
unsuitable for Mr calculations, as it is thought that these enzymes are aggregated into
sub-unit conformation (it should be noted that Ferguson plot analysis may be used for
Mr calculations, although this method involves running the unknown and several
standards in at least five gels of different total concentrations, it is not suitable for Mr
estimations of proteins in subunit form [237] .).
Native PAGE has provided no new information on the Mr of these enzymes, it has
complemented the results obtained with the electrodialysis experiment and provided
additional proof for the concept of four discrete B-lactamases. Moreover, it has also
shown that the B-lactamases present have not been purified adequately or in sufficient
quantities to allow further studies on each discrete enzyme. Clearly, with the
techniques available, these separate B-lactamases were impossible to purify to
homogeneity. However, the B-lactamases could be separated by gel filtration into two
fractions, a B-lactamase with a pi of 6.8, and the other fractions containing the bands
of lower pi (pl<6.8).
These fractions were used for further study.
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Figure 31.
Native PAGE by the PhastSystem employing a homogeneous 12.5





Four pi of (^-lactamase preparation loaded at cathode
*Lane marker dye
Lane 1: concentrated 15-lactamase preparation front A', maltophilia 5B105
Lane 2: fraction 6 from anion exchange step
Lane 3: fraction 11 from anion exchange step
Lane 4: fraction 12 from anion exchange step
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The determination of the presence of sub-units involves characterisation of the protein
under conditions which favour association, followed by analysis under conditions
which favour dissociation. One simple approach is to carry out electrophoresis under
nondenaturing conditions (this we have already accomplished, with the use of low
pressure gel filtration), followed by a second dimension under denaturing conditions.
Sodium dodecyl-polyacrylamide electrophoresis (SDS-PAGE) is one of the most
common electrophoresis methods used today and is an ideal method to examine these
enzymes under denaturing conditions. In practice, the proteins are first dissociated
into their polypeptide subunits by hot SDS, the mixture binds tightly to the protein
imparting a net negative charge, concomitant treatment with 13-mercaptoethanol (a
reducing agent which disrupts disulphide bonds) breaks proteins down to their
constituent sub-units. This technique would allow us to determine not only the Mr of
the subunits (if any), but also their conformation.
It was decided to employ SDS-PAGE to calculate the subunit size of these 13-
lactamases.
7.10. SDS-PAGE on the PhastSystem®
7.10.1. Methodology
Sample preparation
Equal amounts of the concentrated B-lactamase extracts obtained from the G-150 gel
filtration column containing either the J3-lactamase of pi 6.8 or the enzymes of pi <6.8
were treated with 5.0% 13-mercaptoethanol and 2.5% SDS at 100°C for 5 minutes
[238], Four pi of sample was applied to a Phastgel gradient 10-15 mini-gel, and
subjected to electrophoreses as per manufacturer's instructions.
This thesis has shown that purification of the 13-lactamases to homogeneity has been
unsuccessful, and the fractions obtained by gel filtration contain other contaminating
proteins that would also stain by conventional protein staining methods, such as
Coomassie brilliant blue and silver nitrate staining.
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A technique was required that would permit the biological activity of the B-lactamases
to re-establish, and hence allow subsequent staining by nitrocephin.
7.10.2. Renaturation of B-lactamase activity
Massidda et al. [140], demonstrated that the Cpha B-lactamase from Aeromoms
hydrophilci could be renatured after SDS-PAGE, and the biological activity of the
enzyme regained.
7.10.3. Methodology
The technique involved incubating the gel in 50 mM Tris CI buffer (pH 8.0)
containing 1% Triton X-100 and 0.1 mM zinc sulphate for 4 hours at 37°C in a petri
dish. Triton-X is a non-ionic detergent, which removes the bound SDS, the sulfhydryl
groups of the enzyme are slowly oxidised. The protein then refolds to the native
enzyme and recovers its enzymatic activity. The zinc sulphate was included to
enhance any metallo-B-lactamase activity.
7.10.4. Staining
After renaturation was complete, visualisation of B-lactamase activity was obtained by
staining with nitrocephin as before. Low molecular weight protein standards (Biorad)
were run simultaneously under the same conditions and stained with Coomassie
brilliant blue R250. The molecular weight standards were transposed over the gel with
the renatured B-lactamases to enable Mr to be ascertained.
7.10.5. Results
SDS-Page analysis followed by gel renaturation treatment (figure 32) showed in each
case, the presence of a single band of B-lactamase activity, with an apparent Mr of 26
kDa for the enzyme of pi 6.8, whilst the other B-lactamase bands showed the
presence of a single protein with an apparent Mr of 24 kDa.
The data suggest that the conformation of the enzyme of pi 6.8 is a tetramer of four
subunits which are very similar in Mr. The other B-lactamases between them exhibited
a single band of B-lactamase activity on SDS-PAGE, indicating dimeric enzymes
comprised of two subunits of similar size.
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Figure 32.










li-lactamase bands of pl< 6.8
B-lactamase band ofpi 6.8
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7.11. Hydrolysis of B-lactam antibiotics
In preliminary experiments, the B-lactamase of pi 6.8 was found to be unstable in 50
mM sodium phosphate buffer (pH 7.0) at 37°C and 80% of the activity was lost after
5 minutes incubation in the buffer. The enzyme was stable in 50 mM Tris CI with an
optimum pH of 8.0. Therefore all assays on the B-lactamase of pi 6.8 were performed
with this buffer. The other B-lactamases were stable in phosphate buffer, assays for
these enzymes were performed with 50 mM sodium phosphate buffer (pH 7.0).
Assays of B-lactamase hydrolysis of various B-lactams were performed with the
partially purified extracts from the G-150 column on the B-lactamase of pi 6.8, and
the B-lactamases of lower pi (<6.8) For convenience, these B-lactamases shall be
designated XM-A, and XM-B respectively. The Michaelis constant (.Km) and the
maximum rate of hydrolysis (Vmax) were determined by assaying the enzyme in
decreasing substrate concentrations. The results are presented in table 46. The values
are expressed as a percentage of the value for penicillin.
XM-A was primarily a penicillinase and also readily hydrolysed imipenem and
meropenem, it was much less active against all classes of cephalosporins, although the
affinity (low Xm) for cephalosporins was higher than that for penicillins and
imipenem. Aztreonam was not hydrolysed. Between them the XM-B enzymes
exhibited a broad substrate profile, hydrolysing an extensive range of B-lactams but
not imipenem, meropenem, ceftazidime or aztreonam. Affinity for cephalosporins was
higher than for penicillins.
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Table 46.
Hydrolysis of B-lactam antibiotics by XM-A and XM-B B-lactamases
from X. maltophilia 5B105
XM-A XM-B
Substrate V avmax Relative'1
^max
Km (mM) V avmax Relative11
I max
Km (mM)
Penicillin 14.3 100 0.6 1.2 100 0.108
Ampicillin 5.71 39.9 0.34 2.3 191.6 0.22
Carbenicillin 2.0 13.9 0.67 0.45 37.5 0.55
Azlocillin 5.5 38.4 0.24 1.25 104 0.22
Cephaloridine 0.09 0.6 0.22 1.8 150 0.05
Cefuroxime 0.66 4.6 0.133 0.28 23.3 0.076
Cefotaxime 0.303 2.1 0.05 0.19 15.8 0.08
Ceftazidime 0.03 0.2 0.09 NMH - -
Meropenem 1.29 9.0 0.057 NMH
Imipenem 3.33 23.3 0.25 NMH - -
Aztreonam NMH - - NMH - -
a pmols of substrate hvdrolysed/min/ml of enzyme solution.
b Relative to penicillin 100%.
NMH . No measurable hydrolysis.
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7.12. Inhibitor studies
Table 47 shows the effect of the B-lactamase inhibitors, potassium clavulanate and
BRL 42715, expressed as the concentration required for 50% inhibition (ID50) of
enzymatic activity. No inhibition of the enzymatic activity of the XM-A enzyme was
observed by either inhibitor. The XM-B enzymes were sensitive to both potassium
clavulanate (ID50 = 0.16 pM) and BRL 42715 (ID50 = <0.001 pM).
Table 47.
ID50 values (pM) of potassium clavulanate and BRL 42715
Inhibitor XM-A1 XM-B2
Potassium clavulanate >50 0.16
BRL 42715 >10 <0.001
1 Imipenem (100 pM) used as test substrate.
2 Cephaloridine (100 pM) used as test substrate.
Table 48 shows the effect of 0.1 mM EDTA, 0.5 mM mercuric chloride, 0.5 mM p-
CMB.
Table 48.
Effect of various inhibitors on the activity of the XM-A and XM-B 15-
lactamases.
Inhibitor Cone11. (mM) % Inhibition of:
XM-A5 XM-B2
p-chloromercuribenzoate 0.5 69 100
Mercuric chloride 0.5 70 100
EDTA 0.1 100 0
' Nitrocephin (100 pM) used as test substrate.
2 Cephaloridine (100 pM) used as test substrate.
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Treatment ofXM-A with EDTA resulted in complete inhibition of enzymatic activity.
The inhibition was completely reversed after dialysis against 50 mM Tris CI (pH 8.0)
for 30 minutes at 37°C, and addition of 0.1 mM zinc sulphate to the reaction mixture.
Enzymatic activity was partially inhibited by mercuric chloride and p-CMB. The XM-
B enzymes were not affected by the addition of EDTA, but were completely inhibited
by the addition ofboth p-CMB and mercuric chloride.
7.13 Conclusions
We have shown that the XM-A enzyme is a metallo-B-lactamase and clearly belongs
in group 3 (metallo-B-lactamases (MET-N) in the classification scheme ofBush [149],
The XM-B group of enzymes appear to be well placed in Bush Class 2b' (extended
broad spectrum B-lactamases inhibited by clavulanic acid (EBS-Y) [172]; however,
without separation of each individual B-lactamase, it is impossible to say with
certainty, if they share similar biochemical properties.
The similarities of the physical and biochemical characteristics of the XM-B 13-
lactamases to the ubiquitous TEM plasmid-mediated B-lactamases did not go
unnoticed.
The following should be noted: The XM-B enzymes share similar isoelectric points,
subunit Mr, substrate profile. They are also inhibited by potassium clavulanate. The
hypothesis that the XM-B group of B-lactamases may have an ancestral relationship
with the TEM group was investigated.
7.14. PCR-amplification of genomic DNA from X.
maltophilia 5B105
A simple technique to study this hypothesis was to perform the Polymerase Chain
Reaction (PCR) on genomic DNA isolated from A. maltophilia 5B105 with universal
TEM oligonucleotides (Bla3' and Bla4'). Any target TEM DNA present would serve
as a template for amplification of the TEM gene. The sequences of the
oligonucleotides used are shown in figure 33.
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Figure 33.
The sequences of the oligonucleotides, Z?/fl3' and BlaV
Bla3':
5-CTC TCT AGA AAA AGG AAG AGT ATG AGT ATT-3'
Bla4':
5*-CTC GCA TGC GTA AAC TTG GTC TGA CAG TTA-3*
PCR was performed on total genomic DNA preparations ofX maltophilia. E. coli
harbouring plasmids encoding for either TEM-1R1 or SHV-lRR)io-6 production were
included as controls. Ten percent of the reaction mixture was applied to a 1% agarose
gel. After electrophoresis, the gel was stained with ethidium bromide solution and
visualised under UV transillumination.
7.14.1. Results
The result of PCR on genomic DNA from X maltophilia 5B105 is shown in figure
34. Amplification of any structural TEM DNA occurred only with the TEM control.
No amplification of TEM DNA was observed from either the DNA ofX. maltophilia
5B105 or the E.coli encoding for SHV-1 B-lactamase.
7.14.2. Conclusions
This result demonstrates that the there is no significant homology within the
chromosomal DNA ofA! maltophilia 5B105 to the TEM structural gene.
8.0. Utilisation of selective pressure on E. coli with
imipenem
It was originally thought unlikely that the common plasmid-mediated B-lactamase
genes, in particularly the TEM-1 gene would mutate to encode for B-lactamases with
the capability to hydrolyse third generation cephalosporins or show increased
resistance to B-lactamase inhibitors. We now know that this early assumption was
misplaced with numerous reports of ESBLs in the literature. Payne [235] and
Thomson & Amyes [239], demonstrated that the application of selective pressure
with either third generation cephalosporins or co-amoxiclav in vitro, on
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Figure 34.
Agarose gel electrophoresis of PCR amplified products from











Lane 1: X DNA digested with hind III
Lane 2: genomic DNA preparation from E. coli R1tem-i
Lane 3: genomic DNA preparation from E. coli R1010-6SHV-i
Lane 4: genomic DNA preparation from X maltophilia 5B105
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E.co/i harbouring plasmids encoding for TEM-1 B-lactamase resulted in selection of
ESBLs or TEM enzymes resistant to inhibitors (TRC-1) respectively. The same
assumption has been made for the carbapenems, although in this case, the assumption
may be correct. To date, there has been no reports of TEM or SHV derived 13-
lactamases with increased resistance to carbapenems. The object of this experiment
was to determine if E. coli expressing TEM-1 B-lactamase could be mutated iti vitro
to carbapenem resistance.
8.1. Methodology
The method employed was based on that described by Thomson & Amyes [239], The
antibiotic susceptibility of the host organism expressing the TEM-1 B-lactamase, E.
coli J62-2Ri to imipenem (0.12 mg/1) was determined. Twenty pi of an overnight
culture of E. coli J62-2R1, encoding for the TEM-1 B-lactamase in 1ST broth was
inoculated into three 100ml volumes of 1ST broth containing 0.12 mg/1 imipenem,
0.25 mg/1 imipenem and 0.5 mg/1 imipenem respectively. After overnight incubation at
37°C with constant shaking, the cultures that had grown were subcultured into the
same broth/antibiotic mixture. This procedure was repeated over five days. After the
final subculture, 10 ml of broth from each flask that exhibited growth was removed.
The bacteria were harvested by centrifugation (2500 xg., 15 min). The bacterial pellet
was resuspended in the same volume of single strength Davis-Mingioli minimal media
(SSDM). This was further diluted 10"6 in SSDM and 0.1 ml of dilution spread onto
1ST agar containing imipenem at the same concentration as the strain had been
cultured in.
8.2. Results
The flasks containing 0.5 mg/1 imipenem remained clear throughout. Five single
colonies were selected from the plates that contained either 0.12 mg/1 or 0.25 mg/1
imipenem. The auxotrophic requirements of the colonies selected were examined to
ensure they were E. coli J62-2.
8.2.1. Antibiotic susceptibilities
In total, 10 colonies ofE. coli J62-2Rj were assessed for imipenem resistance. MICs
for five colonies challenged with 0.12 mg/1 imipenem were identical to those of the
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original host (0.12 mg/1). The five colonies challenged with 0.25 mg/1 imipenem all
displayed MIC levels of 0.25 mg/1 to this drug. Stoke's sensitivity testing on all
colonies, employing the original E. coli J62-2 as control, showed no reduction in zone
size to any other B-lactam.
8.2.2. Isoelectric focusing
The 10 colonies selected were used to prepare small scale B-lactamase preparations.
These were subjected to isoelectric focusing employing ampholines with a pH range
of 3.5-10.6. All colonies co-focused at exactly the same pi as TEM-1 B-lactamase
from the original E. coli strain (data not shown).
8.3. Conclusions
Despite a single dilution increase in resistance to imipenem by five colonies ofE. coli
J62-2R1 there was no alteration in enzyme production, with the TEM-1 B-lactamase
produced on each occasion. Although not examined here, the slight increase in MIC
to imipenem in these strains is unlikely to be associated with increased levels of
enzyme production as no concomitant resistance to other B-lactams was observed.
The most likely explanation for this increase may be as a result of permeability
changes or altered PBPs, although this has not been examined in this thesis.
We have shown in our experiments that the TEM-1 gene appears to be unable to
undergo mutation to allow hydrolysis of imipenem. This was perhaps anticipated.
Despite the steady global increase in the use of imipenem, especially in those areas
where treatment with third generation B-lactams has failed, there have been no reports






The initial aim of this thesis was to examine the antibiotic resistance levels of Gram
negative aerobic bacilli responsible for septicaemia over a 12 year study period. There
have been reports concerning the development of resistance by these organisms over
the past decade, to all classes of B-lactam antibiotics. This resistance has prompted
the search for newer, more effective antibiotics and has perhaps culminated in the
discovery, and use, of the most powerful B-lactam family to date; the carbapenems.
As previously discussed, resistance to these drugs by virtue ofOMP changes has been
well documented but carbapenem resistance mediated by metallo-B-lactamases has
been confined to relatively non-pathogenic species. At the concept of this thesis, no
serine B-lactamase on its own, had been shown to mediate resistance to this group of
antimicrobials.
The blood culture stock collection from the clinical bacteriology section of the Dept.
ofMedical Microbiology, Edinburgh University, has afforded a unique opportunity to
examine the in vitro susceptibility of a range of organisms responsible for serious
sepsis. This collection represents strains collected prior to the introduction of the
second and third generation cephalosporins and latterly the introduction of
carbapenems and quinolones, into clinical practice. Subsequently, over the years,
these strains have endured a progressive increase in the use of more powerful and
broader-spectrum antibiotics, and hence the opportunity to develop resistance by
selection.
In this thesis, the incidence of resistance to various antimicrobials within the
population of Gram negative aerobic bacilli has been investigated. Strains resistant to
cefuroxime have been studied, to detect any evidence for the evolution of extended
spectrum TEM and SHV B-lactamases in our hospital. Carbapenem resistance has
been examined, culminating with the discovery of the B-lactamase, ARI-1, in a strain
ofA baumannii, the first documented serine active site carbapenemase.
The species X. maltophilia is the only Gram negative aerobic bacillus isolated with
any frequency from clinical material resistant to imipenem. The B-lactamase
complement of this species has been examined and clarified.
These results and their significance are discussed in the following chapter.
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2.0. The prevalence of Gram negative aerobic bacilli
collected over a 12 year period
Gram negative bacilli (1453 strains) were collected over a 12 year study period. As
expected E. coli was the predominant isolate (53%) with Klebsiella spp. and
Pseudomonas spp. the next most prevalent (10%). These results are comparable with
a three year UK survey performed by Spencer et al. [240] who reported the frequency
of hospital isolates that were E. coli as 57% with Pseudomonas spp. and Klebsiella
spp. as 9% and 5% respectively. Although it should be noted that these figures
represent strains isolated from a general survey rather than from a specific site.
In parallel with the overall incidence of isolation, E. coli remained the most frequently
isolated pathogen throughout the entire study period. There appeared to be no
obvious trend to the regularity of isolation of any particular species, although Phillips
et al. [241] reported an overall 4% to 6% increase in the isolation of those organisms
that produce a Class I cephalosporinase over a 20 year period in their study.
2.1. Resistance of the survey strains to various
antimicrobials
The highest incidence of resistance to all strains was for ampicillin (63%). Resistance
to aminoglycosides was surprisingly high (gentamicin 12%, tobramycin 15% and
netilmicin 21%), although cumulative MICs indicated that most of these resistant
strains fell close to the recommended breakpoint value (lmg/1). In a similar study,
Phillips et al. [241] employed an intermediate breakpoint value of 4 mg/1 for
aminoglycosides. A similar value employed in this study, would decrease resistance
levels to approximately 10% or less for all species against all aminoglycosides tested.
Aminoglycoside serum levels of >1 mg/1 are readily achievable, and the general
application of a breakpoint value of 4 mg/1 may be more relevant to the clinical
setting.
Ceftazidime was the most effective cephalosporin with 16% resistance, cefotaxime
resistance was 21% and cefuroxime 32%. The most effective agents were the
carbapenems, imipenem and meropenem with resistance levels of 4% and 2%
respectively. The only quinolone tested, ciprofloxacin, demonstrated an efficacy
commensurate with that of the carbapenems (3%).
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When the resistance pattern of individual species was analysed the results were much
as expected. The Pseudomonas spp. and X maltophilia displayed the most impressive
pattern of resistance to almost all antimicrobials. The Enterobacteriaceae were
exquisitely sensitive to the carbapenems with the exception of the Proteus spp. Ten
per cent of all strains were resistant to imipenem while meropenem was more active
with only 2.8% resistance. These results are in broad agreement with those reported
by Edwards and Turner [242], who demonstrated in a European multi-centre survey
that approximately 20% of 1280 strains of Proteeae were resistant to imipenem but
sensitive to meropenem. It is known that imipenem is intrinsically less active than
meropenem [242], this resistance is thought to be as a result of OMP changes
[54,56], rather than B-lactamase mediated.
The species known to produce a Class I cephalosporinase were generally more
resistant to antimicrobials particularly to the cephalosporins than those organisms
such as E. colt and Klebsiella spp. that do not produce these enzymes. Only a strain
ofA. baumannii was resistant to both carbapenems.
These results have demonstrated the excellent in vitro efficacy of carbapenems and
ciprofloxacin against those species that cause Gram negative sepsis, and the use of
these drugs may be worthwhile in this setting. Other workers [243] have
recommended the use of carbapenems for empirical therapy for both Gram positive
and Gram negative sepsis without the administration of a codrug such as an
aminoglycoside.
The importance of such susceptibility data cannot be underestimated. Spencer [240]
made the following points concerning susceptibility data:
1. Locally, surveillance can improve the quality of antibiotic prescribing for the
individual and influence the antibiotic usage in hospital.
2. Nationally, it can assist the formulation of policies for the supply and use of
antibiotics in man or animals and encourage responsible action by antibiotic
manufacturers in the promotion of their products.
3. The results would supply clinicians with the latest surveys of the prevalence of
pathogenic micro-organisms and their susceptibility patterns.
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4. The information gathered may be used to monitor the incidence of resistance and
changes in the prevalence of resistance to newly released antibiotics.
2.2. Cefuroxime-resistant strains
Two hundred and forty five cefuroxime resistant strains (MIC>4 mg/1) were selected
from the original survey strains for further study. This group excluded those species
such as X. maltophilia and Pseudomonas spp. that are intrinsically resistant to this
compound.
The species represented within this sub-group were very much as expected with the
majority of these organisms known to produce a Class I cephalosporinase (61%
Enterobacter spp., 59% Acinetobcicter spp., 37% Serratia spp., 12% Citrobacter spp.
and 15% ProtenslMorganellalProvidencia spp).
Almost all of the cefuroxime resistant strains were concomitantly resistant to
ampicillin (93%), and cross resistant to most other classes of antimicrobials. The
carbapenems were the most efficacious (<1.0% resistance).
2.3. B-lactamase production by the cefuroxime-resistant
strains
Of the 245 cefuroxime-resistant strains examined, 198 produced a chromosomal
enzyme alone, 28 produced a chromosomal enzyme plus the TEM-1 B-lactamase, 1
produced a chromosomal B-lactamase plus the SHV-1 B-lactamase, 6 produced the
TEM-1 B-lactamase alone. None of the strains demonstrated the presence of
transferable ESBLs.
These findings suggest that the cefuroxime resistance in most of these strains is
mediated by "typical" Class I chromosomal cephalosporinases, and it appears that
these enzymes are more problematic from the clinical aspect than the ESBLs.
Although it should be borne in mind that other mechanisms such as permeability
changes and affinity for PBPs should not be discounted. The ESBLs that have been
reported in several other countries, at present, do not appear to be a problem in our
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hospital, despite a steady increase in the use of second and third generation
cephalosporins. However, these results should not let us become complacent. In
Glasgow Royal Infirmary it appears that ESBLs, similar to the SHV-derived ESBLs
may be present (Dr C. Thomson, personal communication), and continued vigilance,
with respect to screening programmes should be a priority.
These results are similar to those obtained by Hood [13]. Hood examined 200 general
isolates of cefuroxime-resistant Gram negative bacilli from the same hospital, and
found no evidence of transferable ESBLs.
It is not thought that the increased use of imipenem over the last few years should
become a major concern. The carbapenems have no potential for selecting the
constitutively derepressed subpopulation, neither does the induced high level enzyme
production affect the efficacy of the antibiotic, furthermore, they are they not thought
to select ESBLs derived from TEM or SHV B-lactamases. However, the discovery of
novel B-lactamases is a more difficult problem to address.
3.0. Discovery of ARI-1 (Acinetobacter resistant to
imipenem), a carbapenemase, in A. baumannii 6B92
As previously alluded, the only isolate to display resistance to the carbapenems among
the cefiiroxime-resistant population was a strain ofA. baumannii 6B92 with MICs to
imipenem and meropenem of 16.0 mg/1 and 32.0 mg/1 respectively. The isolate was
also resistant to all other B-lactams tested, but not gentamicin or ciprofloxacin.
Although carbapenem resistance in Acinetobacter spp. has been reported [60,188],
this resistance has been attributed to changes in affinity for PBPs [60] or the interplay
between penicillin binding proteins with altered expression and/or affinity and
decreased permeability of the outer membrane [184], as a consequence of treatment
with carbapenems. To our knowledge, there have been no reports of enzymatic
degradation of carbapenems by fl-lactamases in this species.
This strain was isolated in 1985 from a surgical ward in Edinburgh Royal Infirmary,
long before the introduction of carbapenems in this hospital in early 1990. Although
the medical records of this patient have not been studied, it was unlikely that this
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resistance had been selected by the use of any other antimicrobial. As already
discussed, ESBLs or hyperproduction of Class I B-lactamases on their own have no
significant hydrolytic action on carbapenems without a concomitant increase in
impermeability, and it has already been suggested that carbapenems enter the cell by a
different route from other agents [58], Therefore any selective pressure by other B-
lactams would be highly unlikely to select carbapenem resistance. The sensitivity of
this organism to ciprofloxacin and gentamicin would also intimate that the
carbapenem resistance was B-lactamase-mediated, and not a permeability mutation.
3.1. Isoelectric focusing
A B-lactamase of pi 6.65 was identified in this isolate, as well as a typical
chromosomal Acinetobacter cephalosporinase ofpi >9.0. The isoelectric point of 6.65
is similar to those values exhibited by plasmid-mediated enzymes, rather than a
chromosomal enzyme. These chromosomal enzymes are usually of basic pi. Plasmid-
mediated B-lactamases do exist in Acinetobacter spp. but they have usually been
penicillinases, which have previously been identified in Pseudomonas spp. or the
Enterobacteriaceae [244], The same workers did report a carbenicillinase of pi 6.3 in
several strains of Acinetobacter spp., designated CARB-5, however none of these
strains exhibited carbapenem resistance.
3.2. Molecular mass
The ARI-1 B-lactamase demonstrated a Mr of 23kDa by gel permeation, the other
enzyme identified exhibited a Mr of 58kDa. The Mr of the ARI-1 enzyme is clearly
different from the Mr of those enzymes normally produced by the species. Hood
demonstrated that the Mr of these enzymes is usually >60kDa [229],
3.3. Substrate profile
Hydrolysis of B-lactam substrates by ARI-1 was very slow and only hydrolysis of
penicillin, ampicillin, azlocillin and cephaloridine could be demonstrated by
spectrophotometry means. The substrate profile did indicate that ARI-1 was a
penicillinase rather than a cephalosporinase, most other carbapenemases have also
been shown to hydrolyse penicillins preferentially [128], this is not surprising
considering both classes of B-lactams have a 5-membered ring.
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The microbiological assay however, clearly demonstrated that the enzyme possessed
the ability to inactivate imipenem and azlocillin but not any of the second or third
generation cephalosporins. The inability of the spectrophotometric assay to
demonstrate direct hydrolysis of carbapenems was puzzling, however, it is known that
this technique is not suitable for assay of all B-lactamases, especially if that hydrolysis
is extremely slow. Microbiological assay is extremely sensitive and although not as
convenient, a very useful technique to demonstrate the hydrolytic action of these 6-
lactamases.
It has been postulated, particularly for inducible B-lactamases, that the B-lactamase
protects the cell by "binding" rather than hydrolysing the antibiotic molecules as a
result of the low Km of these enzymes. It has been said that these B-lactamases act as
"periplasmic sponges" that prevent antibiotics from reaching their target sites on the
cytoplasmic membrane [245,246], Alternately, Vu and Nikaido [247] have proposed
that the contribution of trapping alone to the resistance level is of negligible
magnitude in comparison with the contribution of hydrolysis, even in species with
fairly low outer membrane permeability. They calculated that trapping alone would
raise the MIC by only around 2mg/l whereas slow hydrolysis would explain a much
higher increase. They state that the periplasmic concentrations of B-lactamase are
much higher than those observed in in vitro assays, and secondly, enzyme-antibiotic
affinity ensures that the drug turnover remains efficient, even at low substrate
concentrations.
It seems most likely therefore, that the inactivation of imipenem by ARI-1 is probably
as a result of extremely slow hydrolysis in concert with high affinity for the substrate.
3.4. Inhibitor studies
Although the ARI-1 B-lactamase demonstrated physical properties similar to those of
the broad-spectrum plasmid-mediated B-lactamases such as TEM and SHV, unlike
these enzymes it was not inhibited by the action of potassium clavulanate. It was,
however, inhibited by BRL 42715 a mechanism-based B-lactamase inhibitor, which
inactivates serine B-lactamases but not those with a metal ion at their active site.
Coupled with the non-inhibition by EDTA these results strongly suggest that the ARI-
1 enzyme is a serine active site B-lactamase rather than a zinc centred enzyme, and as
such, is the first reported isolation of a serine active site enzyme with significant
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activity against carbapenems. ARI-1 was also very susceptible to the carbapenems,
meropenem and imipenem when used as inhibitors, much more so than TEM-1. This
shows that the enzyme binds these substrates and is indicative of the high affinity of
ARI-1 for carbapenems, and is further evidence for the binding/slow hydrolysis
hypothesis discussed in the preceding section.
3.5. Genetic studies
The previous results demonstrating the clear dissimilarity of the ARI-1 B-lactamase
from the normal complement of Acinetobacter B-lactamases, infers that the gene
encoding the enzyme was introduced from an extraneous source; yet, despite
extensive experimentation to demonstrate the presence of, or transfer of an
extrachromosomal source, no resistance plasmid could be visualised or transferred.
The existence of a small plasmid of 6.5kb was observed, however, it would be
unlikely that antibiotic resistance genes would be carried on such indigenous plasmids,
and in any event, probably not carry the necessary information for genetic transfer to
occur [248], It is known that genetic studies on Acinetobacter spp. are notoriously
difficult to perform.
Unlike some species, such as Aeromonas spp., and X. maltophilia which appear to
have a paucity of plasmids, plasmids are common amongst strains of Acinetobacter.
Gerner-Smidt [222] demonstrated the existence of indigenous plasmids in 75 of 93
strains of Acinetobacter spp. examined, with a range of 0-20 plasmids/strain. The
majority were less than 23 kb in size, with two thirds of strains harbouring two or
more plasmids.
The more likely explanation for the failure to detect an extrachromosomal source is
that the resistance gene is carried on a large plasmid that has broken up during the
extraction process, and hence we have failed to isolate it, despite the utilisation of a
variety of plasmid extraction procedures. This plasmid, despite it's presumed large
size, was not transferable. Lambert et al. [249] stated that the failure to transfer
resistance genes between Acinetobacter spp. and other organisms did not result from
lack of expression of Acinetobacter genes in heterologous systems, but rather from
defects in conjugation donor or recipient ability, or plasmid replication in the new
host, or both.
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Plasmid transfer from Acinetobacter spp. to other genera, has been shown to be
difficult. In other studies it has been shown that self transmissible R plasmids
transferred from E. coli to Acinetobacter spp. required a mobilising plasmid for re-
transfer to occur [250], In our experiments the use of the incP group plasmid, RP4,
failed to mobilise any resistance gene. RP4 was chosen because it, and its relatives,
have been known to mobilise the chromosomes of a variety of Gram negative
bacteria, although at a low frequency [251],
It may have been useful to attempt transfer of any resistance gene on solid surfaces, as
Towner and Vivian [252] demonstrated that transfer only occurred at detectable
frequency on solid surfaces, not in liquid mating. Moreover, Towner [248] suggested
that tests with a single "representative" plasmid, even those of the same
incompatibility group, cannot always be regarded as conclusive as a result of their
divergent behaviour in the host system, and it may have been prudent to attempt
mobilisation of the ARI-1 gene with a different plasmid.
In conclusion, it is most probable that the failure to detect plasmid-mediated transfer
of an antibiotic resistance gene for ARI-1 may simply reflect the absence of a suitable
test system rather than the absence of a plasmid. Another possible scenario is the
resistance gene has originally been plasmid mediated but has been unstable in the host
system and incapable of sustained stable maintenance, and subsequently undergone
introduction into the host chromosome by transposition. There is much evidence for
this hypothesis in Acinetobacter spp. Bergogne Berezin and Joly-Guillou [188] stated
that much of the resistance mechanisms observed in Acinetobacter spp. were
essentially identical to those encoded by genes carried on plasmids commonly found
in the Enterobacteriaceae.
3.6. Plasmid curing experiments
Despite the failure to isolate or visualise a resistance plasmid, the presence of a
plasmid location for the ARI-1 gene was strengthened by the confirmation that the
production of the enzyme can be cured by the addition of ethidium bromide to the
growth medium. The rate of cure was 10%, this is in contrast with previous work by
Goldstein et al. [253] who, by employing the same plasmid curing technique with A.
calcoaceticus BM200 demonstrated a rate of cure of resistance traits of only 0.3% (1
of 300 colonies). The rate of cure of resistance plasmids in Enterobacteriaceae
appears higher than that in Acinetobacter. Bouanchaud et al. [232] employing
Discussion 172
ethidium bromide, reported loss of resistance traits at high frequency in E. coli K12,
ranging from 30% to 70%. Our results, as well as those of Goldstein, appear to
suggest that resistance plasmids present in Acinetobacter spp. are not as easily
eliminated by ethidium bromide curing as those found in Enterobacteriaceae.
The loss of the ARI-1 B-lactamase coincided with the concurrent loss of high levels of
resistance to penicillins and all resistance to carbapenems, whose MICs fell to basal
levels normal for the species. The residual resistance to the penicillins is probably as a
result of some hydrolysis by the cephalosporinase of pi >9.0. Carbapenems are
resistant to the hydrolytic action of Acinetobacter B-lactamases.
3.7. The action of BRL 42715 on the MIC values to
carbapenems
Despite the evidence of the presence of a novel B-lactamase in A. baumannii 6B92
and the elimination of carbapenem resistance, with the subsequent loss of this enzyme,
the work suffered from the inability to transfer the resistant gene into a well-
characterised host. This would have allowed the contribution of OMP changes or
alteration in affinity for PBPs to be examined. It could be argued therefore, that the
ARI-1 B-lactamase only helps contribute to carbapenem resistance in concert with
other factors. This problem was circumnavigated by the utilisation of the B-lactamase
inhibitor BRL 42715. Use of this agent inhibited the activity of any B-lactamase and
demonstrated that without the protective action ofARI-1 the strain succumbed to the
carbapenems, with MIC levels of the parent strain, falling to almost the same values
as those for the cured strain, thus, confirming the importance of ARI-1 in the
contribution of carbapenem resistance in ,4. baumannii 6B92.
3.8. The significance of ARI-1
Serine active site carbapenemases are perhaps the rarest of all the B-lactamases. The
only other reports of B-lactamases that are not inhibited by EDTA (i.e. enzymes which
are presumed not to have a zinc centred active site), with carbapenem hydrolysing
properties, are those of the NMC-A B-lactamase described by Nordmann et a/, from
E. cloacae NOR-1 [152,254], and very recently, SME-1 (pi 9.7), from S. marcescens
S6 [153], Both enzymes have been sequenced [153,254] and are Ambler Class A B-
lactamases. SME-1 was initially inferred to be a metallo-B-lactamase on the basis of
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data suggesting inhibition by EDTA [154], however the b/asme-1 gene shows no
homology with the Class B metallo-B-lactamases, but did show 70% identity with
NMC-A. The NMC-A B-lactamase shares several similarities with ARI-1, i.e. the pis
are similar (NMC-A=6.9), and both enzymes preferentially attack penicillins,
carbapenems and cephaloridine, although NMC-A did confer some resistance to
expanded spectrum cephalosporins and was also partially inhibited by clavulanate.
There has also been an enzyme reported from a strain of B. distasonis TAL 7860
[150], The enzyme from B. distasonis has a pi of 6.9 and a Mr of >60kDa which
suggests that it differs from ARI-1. However full biochemical characterisation is
unavailable for this enzyme and a valid comparison is not possible.
ARI-1 is unlikely to have been selected by antibiotic usage, therefore it is interesting
to speculate on the origin of this enzyme. It is vital therefore, that the gene encoding
for ARI-1 is cloned into a suitable shuttle vector with subsequent sequencing, only
then will we be able to ascertain whether ARI-1 has evolved from a point mutation of
a known gene or whether we have discovered a new class of B-lactamase, previously
undetected. It would be interesting to perform hybridisation experiments with a probe
constructed from the NMC-A gene, which has been cloned into a plasmid vector and
expressed in E. coli. Hybridisation experiments with a 1.2 kb fragment from the
recombinant plasmid harbouring the structural gene for NMC-A failed to hybridise
with any known B-lactamase. Although, the hybridisation experiments did not include
a gene probe for SME-1.
Whatever the origin of ARI-1, our results intimate that the enzyme has almost
certainly been introduced into A. baumannii 6B92 from an extraneous source. This
implies that the B-lactamase is already in the general population of organisms and has
been for some time. If the gene has transposed into the genome of A. baumannii, it
would seem logical to assume that the same transfer would occur in other, more
clinically relevant species. With the increase in use of carbapenems, this would allow
these resistant organisms to be selected, as has occurred with the ESBLs, particularly
in intensive therapy units (ITUs) in France and the USA. This would greatly
compromise our ability to treat nosocomial infections for which imipenem is, often,
the last efficient B-lactam for use in patients in ITUs.
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4.0. Investigation of the susceptibility pattern and the 15-
lactamases of the species, X. maltophilia
4.1. Antimicrobial susceptibilities ofX. maltophilia
There was a significant disparity between the susceptibility data obtained with the two
different sensitivity test media employed. In general, there was a higher degree of
resistance demonstrated to those strains examined on MHA rather than those on
1STA, this was particularly apparent with the B-lactams. The results with
ciprofloxacin and gentamicin were more in agreement. This phenomenon has
previously been well publicised, and our results are consistent with work reported by
other authors [205,226-228],
Our understanding of the susceptibility behaviour ofX maltophilia on differing media
has been clarified (but not fully explained) by previous studies. There have been
several attempted explanations for this occurrence. Akova el al. [228], reported that
this effect was independent of B-lactamase production. Their studies with mutations
of X. maltophilia expressing low and high levels of LI and L2 B-lactamase,
demonstrated that these medium-determined effects were independent of the mode of
expression of B-lactamase, and that this behaviour may reflect a permeability
difference between cells grown on different media. Conversely, Hawkey et al. [226]
reported that the degree of resistance displayed by X maltophilia strains to imipenem,
and other B-lactams, correlated positively with the zinc content of the test media
employed. The authors assumed that this increased resistance was as a result of
increased activity by the zinc dependent LI enzyme.
Bonfiglio and Livermore [255] argued against the latter hypothesis on several counts.
1. X maltophilia isolates were more resistant to B-lactams when tested on different
formulations of media in which the nutrient concentration had been reduced,
with a concomitant reduction in zinc concentration [227],
2. Their own observations showed that cefsulodin MICs to a variety of strains were
lower on 1ST than MH agar. This would be independent of LI activity because
cefsulodin has been shown to be stable to LI [123],
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3. Imipenem MICs have been shown to be less affected by the test medium than
were those of other B-lactams [228], The opposite pattern would be expected if
the zinc concentration were critical.
They too postulated that changes in permeability were the most likely explanation,
although they did state that the effect of zinc content in the media formulation should
not be entirely discounted.
These previous studies have extended our understanding on the susceptibility
behaviour ofX maltophilia but have not offered a complete explanation. We have
not attempted to resolve this puzzling occurrence in this thesis, suffice to say that
susceptibility testing of X maltophilia has been shown to be a difficult task, and
extreme caution should be exercised in the interpretation of in vitro assay results in
correlation with the clinical performance of B-lactams.
The above findings pose the question, "Which medium more correctly reflects the
susceptibility situation in vivo?" Hawkey et al. [226], suggested that the
concentration of the test medium be monitored to reflect the normal serum levels of
zinc ions (11-20 pmol). Realistically, this form of quality control would be difficult to
establish in the routine laboratory, the same workers also suggest that exogenous
levels of zinc ions from such sources as metal caps with rubber washers be controlled!
Most recent studies have employed MH agar as the test medium [200,201,256], and
our MIC results correlate well with those findings. Generally, on MH agar, all isolates
ofX maltophilia were resistant to most antibiotics tested, with no particular drug, or
class of drug exhibiting any consistently useful activity. X maltophilia is an up and
coming pathogen, especially among those patients with a compromised immune
system, therefore, the lack of a suitable antimicrobial for these patients is an obvious
concern.
Although not examined in this present work, other workers have demonstrated useful
in vitro activity with combination therapy, employing either
trimethoprim/sulphamethoxazole, aztreonam/clavulanate or ticarcillin/clavulanate
[200,257], Vartivarian et al., [257] demonstrated that the new investigational
quinolones PD 117558, PD 117596 and PD 127391 show promise against this
difficult organism.
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4.2. B-Iactamases ofX. maltophilia
Any significant B-lactamase activity exhibited by any of the 28 strains examined
required the addition of an inducer prior to extraction of the enzyme. This result was
anticipated, previous studies have also shown that enzyme production in this species
is inducible [123,202-205], What was surprising was the diversity of different 13-
lactamases produced by the species, with most strains encoding for the production of
two or more B-lactamases. This is contrary to the work of Cullmann and Dick [205]
who reported only single enzymes present in each of 20 strains examined. On the
basis of pi, it was possible to categorise the B-lactamases into 12 distinct isoelectric
patterns. The induciblility of these enzymes and the failure of the conjugation studies
would suggest that these enzymes were all chromosomally mediated. They were thus
designated as Xanthomonas maltophilia chromosomal enzymes (XMCEs), and were
classified (on the basis ofpi) into twelve enzyme sub-types.
Only one IEF pattern appeared with any regularity, XMCE type-1. This B-lactamase
pattern was observed in 7 (25%) of the strains examined, and was the only IEF
pattern common to more than two strains. Although it should be noted that some
isolates did harbour identical B-lactamases, these were mostly found to have been
isolated from the same patient, and were probably the same strain. None of the strains
appeared to code for the original LI and L2 enzymes. The B-lactamase patterns were
so diverse that B-lactamase profiles would perhaps serve as a useful tool for
epidemiological typing, along with other techniques, forX. maltophilia species!
There appeared to be no obvious correlation between antibiogram and enzyme type
(most strains were resistant to most drugs anyway); however, this would be a difficult
comparison to assess, as it is known that permeability is an important consideration in
the sensitivity of this species to antimicrobials.
XMCE type-1, was the most prevalent of all enzyme types detected, and strain 5B105
was selected as representative of the group for extensive biochemical examination.
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4.3. Characterisation of the XMCE type-1 B-lactamase
from strain 5B105.
All enzyme production in this strain was inducible, with imipenem a more potent
inducer of the B-lactamase than cefotaxime. This is in agreement with other studies
[205,228], No enzyme activity was detected in the culture filtrate, indicating that the
B-lactamase was located in the periplasm.
All B-lactamases were produced with a single inducer, this might infer that the
enzymes share a common regulatory region, although it is known that imipenem is an
effective inducer for more than one B-lactamase [258], An analogous situation is
thought to occur with LI and L2. Nevertheless, the genetic basis for the linkage of
the LI and L2 enzymes is largely speculation. Dufresne et al.[259] successfully cloned
the LI gene into a plasmid vector, complete with considerable flanking sequences, but
this did not result in simultaneous production of the L2 enzyme, which would make it
highly unlikely that the LI and L2 genes are located within the same operon.
The production ofmore than one inducible B-lactamase is unusual, although they have
previously been reported in strains of Aeromonas spp. [122], B. cereus [145], and
Yersinia enterocolitica [260], Some Aeromonas spp. have been reported to produce
up to three different B-lactamases [261],
Polyacrylamide gel overlays with various inhibitors demonstrated that the B-lactamase
ofpi 6.8 was inhibited by EDTA but not BRL 42715, indicating that this enzyme was
distinct from the other bands of activity. Inhibitor overlays also demonstrated that the
enzymes of lower pi were inhibited by both BRL 42715 and potassium clavulanate.
Aztreonam and cloxacillin overlays had no significant effect on any of the enzymes.
These results initially indicated that the enzyme of pi 6.8 was a metallo-B-lactamase,
and the enzymes of pl< 6.8 were broad-spectrum penicillinases, these preliminary
findings were to prove surprisingly accurate.
Purification of the B-lactamase bands of pi <6.8 by electrodialysis and subsequent
isoelectric focusing demonstrated that each preparation focused as a single band of
activity at exactly the same pi it had originally migrated to. The small yield of enzyme
made this technique unsuitable for purification of enzyme for further studies. Native
PAGE of the concentrated partially purified B-lactamase preparation revealed the
presence of four distinct bands of activity. These results indicated that the fi-lactamase
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presence of four distinct bands of activity. These results indicated that the B-lactamase
activity of pi <6.8 was the result of at least three distinct enzymes and not satellite
bands. The differences in pi of these B-lactamase bands of lower pi suggest that they
may have undergone amino acid substitution or addition away from the active site of
the enzyme and may physically differ in their primary structure.
When partially purified by gel filtration, the B-lactamase activity could be separated
into two fractions, a B-lactamase with a pi of 6.8, and the other fractions containing
the bands of lower pi (pl<6.8).
The bands of pl< 6.8 that were inhibited by BRL 42715 were eluted at the same rate,
with an apparent Mr of 48 kDa. When the Mr was estimated by SDS-PAGE with
subsequent renaturation of B-lactamase activity, only one band was observed with a
Mr of 24 kDa, suggesting a dimeric enzyme. It would be improbable that an organism
would encode for three or more B-lactamases with identical molecular masses and sub
unit conformation unless they were closely related, like the TEM enzymes, and in
parallel with the TEM B-lactamases the difference in pis arise from a few amino acid
substitutions.
Unfortunately, the identical molecular mass of these enzymes and the similarity of
their pis made separation of these enzymes virtually impossible, despite employing
cation and anion exchange chromatography with different pH buffers (i.e. above and
below the pi of the B-lactamases). Not only were the distinct bands of B-lactamase
not separated adequately, the resultant enzymatic activity of the elutate was very
poor, and of limited value for further studies. The technique was especially
detrimental to the enzyme ofpi 6.8.
It was clear that further separation of these enzymes was impossible, and the two
fractions separated by gel-filtration were used for further studies. The B-lactamase of
pi 6.8 was designated XM-A. The B-lactamases of pl< 6.8 were named XM-B.
4.4. XM-A
The XM-A enzyme was very similar in physical and biochemical profile to the LI
enzyme. It was unstable in sodium phosphate buffer. This probably results from the
formation of zinc phosphate with the subsequent removal of free Zn++ from the
buffer. The plasmid-mediated metallo-B-lactamase from Ps. aeruginosa is also
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unstable in phosphate buffer [126], The catalytic activity of the XM-A enzyme was
dependant on Zn++ for activity. Although restoration of activity with other metal ions
was not attempted in this study, the results suggest that the enzyme is a metallo-B-
lactamase. Both enzymes share similar pis (LI, pi 6.9). In parallel with the LI enzyme
the XM-A enzyme also exists as a tetramer in the active state (Mr 96kDa), with a
subunit Mr of 26kDa. Inhibitory profiles for both enzymes are very similar. Both are
insusceptible to potassium clavulanate but susceptible to mercuric chloride. Iaconis &
Sanders [122], reported that the LI producing strain that they examined was inhibited
by p-CMB (20%), whereas Saino et al. [123] reported no inhibition by this
compound. Under our test conditions, p-CMB inhibited the enzymatic activity of the
XM-A enzyme by 69%. The zinc active sites of metallo-B-lactamases are thought to
include a conserved cysteine residue [119], therefore, inhibition by p-CMB would be
expected. As with other metallo-B-lactamases [58], XM-A, although exhibiting
predominantly penicillinase activity, also hydrolysed a broad range of B-lactams
including imipenem but not the monobactam, aztreonam.
It has been shown that the XM-A enzyme shares similar bio- and physiological
properties with the LI enzyme, and clearly belongs in group 3 (metallo-B-lactamases
(MET-N) ) in the classification scheme of Bush [149], however full sequencing is
essential for an absolute determination.
4.5. XM-B
The other enzymes described in this thesis, XM-B, although differing particularly in
isoelectric point to that of the L2 enzyme described by Saino [203] (pi 8.4) shared
some similarities with this enzyme. Although it should be noted that the results
obtained with the combined enzymes should be treated with caution. It has been
shown that these enzymes have distinct physically properties (pi), nevertheless each
individual enzyme has not been purified to homogeneity, therefore it has not been
unequivocally shown that all these enzymes react in the same manner.
The inhibitor profile for XM-B was similar to that reported for the L2 enzyme. All
enzymes were inhibited by clavulanate, p-CMB and mercuric chloride. EDTA had no
effect on the enzymatic activity ofXM-B indicating that they do not require a divalent
metal ion for catalytic activity. Inhibition by BRL 42715 suggests they are serine
active site B-lactamases. The Mr of the enzymes was 48 kDa by gel filtration, whereas
their subunit form was estimated to be 24 kDa by SDS-PAGE. The results show they
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are dimers in the native state, similar to the L2 enzyme. This enzyme has a Mr of
56kDa when measured by gel filtration and a subunit Mr of 27 kDa when measured
by SDS-PAGE. Together, the XM-B group of enzymes hydrolysed a broad spectrum
of antibiotics including penicillins and cephalosporins, but not imipenem or
aztreonam, whereas the L2 enzyme was primarily a cephalosporinase, with poor
hydrolytic activity against the penicillins.
The XM-B group of enzymes appear to be well placed in the Bush Class 2b'
(extended broad spectrum B-lactamases inhibited by clavulanic acid (EBS-Y)) [172],
however without cloning of the individual genes into a suitable host and subsequent
sequencing of the enzymes, it is not possible to determine whether these enzymes
have diverse biochemical profiles.
Neither the XM-A nor the XM-B group of enzymes were shown to hydrolyse
aztreonam despite all strains examined exhibiting a high level of resistance to this
drug. Other workers have shown both LI [123] and L2 [203] to hydrolyse this
compound. This disparity was also noticed by Felici et al. [148], They failed to show
any hydrolysis of this substrate with the LI enzyme used in their study. Another
explanation of the high level resistance to aztreonam may be the low permeability of
the outer membrane ofX. maltophilia to the influx of antibiotics [202],
4.6. Concluding remarks
Although the genetic location of the genes which encode these B-lactamases has not
been precisely determined, the inducibility of the enzymes would suggest that they are
chromosomally mediated. Indeed from this study and others [33,205], there appears
to be a paucity of plasmid mediated B-lactamases in strains ofX maltophilia.
The XM-A and XM-B enzymes may be common amongst strains ofX maltophilia.
Cullmann & Dick [205] reported the presence of 6 distinct B-lactamases in 19 strains
ofX. maltophilia, on close scrutiny of the EEF polyacrylamide gel there appears to be
B-lactamases from strain 858 that are similar to those described in this report,
although Cullmann does not describe these enzymes in the text. Assuming that
Cullmann's strain 858 did code for enzymes similar to XM-A and XM-B, then XM-A
has not been visualised. Several of the strains examined in this study demonstrated
multiple B-lactamases only after prolonged staining. Payne et al. [33] reported similar
results in a recent study, and demonstrated that in some of their strains, metallo-B-
lactamases were visualised only after the gel was overlaid with zinc ions prior to
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B-lactamase, and that prolonged staining or overlaying the gel with zinc ions prior to
staining might have resulted in the visualisation of other enzymes. Further evidence
for this hypothesis stems from the fact that Cullmann was unable to shown any
inhibition by EDTA for any of his B-lactamases, and suggested a new class of
carbapenem hydrolysing B-lactamase, not inhibited by EDTA, and therefore not
metallo-B-lactamases. He does not mention what reporter substrate was used for the
inhibitor assays, but if a substrate was used that was hydrolysed more efficiently by
the serine B-lactamase rather than the metallo-B-lactamase (assuming that all X
maltophilia strains produce serine and metallo-B-lactamases), e.g. nitrocephin, then
he was simply demonstrating hydrolysis of the reporter substrate by the serine active
site B-lactamase, which would not have been inhibited by EDTA, rather than
inhibition of the metallo-B-lactamase.
Recently, Payne et al [33] also reported enzymes with similar pis in two strains ofX.
maltophilia.
It appears that within the species X. mciltophilia a number of different B-lactamases
are produced which differ from the B-lactamases ofmost other genera.
5.0. PCR-ampIification of genomic DNA from X.
maltophilia
The similarities of the physical and biochemical characteristics of the XM-B enzymes
to the TEM enzymes did not go unnoticed, similar isoelectric points, subunit Mr,
substrate profile and inhibition by potassium clavulanate. However, PCR of the
genomic DNA of X. maltophilia 5B105 with universal TEM primers, revealed no
amplification of TEM DNA, and hence no significant homology between the two
enzymes. Although an interesting hypothesis, the result was not unexpected. It has
been previously thought that the TEM-1 B-lactamase evolved from LEN-1, the
chromosomal B-lactamase of K. pneumoniae. This hypothesis was strengthened by
Huletsky et al. [67], who made significant inroads toward answering the question of
how the Class A B-lactamases evolved by studying the phylogeny of the SHV-2 B-
lactamase. They recognised two major groups of proteins, the B-lactamases of Gram
positive bacteria, and the B-lactamases of Gram negative bacteria. In the Gram
negative group, the PSE and CARB enzymes branched off early, followed by LEN-1,
and OHIO-1. SHV-1 and SHV-2 branch off from OHIO-1, and are separated by a
very short evolutionary distance. The TEM enzymes are situated close to the SHY
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family, indicating that they are highly related to this group. This thesis has also been
supported by the work ofArakawa el al. [262], Although sequence comparisons show
that LEN-1 shares only 67% amino acid homology with TEM-1 and SHV-1, the
sequence encompassing the active site is highly conserved, with 22 of 24 residues
identical [263],
6.0. Utilisation of selective pressure on E. coli with
imipenem.
Selective pressure on E. coli with imipenem, failed to select any mutations with the
ability to hydrolyse carbapenems. There was a slight increase in imipenem resistance
but no concomitant change in B-lactamase production. This slight increase is probably
as a result of change in outer membrane permeability. No TEM-derived B-lactamase
to date has been shown to hydrolyse carbapenems. This resistance to most B-
lactamases stems from the trans configurations of the side chains in the carbapenem
molecule rather than the cis configuration of other B-lactams [29],
At present, despite the steady world-wide increase in carbapenem usage, these
enzymes appear to be unable to affect the efficacy of the carbapenems.
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7.0. Epilogue
The primary aim of this thesis was to study the impact of the introduction of the more
powerful B-lactams on the susceptibility of a specific group of organisms isolated over
a 12 year period, with particular interest in the sensitivity of these strains to the newer
carbapenems. It is a concern that the incidence of resistance to the third generation
cephalosporins is probably higher than was anticipated. The extremely low incidence
of resistance to the newer carbapenems was reassuring although the discovery of the
6-lactamase ARI-1 from a strain of A. baumartnii is a concern. It demonstrates that
these enzymes do exist in the general bacterial population, and may be selected with
more extensive usage of carbapenems. Carbapenems are currently employed as a "last
line" defence in the battle against infection, and the spread of those organisms able to
resist these drugs would greatly compromise our ability to treat serious bacterial
infections in the future.
It was also shown that the ubiquitous bacterium, X. maltophilia produces a variety of
B-lactamases that hydrolyse almost the entire spectra of B-lactams. The increased use
of B-lactam drugs, particularly the newer carbapenem compounds, may facilitate the
emergence of this organism as an important pathogen. If the genes encoding these
enzymes acquire the capability to disseminate among the more common pathogens, it
will further diminish the range of antibiotics that are available for use in cases of
serious sepsis.
8.0. Directions for future research
The work in this thesis has perhaps allowed an insight into the types of B-lactamase
that may prove to be of greater clinical concern in the years to follow.
However, there is still work to be performed.
8.1. Screening
• It is vital that adequate screening programmes on the incidence of resistance of
Gram negative aerobic bacilli to various antimicrobials and subsequent analysis of
the resistance mechanisms to those strains be continued. Only by this mechanism
can we monitor future patterns of developing resistance.
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8.2. ARI-1
• It is crucial that the gene encoding for ARI-1 be cloned into a suitable plasmid
vector and the nucleotide sequence determined. This would allow the molecular
class and the evolutionary position of this gene to be determined.
• X-ray crystallography of the protein would provide information on the structure-
activity relationship of the enzyme. Such information would increase our
knowledge of the resistance mechanism of ARI-1 and help in the development of
more effective antimicrobials.
8.3. X. maltophilia XMCE type-1 B-lactamases
8.3.1. XM-A
• The physical and biochemical properties of XM-A are similar to those of LI,
however, only determination of the N-terminal sequence would allow a more
precise comparison. The LI gene has been cloned into E. coli but at present there
is no information on the nucleotide sequence.
8.3.2. XM-B
• Only purification of the enzymes to homogeneity (which has been shown to be
difficult), would allow more precise kinetic and biochemical studies to be
performed.
• Subsequent cloning and sequencing of the individual genes to establish the
nucleotide sequence(s) would allow examination of the molecular relationship
between these enzymes and confirm whether they were diverse enzymes, or
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Presented at the 6th European Congress on Clinical Microbiology and
Infectious Diseases (1993), Seville, Spain, Abstract no 1097.
The incidence of antibiotic resistance in Gram negative aerobic bacilli
isolated from blood cultures during 1980-91 from a large Scottish
teaching hospital.
R. Paton, J. Hood, R. S. Miles, S.G.B. Amyes.
Scottish Antibiotic Reference Laboratory,




This study investigated the susceptibility of 1453 Gram negative aerobic
bacilli isolated from Edinburgh Royal Infinnary during 1980-91. The
isolates were examined for their susceptibility to B-lactams,
aminoglycosides and the fluroquinolone, ciprofloxacin. All strains were
identified by API 20E or if non fermenters API 20NE strips. MICs were
performed on Oxoid isosensitest agar (1ST) with an inoculum of 10^
cfu/spot. Percentage resistance was calculated by referral to established
breakpoint values for each antimicrobial tested. As expected Escherichia
coli was the most prevalent species present (51%), with Klebsiella and
Pseudomonas spp the next most prevalent (10%). Organisms which are
known to produce a Class 1 chromosomal cephalosporinase constituted
approximately 20% of the total number of number of species present.
Overall resistance to ampicillin was 63%. Of the three aminoglycosides
tested gentamicin was the most effective (12% resistance), whereas
resistance to both netilmicin and tobramycin was around 20%. Resistance to
the second generation cephalosporin, cefuroxime was high (32%). The third
generation cephalosporins ceftazidime and cefotaxime displayed 21% and
16% resistance respectively. The carbapenem imipenem (4%) and
ciprofloxacin (3%) were the most efficacious.
Presented at the 33rd ICAAC, New Orleans, USA (1993)
Four Novel Discrete B-lactamases Responsible for Imipenem
Resistance in Xanthomonas maltophilia
Abstract
The B-lactamase complements of 18 strains of Xanthomonas maltophilia
isolated from blood cultures during 1980-91 from Edinburgh Royal
Infirmary were examined by isoelectric focusing (IEF). Seven of the 18
strains (40%) exhibited identical IEF patterns and revealed the presence of
at least four main bands of B-lactamase activity (pi 6.8, 6.2, 5.55, 5.2) when
stained with the chromogenic cephalosporin nitrocefin. The B-lactamase
band of pi 6.8 was eliminated by overlaying the gel with filter paper
containing ImM EDTA prior to staining, all other bands were unaffected. It
was not clear whether the three bands represented three distinct enzymes or
whether they were merely satellite bands of the same enzyme. To elucidate
this, each band was cut out of the acrylamide gel and the B-lactamase was
extracted placing the fragment into a dialysis sack and releasing the enzyme
in an electric field. Each 6-lactamase was then re purified, applied to an IEF
gel and re-separated. Each preparation focused as a single band at exactly
the same pi that it had originally migrated to. No satellite bands were found
with any of these preparations indicating that the original bands were not
satellite bands but discrete B-lactamases. Between them these B-lactamases
were able to hydrolyse and confer resistance to penicillins, all classes of
cephalosporins and imipenem. These results reveal the presence of four
previously unidentified B-lactamases from X. maltophilia, one inhibited by
EDTA (XMA-1), pi 6.8, and three others which focused at pi 6.2 (XMA-2),
pi 5.55 (XMA-3) and pi 5.2 (XMA-4).
Presented at the International Congress on the Management of Infection, Amsterdam,
Holland, Abstract No PI.41
Antibiotic Resistance in Gram Negative Aerobic Bacilli Isolated from Blood
Cultures During 1980-1989
R. Paton, J. Hood, R. S. Miles & S. G. B. Amves
Abstract
This study investigated the susceptibility of 167 aerobic Gram negative bacilli
(excluding Pseudomonas spp. and Xanthomonas spp.) which were isolated from
blood cultures in Edinburgh Rovai Infirmary from 1980-1989. These isolates had
previously been screened for resistance to cefuroxime (MIC> 4mg/l), and this study
examined them further for their susceptibilities to other B-lactams, gentamicin and
ciprofloxacin. All isolates were identified by API20E or 20NE. MICs were perfomied
on Oxoid 1ST (Isosensitest) agar with an inoculum of 104 cfu/spot. Percentage
resistance was calculated by referral to established breakpoint values for each
antimicrobial tested [1], As expected there was a large number of organisms, such as
Enterobacter spp. (49) and Serratici spp. (32), which produce an inducible
cephalosporinase. Despite the fact that Acimtobacter spp. do not normally possess an
inducible B-lactamase, there were 43 resistant members of this species in this sudy.
No single antibiotic was completely effective against all species. Imipenem was the
most effective with an incidence of <1.0% resistance, resistance to ciprofloxacin was
7.1% while resistance to gentamicin was 13%. All other antibiotics tested showed a
high incidence of resistance (>37%). The incidence of gentamicin resistante is
disturbing as aminoglycosides are used as frequently as the 13-lactams in the treatnent
of serious sepsis. Our results show that imipenem and ciprofloxacin remain nost
effective against these types of organisms.
[1] BSAC Working Party (1991). J. Antimicrob. Chemother. 27 (Suppl. D), 1-50.
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ARI 1: p-lactamase-mediated imipenem resistance in Acinetobacter
baumannii
R. Patona, R.S. Miles2, J. Hoodb and S.G.B. Amyesa
"Department ofMedical Microbiology, University ofEdinburgh Medical School, Edinburgh, UKand hDepartment ofBacteriology, Royal
Infirmary, Glasgow, UK
(Accepted 2 September 1992)
A strain of Acinetobacter baumannii 6B92 isolated from the blood culture of a patient at the
Edinburgh Royal Infirmary in 1985 wasfound to be resistant to imipenem, all classes ofcephalosporins
and penicillins. Extraction of the soluble proteins of the cell and isoelectric focusing revealed the
presence of two (3-lactamases: a chromosomal cephalosporinase of high pi (> pi 9.0) and a novel
(3-lactamase ofpi6.65 namedARI 1 (Acinetobacter resistant to imipenem). Despite thefact that the
original cliniccd isolate could be 'cured' of its resistance to imipenem andpenicillins by growing in the
presence ofethidium bromide with the concurrent loss of the ARI 1 enzyme, no resistanceplasmid was
visualised or transferred. The ARI 1 (3-lactamase hydrolysedpenicillin, ampicillin and cephaloridine
slowly during enzyme assay but inactivation of imipenem could only be demonstrated by microbiologi¬
cal means. The molecular size of the ARI 1 enzyme was 23 kDa and it was not inhibited by EDTA,
p-CMB. or clavulanate.
Key words: p-Lactamase; Resistance; Imipenem
Introduction
Acinetobacter spp. are short Gram-negative aero¬
bic bacilli and are important pathogens in noso¬
comial infections [1], They have been shown to pro¬
duce a series of cephalosporinases [2,3] some of
which have been particularly difficult to visualise [4],
Correspondence to: R. Paton F.I.M.L.S., Dept. ofMedical Mi¬
crobiology, University of Edinburgh Medical School, Teviot
Place, Edinburgh EH8 9AG, UK. Tel.: 031-650-8258; Fax: 031
650-6531.
However, all the cephalosporinases identified to
date have been chromosomally-mediated. Plasmid-
mediated P-lactamases do exist in Acinetobacter spp.
but they have always been penicillinases, which have
previously been identified in Pseudomonas spp. or
the Enterobacteriaceae [2], In addition Acineto¬
bacter spp. have developed an impressive pattern of
resistance to other antibiotics [5], In this report we
describe a novel P-lactamase enzyme from a strain of
Acinetobacter baumannii 6B92 isolated in 1985 from
a blood culture in Edinburgh Royal Infirmary. This
enzyme confers resistance to imipenem, penicillins
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and cephaloridine but not to second and third gener¬




All minimum inhibitory concentrations were de¬
termined on Isosensitest (1ST) agar (Oxoid Ltd.,
Basingstoke, UK) with an inoculum of 104 organ¬
isms per spot applied with a Denley multipoint inoc-
ulator. Disc sensitivities were performed and inter¬
preted as sensitive, intermediate or resistant by
Stokes' method as described by Holt and Brown [6]
on 1ST agar with a rotary plater.
p-lactamase preparation and purification
Cells were grown shaking overnight at 37°C in 9
ml of nutrient broth. This was used to inoculate a 1 1
culture of nutrient broth and the cells were grown
with shaking at 37°C for 18 h. The cells were har¬
vested by centrifugation at 6000 rpm for 15 min at
4°C. The pellet was washed in 25 mM sodium phos¬
phate buffer (pH 7.0) and recentrifuged at 4000 rpm
for 15 min. The pellet was resuspended in 4 ml of the
same buffer and disrupted by ultrasonication with
constant cooling (8 pm, 1 min x 3, MSE Soniprep
150, MSE Instruments, Crawley, UK). The debris
was removed by centrifugation at 12500 rpm at 4°C.
The preparation was partially purified by passing it
through a G-75 Sephadex gel filtration column (2
cm2 x 90 cm) (Pharmacia, Uppsala, Sweden). The
samples were eluted with 25 mM sodium phosphate
buffer, p-lactamase activity was detected by testing
each fraction with nitrocefin. Thirty pi of sample was
added to 100 pi of 50 mg/1 nitrocefin. A colour
change from yellow to red indicated the presence of
P-lactamase activity.
Molecular mass determinations
Molecular mass ( Mr) was determined by the
method ofAndrews [7], The molecular weight stand¬
ards were ovalbumin (45 000), chymotrypsinogen
(25 500) and cytochrome-*:' (12 384).
Isoelectric focusing
Samples were applied to a polyacrylamide gel con¬
taining ampholines with a pH range 3.5-10.6 (as de¬
scribed by Matthew et al. [8]). The gels were stained
by overlaying the surface of the gel with filter paper
soaked in nitrocefin (500 mg/1). The p-lactamase ac¬
tivity appeared as red bands on a yellow back¬
ground.
P-lactamase assays
The enzyme preparation was concentrated before
use in a centriprep 10 concentrator (Amicon,
Danvers, MA 01923, U.S.A.). Assays ofP-lactamase
activity were performed at 37°C on a Perkin Elmer
Lambda 2 spectrophotometer with freshly prepared
antibiotic solutions in 25 mM sodium phosphate
buffer (pH 7.0). Values of Umax and Km were derived
by linear regression analysis of Lineweaver-Burk
plots of initial velocity data at different substrate
concentrations.
Inhibition assays
The inhibitory dose for various inhibitors to re¬
duce the enzyme activity by 50% (ID50) was deter¬
mined by spectrophotometric assay at 37°C. The
rate of hydrolysis of nitrocefin (50 mg/1) by the P-
lactamase was measured. This procedure was re¬
peated with increasing concentrations of inhibitor
until the hydrolysis of nitrocefin was inhibited by
50%.
Genetic studies
Isolation of any plasmid DNA was attempted
with three differing techniques [9,10,11], All these
methods are essentially based on alkaline denatura-
tion ofchromosomal DNA but with differing proce¬
dures for purification and extraction of plasmid
DNA. One method has been shown to be especially
suitable for isolation ofplasmid DNA from Acineto-
bacter spp. [9]. Transfer of resistance was attempted
by conjugation to Escherichia coli J62-2, Pseudo-
monas aeruginosa PAO18 and a wild strain ofAcine-
tobacter baumannii at both 30°C and 37°C. Mobili¬
sation of resistance was attempted with the incP plas-
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mid RP4 [12], Ethidium bromide was used as a cur¬
ing agent [13]. Transformation of potential plasmid
DNA was attempted to Escherichia coli C600 [14],
Microbiological assay
This was done by a modification of the technique
described by Masuda et al. [15]. The indicator em¬
ployed was Staphylococcus aureus NCTC 6571. In¬
hibitory zones were determined to the antibiotics to
be tested and filter paper discs each containing 15 pi
of enzyme preparation undiluted or diluted 1:2, 1:4,
and 1:8 in 25 mM sodium phosphate buffer (pH 7.0)
were applied to plates seeded with Staphylococcus
aureus NCTC 6571 so that they would be at the pe¬
riphery of the expected zone of sensitivity. The plates
were incubated at 37°C overnight. Inactivation of
antibiotic was indicated by growth of the indicator
strain within the expected zone of inhibition.
TABLE 1
Disc susceptibility results and MICs of various antibiotics to
both the parent strain and the cured strain
Antibiotic 6B92 6B92 (Cured strain)
Disc MIC+ Disc MIC+
Ampicillin R >256 I 16
Piperacillin R - I -
Azlocillin R 128 I 16
Ampicillin/ R >128 I 8
Clavulanate*
Cephaloridine R - R -
Cephalexin R - R -
Cefuroxime R 32 R 32
Cefotaxime I 16 I 8
Ceftazidime I 4 I 4
Cefoxitin R - R -
Trimethoprim R - R -
Gentamicin S 0.5 S 0.5
Ciprofloxacin S 0.25 s 0.25
Imipenem R 16 s 0.12
Aztreonam R - R -
Abbreviations: R, resistant; I, intermediate; S, sensitive.
*2:1 ratio. The results are expressed in terms of ampicillin.
Not tested; +, MIC expressed as mg/1.
Results
Antibiotic susceptibilities
Acinetobacter baumannii 6B92 was resistant to all
penicillins tested and resistant or of intermediate
sensitivity to all classes of cephalosporins (Table 1)
and, surprisingly, resistant to imipenem. The MIC
value of imipenem was 16.0 mg/1.
Isoelectric focusing
Isoelectric focusing revealed the presence of two
[3-lactamases. One enzyme had several satellite
bands with a main band focusing at pi 6.65. The
other enzyme focused poorly and spread up the gel
towards the cathode (Fig. 1).
Molecular mass determinations
Both these enzymes were partially purified and
their molecular mass determined by gel filtration.





Fig. 1. Isoelectric focusing of Acinetobacter baumannii 6B92 [3-
lactamases. Lane A, TEM 1; B, SHV 1; C, 6B92 parent strain; D,
6B92 cured strain (P-lactamase activity of the enzyme of pi > 9




Hydrolysis ofp-lactam antibiotics by ARI 1 enzyme from Acine-
tobacter baumannii 6B92
Substrate Relative Fmaxa V br max NT
Penicillin 100 0.128 0.048
Ampicillin 153 0.196 0.139
Cephaloridine 35.7 0.07 0.083
''Relative to penicillin 100%.
bgmol 0f substrate hydrolysed/min/ml enzyme solution,
ptmol substrate.
had an Mr of 23 kDa whereas the enzyme of pi > 9
had an Mr of 58 kDa.
Hydrolysis of (3-lactam antibiotics by the ARI 1
enzyme from Acinetobacter baumannii 6B92
The Michaelis constant (Km) and the maximum
rate of hydrolysis (Fmax) of the pi 6.65 enzyme are
shown in Table 2. Penicillin and ampicillin were hy-
drolysed albeit weakly as was cephaloridine. Hy¬
drolysis of imipenem, cefuroxime, cefotaxime and
ceftazidime could not be demonstrated by spectro-
photometric methods even after prolonged assay
times. Although convenient it is known that spectro¬
photometry is not suitable for assay of all (3-lacta-
Fig. 2. Microbiological assay plate showing inactivation of
imipenem by Acinetobacter baumannii 6B92 ARI 1 enzyme.
mases. Microbiological assay is extremely sensitive
and clearly confirmed inactivation of imipenem
(Fig. 2) and azlocillin by the pi 6.65 enzyme. Ce¬
furoxime, ceftazidime and cefotaxime were not inac¬
tivated. This enzyme was thus designated ARI 1
(.Acinetobacter resistant to imipenem).
Inhibitor studies
The effects of inhibitors are shown in Table 3. The
ARI 1 enzyme required much higher amounts of
clavulanate for inhibition than TEM 1. P-chlorom-
ercuribenzoic acid (p-CMB) and EDTA did not in¬
hibit the ARI 1 enzyme. TEM 1 was much less sus¬
ceptible to inhibition with imipenem than the ARI 1
enzyme. This indicates that the ARI 1 (3-lactamase
binds imipenem much more strongly than TEM 1.
Genetic studies
Conjugation experiments uniformly could not
demonstrate the mobility of the ARI 1 gene and no
transfer of plasmid DNA was detected by transfor¬
mation to Escherichia coli C600 (data not shown).
However, Acinetobacter baumannii 6B92 could be
cured of its resistance to imipenem and penicillins. A
rate of cure of the resistance gene was obtained by
subculturing 100 pi of nutrient broth from the bottle
containing the lowest amount of ethidium bromide
(in this case 64 mg/1) which visibly inhibited the
growth of Acinetobacter baumannii 6B92 onto anti¬
biotic free medium. 40 distinct colonies were tested
for susceptibility to a range of antimicrobials. The %
rate ofcure was 10%. No resistance plasmid was vis¬
ualised or transferred. Once the strain had been
cured it contained only the diffuse (presumed chro-
TABLE 3
ID50 values of various inhibitors using nitrocefin (50 mg/1) as
substrate
Inhibitor IDS0 (pM)






mosomal) enzyme (Fig. 2). The ARI 1 (3-lactamase
could not be visualised on 1EF which initially sug¬
gested that the resistance gene was not located on the
bacterial chromosome and was probably situated on
a plasmid. When the resistance to imipenem was
cured with the subsequent loss of the ARI 1 enzyme
the disc sensitivity tests displayed loss of resistance
to penicillins and imipenem. This was further con¬
firmed by the MIC data (Table 1) as MICs of penicil¬
lins were reduced by a factor of at least 8 and the
MIC of imipenem was reduced by a factor of 100.
The MICs of second and third generation cepha¬
losporins were not significantly reduced suggesting
that resistance to these ^-lactams came from the
chromosomal (3-lactamase of high pi.
Discussion
Carbapenems were initially thought to be resis¬
tant to the hydrolytic action of (3-lactamases; how¬
ever, several Gram negative species have been shown
to produce enzymes which hydrolyse this group of
(3-lactams [16-22], No enzymatic resistance to car¬
bapenems by Acinetobacter spp. has been reported
so far. Recent studies on resistant strains ofAcineto¬
bacter spp. selected in the laboratory have indicated
that the resistance mechanism involved results from
the interplay between penicillin binding proteins
with altered expression and/or affinity for (3-lactams
and decreased permeability of the outer membrane
[23,24],
The enzymes which hydrolyse carbapenems are
thought to be of chromosomal origin although there
have been reports of plasmid mediated metalloen-
zymes present in Pseudomonas aeruginosa [25] and
Bacteroidesfragilis [26], The production of the novel
enzyme described in this report can be cured with the
addition of ethidium bromide to the growth me¬
dium. Initially this was thought to indicate a plasmid
location for the resistance gene; however, no resis¬
tance plasmid could be visualised and no transfer of
resistance obtained by a variety of methods. It has
been shown elsewhere that self transmissible R plas-
mids transferred from Escherichia coli to Acineto¬
bacter spp. required a mobilising plasmid for re-
transfer to occur [27], Goldstein et al. [28] demon¬
strated that Acinetobacter R plasmids could transfer
and express in Escherichia coli but at very low fre¬
quency. This leads us to the conclusion that the resis¬
tance might be chromosomally based and the curing
experiments have effected a mutation in the host
chromosome. However, this finding does not ex¬
clude resistance traits introduced into strains from a
plasmid as genetic sequences may be incorporated
into the bacterial chromosome, especially from
transposons [29] and it is clear that the ARI 1 enzyme
is not part of the normal (3-lactamase complement of
this genus [4],
The enzyme of high pi appears to be a chromoso¬
mal cephalosporinase of the type described by Hood
and Amyes [30], These typical Acinetobacter en¬
zymes have been shown to focus poorly on conven¬
tional isoelectric focusing systems [30].
Hydrolysis of all substrates was very slow and in¬
deed inactivation of imipenem and azlocillin could
only be demonstrated bymicrobiological means. No
inactivation of cefuroxime, cefotaxime or cef¬
tazidime was observed. In this instance it is possible
that the ARI 1 enzyme functions by a mechanism
similar to that in which class 1 cephalosporinases
'trap' the antibiotic [31] by high concentrations of
P-lactamase in the periplasmic space; however
Acinetobacter spp. are not known to produce a class
1 cephalosporinase and Bergogne-Berezin and Joly-
Guillou [5] did not think that typical cephalospori¬
nases produced by Acinetobacter spp. were responsi¬
ble for resistance to imipenem and that the mecha¬
nism of resistance in these strains probably results
from a selective decrease in permeability across the
bacterial outer membrane resulting in decreased rate
of antibiotic uptake.
This is the first report of a non zinc dependent
carbapenemase from Acinetobacter spp. Most car-
bapenemases contain a zinc ion at their active site
which is essential for catalytic activity. Yang et al.
[22] reported an enzyme from Serratia marcescens
that was inactivated by EDTA; however, the addi¬
tion ofzinc sulphate did not restore catalytic activity.
Cullman et al. [32] reported non EDTA inhibition in
strains of Xanthomonasmaltophilia. The enzyme de¬
scribed in this report is resistant to inhibition by
EDTA, clavulanate and pCMB, but not to
imipenem.
There has been a plethora of extended spectrum
enzymes [33] reported over the last few years but it
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has been shown that these have little effect on car-
bapenems [34], Many of these enzymes have been
shown to evolve through selective pressure and to be
derived from the TEM and SHV family [33], The
ARI 1 (3-lactamase has an unusual spectrum ofactiv¬
ity, it does not have an extended spectrum profile in
that it does not hydrolyse second and third genera¬
tion cephalosporins, whereas other carbapenemases
reported have a wide substrate specificity.
It is interesting to speculate on the origin of this
enzyme. The isolate described in this report was iso¬
lated in 1985 before carbapenems were in use in our
hospital and the concern must therefore be that these
enzymes have already been in the general population
of organisms for some time. If they are able to dis¬
seminate between species they will greatly reduce our
capability to treat bacterial infections effectively in
the future.
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Antibiotic resistance in urinary bacteria isolated in central Scotland
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The levels ofantibacterial resistance amongst 991 strains responsiblefor significant bacteriuria, isolated in central Scotlandat
the endof J990. have been determined by breakpoint sensitivity testing. Overall resistance to the commonly used antibacterials
for UTI, trimethoprim and ampicillin was 23% and 36%, revealing that resistance to these agents in central Scotland had not
significantly changed over the last ten years. High levels ofampicillin resistance have led to the widespread use ofamoxicillin in
combination with the (3-lactamase inhibitor clavulanic acid. The effectiveness ofthis approach was demonstratedby thefact that
resistance among these urinary isolates to amoxicillin/clavulanic acid was only 6%. More detailed examination ofEscherichia
coli isolates, which were ampicillin-resistant, revealed that the addition of clavulanic acid restored sensitivity in 97.5% of the
strains.
Introduction
Treatment of urinary tract infection represents one of
the main uses of antibacterial agents and monitoring the
sensitivity of urinary isolates reveals essential information
about the changing patterns of antibiotic resistance in a
local bacterial population [1-3]. The purpose of this study
was to establish the incidence of antibiotic resistance in
urinary bacteria isolated in central Scotland. Local factors
greatly influence the incidence of resistance and therefore
assessments of changes in resistance are more significant if
they are made from follow up surveys from the same cen¬
tres [4], We compare the results from this survey with simi¬
lar investigations on specific common antibacterials car¬
ried out between 1981 and 1984 [5-7].
Owing to the development of resistance the early main¬
stays of treatment; namely cotrimoxazole, trimethoprim,
nalidixic acid and ampicillin have been joined by many
further (3-lactam antibiotics, (3-lactam/|3-lactamase inhibi¬
tor combinations and the 4 quinolones. In this study partic¬
ular attention was paid to resistance to (3-lactams and to
Correspondence to: Dr C.J. Thomson, Scottish Antibiotic Reference
Laboratory, Dept. of Medical Microbiology, The Medical School, Uni¬
versity of Edinburgh, Teviot Place, Edinburgh EH8 9AG, Scotland,
United Kingdom. Fax: International Code +44+31 650 6531. Tel.: Inter¬
national Code+44+31 650 3127.
(3-lactam/p-lactamase inhibitor combinations, reflecting
the importance of this antibiotic group for treatment of
urinary tract infection.
Materials and Methods
Isolation of causative bacteria
Approximately 1000 consecutive urinary isolates, ob¬
tained at the end of 1990 from patients with >105 organ¬
isms/ml, were examined. The specimens were sent to the
diagnostic laboratories of the Royal Infirmaries of
Glasgow and Edinburgh, cultured onto CLED agar and
the causative organism isolated. The organism was identi¬
fied by the API 20E system unless it was a non-fermentor
when it was identified by the API 20NE strip.
Minimum inhibitory concentrations
Minimum inhibitory concentration (MIC) plates were
made up with doubling dilutions of the antibacterial drug
in Isosensitest Agar (Oxoid, Basingstoke, Hants). Each
urine isolate was cultured overnight in nutrient broth and
diluted in Davis-Mingioli medium to provide 104cfu per pi
[8,9]. One pi was inoculated onto the surface of each plate
with a Denley multipoint inoculator and the plates were
224
incubated aerobically at 37°C for 24 h. The amoxicillin
plus clavulanic acid determinations were performed at a
ratio of 2:1 (amoxicillinxlavulanic acid) and expressed in
terms of the amoxicillin concentration [10]. The MIC was
taken as the lowest concentration which gave no visible
growth.
Antibiotic breakpoint sensitivities
Antibiotic breakpoint sensitivities listed in Table 1 were
performed on Oxoid Isosensitest Agar according to the
BSAC guidelines [9], Drug containing plates were checked
with a variety of control organisms of known sensitivity.
Results
Overall resistance to the antibiotics tested
The resistance of all the urinary strains was tested at
fixed antibiotic concentrations. The total number of bacte¬
ria resistant to each antibiotic is shown in Table 1. So that
the results may more easily be compared, the percentage
resistance has been listed alongside. The highest incidence
of resistance was against ampicillin, where nearly 37% of
the strains were not susceptible to the drug. However,
many diverse species were included in this overall result
including Pseudomonas spp. and there may be consequent
bias. The breakdown of the species involved can be seen in
Table 2. Most of the bacteria were Escherichia coli, as
TABLE 1
The overall resistance of all species tested from both Glasgow and Ed¬
inburgh - total 991 strains
Antibiotic Cone, (mg/1) Not resistant resistant (%)
Ampicillin 32 363 36.6
Amoxicillin 32 65 6.6
+ clavulanic acid 16
Cephalexin 32 146 14.7
Cefuroxime 32 112 11.3
Cefotaxime 16 71 7.2
Ceftazidime 32 70 7.0
Imipenem 4 4 0.4
Nalidixic acid 32 138 13.9
Ciprofloxacin 4 14 1.4
Ofloxacin 16 10 1.0
Gentamicin 8 28 2.8
Nitrofurantoin 32 104 10.5
Trimethoprim 8 230 23.2
would be expected in a study of aerobic urinary bacteria
such as this.
Breakdown of bacterial genera or species and the incidence
of resistance within each genus
Because of the bias produced by inherently resistant bac¬
teria, the incidence of resistance within each genus of spe¬
cies group was determined. The breakdown of bacterial
genera and species and the number of resistant strains is
shown in Table 2. The blanks record no resistant bacteria.
So that easy comparisons may be made, the percentages
are shown in Table 3. As predicted, Pseudomonas had a
high incidence of inherent resistance to many antibacterial
drugs. Interestingly there were no Pseudomonas spp. resis¬
tant to ceftazidime or gentamicin and very low resistance to
the 4-quinolones was demonstrated. There was a small in¬
cidence of resistance to imipenem. The 4-quinolones were
less effective against the Staphylococcus aureus but all the
[3-lactam antibiotics were effective. There was no evidence
ofmulti-resistant variants of this species. Streptococci and
enterococci remained sensitive to 4-quinolones but, as ex¬
pected, showed more resistance to cephalosporins . They
do, however, remain sensitive to ampicillin.
Ampicillin alone fares less well against members of the
Enterobacteriaceae, in particular Escherichia coli. The
combination of clavulanic acid with amoxicillin rendered
most members of this family of bacteria sensitive. This was
particularly noticeable with Escherichia coli but barely ap¬
parent with Citrobacter.
The concentration at which the antibiotic is tested is cru¬
cial in the evaluation of the proportion of resistant strains.
In Table 4 we have compared the proportion of resistant
strains to three cephalosporins at two concentrations. The
higher concentrationmay be more appropriate for the test¬
ing of urinary bacteria but would be too high for testing
bacteria isolated from other sites. This is an important
point aswithin hospitals there is a well documented spread
of resistant organisms and breakpoint testing of urinary
isolates will not reveal potential problems such as the pres¬
ence of extended spectrum p-lactamases.
Comparison of incidences of resistance between Edinburgh
and Glasgow
The strains for this study were taken from the twomajor
teaching hospitals in the two major cities of central Scot¬
land. It is known that geographic variation may be impor¬
tant in the incidences of bacterial resistances. Indeed in a
previous study carried out in 1984 a considerable differ¬
ence was found between urinary isolates from Edinburgh
and Glasgow with the levels of ampicillin resistance found








































































































































































































































































































































































































The differential proportion of resistant bacteria, from both Glasgow and
Edinburgh, tested at two different concentrations
Species (AO Cefuroxime Cefotaxime Ceftazidime
32 8 16 2 32 4
TABLE 6
Comparison of the incidences of resistance in Escherichia coli from Ed¬
inburgh (336 strains) and Glasgow (307 strains)
Antibiotic Number Percentages
Edinburgh Glasgow Edinburgh Glasgow
E. coli (643) 10 64 - 5 3 11 Ampicillin 125 147 37.2 47.8
Coliforms (3) 1 2 - - - - Augmentin 6 4 1.8 1.3
Proteus (80) 10 16 - - - - Cephalexin 14 13 4.2 4.2
Morganella (3) - 2 - - - - Cefuroxime 2 8 0.6 2.6
Klebsiella (59) 4 10 1 1 - 1 Cefotaxime - - - -
Enterobacter (21) 4 9 2 4 - 3 Ceftazidime 3 - 0.9 -
Citrobacter (12) 2 5 - 2 - 2 Imipenem - - - -
Serratia (2) - - - - - - Nalidixic acid 20 5 5.9 1.6
Pseudomonas (47) 45 45 30 44 - 11 Ciprofloxacin 1 - 0.3 -
Acinetobacter (2) 2 2 2 2 - 2 Ofloxacin 1 - 0.3 -
S. aureus (19) 1 1 1 5 7 18 Gentamicin 5 - 1.5 -
Coagulase-negative Nitrofurantoin 12 7 3.6 2.3
staphylococci (38) 2 5 2 12 12 27 Trimethoprim 64 65 19.0 21.2
Streptococcus (42) 29 29 28 29 31 31
Enterococcus (18) 2 6 4 5 17 18
Undefined (2)
to be 48.5% and 71.9%, respectively [5]. Therefore, we com¬
pared the incidences of resistance between Edinburgh and
Glasgow, for all the strains (Table 5) and for the Escheric¬
hia coli strains (Table 6). The results in Table 5 suggest that
Glasgow had a slightly more resistant population, except
perhaps for nalidixic acid and the fluorinated 4-qui-
nolones. This would be difficult to quantify because of the
variation in species distibution. However, when we exam¬
ined the Escherichia coli strains separately (Table 6), the
TABLE 5
Comparison of the incidences of resistance in all strains from Edinburgh
(491 strains) and Glasgow (500 strains)
Antibiotic Number Percentages
Edinburgh Glasgow Edinburgh Glasgow
Ampicillin 162 201 33.0 40.2
Augmentin 27 38 5.5 7.6
Cephalexin 65 81 13.2 16.2
Cefuroxime 32 80 6.5 16.0
Cefotaxime 17 54 3.5 10.8
Ceftazidime 27 43 5.5 8.6
Imipenem 1 3 0.2 0.6
Nalidixic acid 72 66 14.7 13.2
Ciprofloxacin 11 3 2.2 0.6
Ofloxacin 8 2 1.6 0.4
Gentamicin 13 15 2.6 3.0
Nitrofurantoin 47 57 9.5 11.4
Trimethoprim 98 132 20.0 26.4
converse appeared to be true, as the bacteria from Ed¬
inburgh were invariablymore resistant except to ampicillin
and trimethoprim.
TABLE 7
The different amoxycillin and amoxycillin/clavulanic acid sensitivity phe-
notypes in Escherichia coli.
Minimum inhibitory concentration (mg/1) Number Percentage
Amoxicillin Amoxycillin+clavulanic acid
1024 64 3 1.2
1024 32 8 3.2
1024 16 86 34.8
1024 8 74 30.0
512 256 1 0.4
512 64 1 0.4
512 32 4 1.6
512 16 2 0.8
512 8 44 17.8
512 4 7 2.8
256 128 1 0.4
256 32 1 0.4
256 16 1 0.4
256 8 1 0.4
256 4 4 1.6
128 32 2 0.8
16 32 1 0.4
8 8 1 0.4
8 4 2 0.8
4 4 2 0.8
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Detailed examination of the ampicillin resistant Escherichia
coli strains
All ampicillin resistant Escherichia coli strains were
tested for the minimum inhibitory concentration (MIC) of
amoxicillin and amoxicillin plus clavulanic acid. The dif¬
ferential results obtained with amoxicillin and the combi¬
nation revealed a considerable number of different pheno-
types. In other words, resistance in the population was not
a result of the clonal spread of one bacterial type. In Table
7, the different phenotypes are listed in descending order of
their amoxicillin MICs. The results demonstrate the effec¬
tiveness ofclavulanic acid in restoring amoxicillin resistant
strains to sensitivity
Discussion
In this first comprehensive study of general antibiotic
resistance in Central Scotland, we have compared the rela¬
tive sensitivities of a block of clinical urinary isolates to a
series of antibiotics. Some of the antibiotics such as ampi¬
cillin, amoxicillin plus clavulanic acid, cephalexin, ce-
furoxime, ciprofloxacin, ofloxacin and trimethoprim are
commonly-used against urinary infections. Some of the
drugs such as nitrofurantoin and nalidixic acid, despite the
low incidences of resistance, are now rapidly falling from
favour. The remaining drugs tested ceftazidime and ce¬
fotaxime are not currently used against urinary pathogens;
however, their inclusion gave a measure of the incidence of
resistance in each species to these newer drugs and oral
versions of them may soon be used.
The results in this survey show that amongst the Escher¬
ichia coli the highest incidence of resistances were found to
the ampicillin/amoxicillin group and to trimethoprim the
resistances being 42.3% and 20.1%, respectively. This is
similar to other studies in the UK [1,2,11,12]. However,
when amoxicillin was combined with clavulanic acid
(tested at a ratio of 2:1 amoxicillinxlavulanic acid), 97.5%
of the ampicillin/amoxicillin resistant strains were now
sensitive, indicating the continuing efficacy of clavulanic
acid to combat [[-lactamase mediated resistance to ampi¬
cillin. Similar conclusions have been reported by other
workers [13]. The sensitivity to the amoxicillin/clavulanic
acid combination amongst the E. coli was better than tri¬
methoprim and cephalexin and similar to the second-gen¬
eration cephalosporin cefuroxime. The amoxicillin/clavu¬
lanic acid combination was also effective in challenging the
ampicillin/amoxicillin resistant strains of Proteus spp. and
Klebsiella spp. It was less effective against Enterobacter
spp. and virtually without effect on resistant Pseudomonas
spp., as would be expected. The results showed little differ¬
ence between the incidences of resistance in Glasgow and
Edinburgh, in contrast to earlier studies [5] except that Ed¬
inburgh had a slightly greater problem with 4-quinolone
resistance and Glasgow with ampicillin/amoxicillin resis¬
tance. However, when the Glasgow E. coli strains were
tested with the combination, there was no significant dif¬
ference between Glasgow and Edinburgh.
In comparison with our earlier studies it is encouraging
to see that there has been no rise in resistance to the com¬
mon urinary antibacterials trimethoprim and ampicillin.
Resistance to trimethoprim in 1981 was 21% in Edinburgh
compared with 20% ten years later [7], Ampicillin resis¬
tance in fact appears to have fallen from 48.5% to 33% in
Edinburgh and from 79% to 47.8% in Glasgow. Whether
this results from a more judicious use of antibacterial
agents or simply that there are more antibiotics to choose
from and the resistance load is spread more widely is not
clear.
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The incidences of resistance to cephalosporins and fluorinated 4-quinolones
in similar strains isolated in Glasgow and Edinburgh
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Bacterial sensitivity to cefuroxime, ceftazidime, cefotaxime, ciprofloxacin and ofloxacin was deter¬
mined for 1386 urinary andbacteraemia isolatesfrom Glasgow and Edinburgh to determine the impact
ofthese antibacterials on the development ofresistance. The M1CS0 andMICgo values were determined
for each species or genus. Cefuroxime was the least effective antibacterial drug and cefotaxime was the
most potent cephalosporin, but it rarely matched the efficacy of the 4-quinolones. There was little
difference in the sensitivities ofGram-negative bacteria from Edinburgh or Glasgow but Gram-positive
bacteria isolated in Glasgow were usually more resistant. There has been no significant emergence of
resistant Gram-negative bacteria even amongst the Pseudomonas spp.; however, the proportion of
Gram-positive bacteria resistant to these drugs is higher in Scotland than elsewhere.
Key words: Cephalosporins; 4-Quinolones; Resistance; Bacteremia; ScotlandK I |HH T1
Introduction
In central Scotland there has been a steady use of
cefuroxime, ceftazidime, cefotaxime and cip¬
rofloxacin during the last few years. During the
1980s these drugs represented the ultimate weapons
in our arsenal to control multiresistant bacteria [1,2].
Correspondence to: Prof. S.G.B. Amyes. Scottish Antibiotic
Reference Laboratory, Dept. of Medical Microbiology, The
Medical School, University of Edinburgh, Teviot Place, Edin¬
burgh EH8 9AG, Scotland, United Kingdom. Tel.:
44 31 650 3163; Fax: 44 31 650 6531.
Ceftazidime has mainly been used for the treatment
of infectious diseases in immunocompromised pa¬
tients [3] and cefuroxime as an alternative to amino¬
glycosides to control nosocomial infections [4], Cip¬
rofloxacin has been the only fluorinated 4-quinolone
drug used in this area before the strains were col¬
lected. These drugs were genuinely believed to be so
sophisticated that no bacterial resistance would
emerge in species that are normally sensitive to them.
This has, however, been far from the truth. In many
areas in Europe and elsewhere, many clinical bacte¬
ria have emerged which are resistant to the extended-
spectrum cephalosporins [5], In some part this has
resulted from the capability of the plasmid-encoded
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TEM and SHV beta-lactamase genes to undergo
simple mutation which allowed the resultant enzyme
to hydrolyse all extended spectrum cephalosporins
[5]. Similarly clinical strains of staphylococci and
pseudomonas have emerged which are resistant to
ciprofloxacin [6,7], Unlike their beta-lactam resis¬
tant counterparts, the strains resistant to cip¬
rofloxacin possess mutations exclusively in the chro¬
mosomal DNA and the resistance is still not plas-
mid-mediated [8], Despite this, however, the prob¬
lem of resistance is still increasing.
In order to evaluate the impact of the introduction
of these drugs on the development of resistance we
examined 1386 strains isolated consecutively in the
diagnostic laboratories of the two main teaching
hospitals in central Scotland, the Royal Infirmaries
in Glasgow and Edinburgh.
Materials and Methods
Isolation of causative bacteria
Consecutive significant urine specimens sent to
the diagnostic laboratories of the Royal Infirmaries
of Glasgow and Edinburgh at the end of 1990 were
cultured onto CLED agar and the causative organ¬
ism isolated. The organism was identified by the API
20E system unless it was a non-fermenter whereby it
was identified by the API 20NE strip.
Minimum inhibitory concentrations
Minimum inhibitory concentration (MIC) plates
were made up with doubling dilutions ofcefuroxime,
ceftazidime, cefotaxime, ciprofloxacin and ofloxacin
in Isosensitest Agar (Oxoid, Basingstoke, Hants).
Each urine isolate was cultured overnight in nutrient
broth and diluted in Davis-Mingioli medium to pro¬
vide 104cfuperpl [9,10], One pi was inoculated onto
the surface of each plate with a Denley Multipoint
Inoculator and the plates were incubated aerobically
at 37°C for 24 h. The MIC was taken as the lowest
concentration which gave no visible growth. Simi¬
larly the positive blood cultures were isolated on the
Roche slide and these organisms were diluted to pro¬
vide 104cfuper pi. This dilution was inoculated onto
the MIC plates as before. For those bacteria requir¬
ing blood, the MIC plates were supplemented with
5% whole horse blood.
Results
At the end of 1990 we examined 975 isolates
responsible for significant bacteriuria (491 from
Edinburgh and 484 from Glasgow) and 411 strains
TABLE 1




Urine isolates 491 484
All Gram-positives 58 50
Streptococcus and Enterococcus 20 32
Staphylococcus spp. 38 18
All Gram-negatives 433 434
Acinetobacter 2
Citrobacter spp. 10 2
Coliforms 3
Enterobacter spp. 8 13
Escherichia coli 336 305
Klebsiella spp. 29 30
Proteus and Morganella spp. 28 53
Pseudomonas 15 31
Serratia 2
Blood isolates 228 183
AH Gram-positives 121 114
Diphtheroids 1 5
Enterococcus 12 3
Staphylococcus aureus 53 40
Coagulase-negative staphylococcus 39 49
Streptococcus spp. 16 17
















Range 50% 90% Range 50% 90%
All Gram-negatives
Cefuroxime <0.008—> 128 2 8 <0.008-64 4 32
Ceftazidime <0.008-128 0.12 0.5 0.015-16 0.25 1
Cefotaxime <0.008-64 0.03 0.12 <0.008-64 0.03 0.12
Ciprofloxacin <0.008-32 0.03 0.06 <0.008-1 0.016 0.06
Ofloxacin <0.008-32 0.12 0.25 <0.008-8 0.12 0.25
Escherichia coli
Cefuroxime <0.008->128 2 4 <0.008-128 4 8
Ceftazidime 0.03-128 0.12 0.25 0.015-16 0.25 0.5
Cefotaxime <0.008-8 0.03 0.06 <0.008-2 0.03 0.12
Ciprofloxacin <0.008-16 0.03 0.06 <0.008-1 0.016 0.03
Ofloxacin <0.008-32 0.06 0.12 <0.008-8 0.06 0.12
Klebsiella spp.
Cefuroxime 0.25-128 1 4 0.12-128 2 16
Ceftazidime 0.03-0.5 0.06 0.25 0.06-16 0.12 0.5
Cefotaxime <0.008-0.5 0.015 0.12 <0.008-16 0.03 0.12
Ciprofloxacin <0.008-0.5 0.03 0.06 <0.008-1 0.03 0.06
Ofloxacin 0.03-2 0.12 0.25 0.03-1 0.12 0.5
Proteus andMorganella spp.
Cefuroxime <0.008—> 128 0.5 16 0.25-128 1 32
Ceftazidime <0.008-16 0.03 0.06 0.06-1 0.12 0.25
Cefotaxime <0.008-0.5 <0.008 0.016 <0.008-0.12 0.015 0.03
Ciprofloxacin <0.008-2 0.03 0.06 <0.008-0.25 0.03 0.06
Ofloxacin 0.03-2 0.12 0.25 0.03-0.25 0.06 0.25
Pseudomonas aeruginosa
Cefuroxime 64—> 128 >128 >128 1-128 128 128
Ceftazidime 0.5-16 1 16 0.5-8 2 4
Cefotaxime 2-64 8 16 0.06-64 16 16
Ciprofloxacin 0.12-32 0.25 0.5 <0.008-0.25 0.06 0.25
Ofloxacin 0.5-32 1 4 <0.008-* 1 2
isolated from blood culture (228 from Edinburgh
and 183 from Glasgow).
Gram-negative isolates responsible for significant
bacteriuria
Amongst the urinary isolates, 867 were Gram-
negative bacteria ofwhich 641 were identified as Es¬
cherichia coli (Table 1). Examination of all the
Gram-negative bacteria revealed that cefuroxime
was considerably less effective than the four other
drugs tested; the MIC90 for cefuroxime was between
16- and 32-fold higher than it was for the least effec¬
tive of the other drugs (Table 2). This differential was
found within individual species; amongst the E. coli
strains there was a 16-fold increase in the MIC90 of
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TABLE 3




Range 50% 90% Range 50% 90%
All Gram-positives
Cefuroxime <0.008->128 1 8 <0.008-128 128 128
Ceftazidime 0.12—>128 16 >128 0.12-128 128 128
Cefotaxime 0.015—> 128 1 8 0.015-128 128 128
Ciprofloxacin 0.03-64 0.5 4 <0.008-128 1 2
Ofloxacin 0.12-128 1 4 <0.008-64 1 2
Streptococcus and Enterococcus spp.
Cefuroxime <0.008—> 128 4 8 <0.008-128 128 128
Ceftazidime 0.12—> 128 128 >128 0.25-128 128 128
Cefotaxime 0.015—> 128 1 64 0.015-128 128 128
Ciprofloxacin 0.5M 1 2 0.03-4 1 2
Ofloxacin 1-4 2 4 0.12-4 2 2
Staphylococcus spp.
Cefuroxime 0.03->128 0.5 8 <0.008-64 0.5 4
Ceftazidime 0.12—> 128 8 32 0.12-128 32 64
Cefotaxime 0.015-128 1 4 0.06-32 1 8
Ciprofloxacin 0.03-64 0.25 64 <0.008-128 0.5 1
Ofloxacin 0.12-128 1 4 <0.008-64 0.25 0.
cefuroxime compared with the MIC90 of cef¬
tazidime.
Ceftazidime was always less active than cefotax¬
ime or the two fluorinated 4-quinolones. There was
little to choose between the efficiencies of these three
drugs especially in the strains isolated in Edinburgh.
Amongst the Glasgow isolates, the MICs of cip¬
rofloxacin were consistently lower than those of ce¬
fotaxime and ofloxacin. On the other hand, cefotax¬
ime was at least as effective as ciprofloxacin and
rather more effective than ofloxacin when Proteus/
Morganella and Klebsiella species were examined
individually. The results with the Pseudomonas spp
showed that only ciprofloxacin remained efficient;
almost all the strains were cefuroxime resistant and
showed limited susceptibility to cefotaxime (Table
2). There was considerable variation between the
ratio of the MICs of ciprofloxacin and ofloxacin,
suggesting that the latter drug was more vulnerable
to the inherent resistance properties of this species.
Gram-positive isolates responsible for significant
bacteriuria
There were 108 Gram-positive urinary isolates
(Table 3). Examination ofall the Gram-positive bac¬
teria revealed that ceftazidime was the weakest of the
five drugs tested. This also showed up when the bac¬
teria were examined in species groups. Amongst the
Gram-positive bacteria, the strains isolated in
Glasgow were consistently more resistant to the
cephalosporins than those isolated in Edinburgh.
The results of the species groups suggest that this
may result from the Streptococci and Enterococci in
the Glasgow population; these isolates seem to have
a particularly high incidence of cephalosporin resis¬
tance. The fluorinated 4-quinolones were usually
more active than the cephalosporins; it was difficult
to distinguish between ciprofloxacin and ofloxacin
against the Streptococci and Enterococci but oflo¬
xacin was more efficient against the Staphylococci.
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Gram-negative bacteraemia isolates
Examination of the Gram-negative bacteria re¬
sponsible for bacteraemia (Table 4), revealed fewer
differences between the efficacies of the drugs than
there had been with the Gram-negative urinary bac¬
teria except that cefuroxime was always considera¬
bly less effective than the others. At the bottom of the
MIC range the Glasgow isolates tended to be more
resistant to cefuroxime than those from Edinburgh;
the lowest Glasgow MIC was 1 mg/1 compared with
less than 0.01 mg/1 in Edinburgh. This differential
stemmed mainly from isolates other than E. coli. The
sensitivity of the E. coli strains to the other four
drugs was very similar to the E. coli in the urinary
isolates. No significant distinction could be made be¬
tween the drugs; however, amongst the strains over¬
all the two 4-quinolones were more effective than
ceftazidime or cefotaxime, with the strains margin¬
ally more resistant to ofloxacin than ciprofloxacin.
Gram-positive bacteraemia isolates
The fluorinated 4-quinolones were usually more
effective against the Gram-positive bacteraemia iso¬
lates than the cephalosporins (Table 5). This was ap¬
parent with the Streptococcus and Enterococcus
group from Edinburgh as it had with the urinary
bacteria; however, the strains from Glasgow ap¬
peared more sensitive. The proportion of inherently-
resistant enterococci in the Glasgow population was
rather lower than in the group from Edinburgh and
this probably accounts for the differential. Staphylo¬
coccus aureus remained susceptible to all the drugs
except ceftazidime. This was not the case with the
coagulase-negative staphylococci; in both Edin¬
burgh and Glasgow, a considerable proportion of
these isolates were resistant to each drug. In
Glasgow the coagulase-negative staphylococci were
more resistant to the cephalosporins than the Edin¬
burgh isolates had been.
TABLE 4




Range 50% 90% Range 50% 90%
All Gram-negatives
Cefuroxime <0.008—> 128 4 128 1—> 128 4 32
Ceftazidime <0.008-128 0.06 2 0.06-64 0.25 8
Cefotaxime <0.008-32 0.03 8 0.015-32 0.06 4
Ciprofloxacin <0.008-2 0.03 0.5 <0.008-0.5 0.015 0.12
Ofloxacin <0.008-4 0.12 1 0.03-1 0.06 0.12
'scherichia coli
Cefuroxime 0.5-64 2 4 1—>128 4 4
Ceftazidime <0.008-2 0.06 0.12 0.06-64 0.25 0.5
Cefotaxime <0.008-1 0.03 0.06 0.015-16 0.06 0.12
Ciprofloxacin <0.008-2 0.03 0.06 <0.008-0.03 0.015 0.03
Ofloxacin 0.03^4 0.06 0.12 0.03-0.12 0.06 0.12
'lebsiella spp.
Cefuroxime <0.008-16 1 4 1-4 2 4
Ceftazidime 0.03-1 0.06 0.25 0.06-0.5 0.25 0.25
Cefotaxime <0.008-0.12 0.03 0.06 0.015-0.25 0.06 0.06
Ciprofloxacin 0.03-0.5 0.06 0.12 0.015-0.12 0.06 0.06
Ofloxacin 0.03-2 0.12 0.25 0.06-0.5 0.12 0.12
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Range 50% 90% Range 50% 90%
All Gram-positives
Cefuroxime <0.008—> 128 1 128 0.015—> 128 1 32
Ceftazidime 0.03—> 128 8 >128 0.03—> 128 8 128
Cefotaxime <0.008—> 128 1 16 0.015—> 128 2 64
Ciprofloxacin 0.03-64 0.5 4 0.12—> 128 1 8
Ofloxacin 0.12-32 0.5 4 0.12-128 1 4
Streptococcus and Enterococcus spp.
Cefuroxime <0.008—> 128 1 >128 0.016—>128 0.03 2
Ceftazidime 0.03—> 128 16 >128 0.03—> 128 0.5 4
Cefotaxime <0.008—> 128 1 >128 0.015—> 128 0.03 2
Ciprofloxacin 1-8 2 8 2-32 4 16
Ofloxacin 1-8 4 4 2-16 4 8
Staphylococcus aureus
Cefuroxime 0.5—> 128 1 1 0.5-8 1 2
Ceftazidime 8-16 8 16 4-32 8 16
Cefotaxime 0.5-2 1 2 1-16 2 2
Ciprofloxacin 0.12-2 0.5 1 0.5—4 1 2
Ofloxacin 0.12-1 0.5 0.5 0.5—4 1 1
Coagulase-negative staphylococci
Cefuroxime 0.12—> 128 2 32 0.25—> 128 1 >128
Ceftazidime 0.25—> 128 16 32 4->128 32 >128
Cefotaxime 0.06->128 4 16 0.5—> 128 4 >128
Ciprofloxacin 0.03-64 0.25 16 0.12—> 128 1 32
Ofloxacin 0.12-32 0.5 8 0.12-128 1 16
Discussion
This study has demonstrated that isolates in Cen¬
tral Scotland largely remain sensitive to the ex¬
tended-spectrum cephalosporins and the fluorinated
4-quinolones. Cefuroxime is less effective against
any of the urinary isolates and the Gram-negative
bacteraemia strains; however it remains clinically ef¬
fective in Edinburgh for urinary tract infections.
Ceftazidime has lost little of its potency from seven
years ago when Gram-negative bacteria from Japan
showed very similar resistance patterns to cef¬
tazidime [1], The MIC90 of ceftazidime for E. coli in
the Japanese study was 0.17 mg/1 compared with
0.12-0.5 mg/1 found in the urinary and bacteraemia
isolates in this study. A more recent survey on strains
collected in the USA showed that the MIC90 ofE. coli
was 0.25 mg/1 [11]; these results suggest that cef¬
tazidime resistance in Scotland, as elsewhere, may
not be increasing markedly. Indeed none of the
MIC90 of ceftazidime for Klebsiella spp. in the cur¬
rent study were as high as the 1 mg/1 found for the
Japanese strains isolated in 1985 [1] or for American
strains collected in 1981 [12] or in 1989-90 [11], On
the other hand, the MIC90 values of ceftazidime for
95
staphylococci in the Scottish strains were higher
than those obtained in Japan [1],
The trends seen with ceftazidime susceptibility
were mirrored with cefotaxime. As would be ex¬
pected, except in a Pseudomonas spp., the Scottish
isolates were invariably more sensitive to cefotaxime
than ceftazidime and strains from Glasgow were
marginally more resistant than those from Edin¬
burgh. The MIC90 value ofcefotaxime (0.08 mg/1) for
E. coli found for the Japanese isolates seven years
ago matched the range of 0.06-0.12 mg/1 found in
this Scottish study. On the other hand the Klebsiella
strains examined in Scotland were generally more
resistant to cefotaxime than their Japanese counter¬
parts. Cefotaxime was the only cephalosporin which
approached the efficacy of the 4-quinolones.
Generally ciprofloxacin was more effective than
ofloxacin though this trend is often reversed with
Gram-positive cocci. This has not been a general
phenomenon. In London, the MIC90 values of
ofloxacin have either equalled or been greater than
those of ciprofloxacin and this situation has re¬
mained static over five years [2,13]. Elsewhere the
MIC90 values of ciprofloxacin and ofloxacin for
methicillin-sensitive staphylococci have largely re¬
mained equivalent [11,14—20],
The MIC90 values of ciprofloxacin for E. coli
ranged between 0.03 and 0.06 mg/1 in the current
Scottish study. This is rather lower than the level
found in London over the past five years [2,13] but
was more in line with the susceptibilities found in
Switzerland [21] and the USA [11,15,22], The prob¬
lem bacteria for the 4-quinolones are P. aeruginosa
and 5. aureus. In London, two sequential surveys
showed that over a five year period the MIC90 of
ciprofloxacin for P. aeruginosa rose from 0.5 to 4
mg/1 although the MIC50 did remain constant [2,13],
Our results from Glasgow and Edinburgh show that
this species has retained its sensitivity to cip¬
rofloxacin; indeed, they suggest that the susceptibil¬
ity to ciprofloxacin of P. aeruginosa in Scotland was
more in line with that found in the USA [11,15,22],
The S. aureus strains from the Royal Infirmary Ed¬
inburgh are rarely methicillin-resistant; however,
more of them appear resistant to ciprofloxacin than
the equivalent strains in London [2,13] and else¬
where [16-20,23]. The study in the USA by Fuchs et
al. [22] shows a greater proportion of resistant
strains but they did not sub-classify the Staphylococ¬
cus spp. The urinary staphylococci in the present
study were not subdivided and a notable number of
them were highly resistant to ciprofloxacin in Ed¬
inburgh. Extrapolation from the bacteraemia iso¬
lates suggests that this may derive from the coagu-
lase-negative staphylococci. The proportion of the
coagulase-negative staphylococci resistant to cip¬
rofloxacin in the bacteraemia strains was higher
than reported in most centres [2,11,13,16-20,23],
The results from strains isolated in Edinburgh and
Glasgow suggest that the Gram-negative bacteria re¬
tain their sensitivity to the five drugs tested but the
proportion of resistant Gram-positive bacteria may
be on the increase.
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Four different ({-lactamases have been found in several strains of Xanthomonas maltophilia isolated front
blood cultures during 1984 to 1991 at the Edinburgh Royal Infirmary. One was a metallo-fl-lactamase with
predominantly penicillinase activity and an isoelectric point of 6.8. Its molecular size as determined by gel
filtration was 96 kDa but was only 26 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), suggesting a tetramer of four equal subunits. The enzyme hydrolyzed all classes of ({-lactams
except the monobactam aztreonam. This enzyme was not inhibited by potassium clavulanate or 11RL 42715 but
was inhibited by p-chloromercuribenzoate, mercuric chloride, and EI)TA. The ({-lactamase was unstable in 50
mM sodium phosphate buffer (pH 8.0) but stable in 50 inM Tris HCI (pll 8.0). The other p-lactainases focused
as a series of different isoelectric points, ranging from pi 5.2 to 6.6. Together, these enzymes exhibited a broad
spectrum of activity, hydrolyzing most classes of p-lactams but not imipenem or aztreonam. Their molecular
size was 48 kDa by Sephadex gel filtration and 24 kl)u by SDS-PAGE, indicating that they were enzymes
consisting of two equal subunits. They were inhibited by p-chloromercuribenzoate, mercuric chloride,
potassium clavulanate, and URL 42715 but not EDTA. This study demonstrated that V. maltophilia produces
more than just the LI and L2 p-lactamases.
W
Xanthomonas maltophilia is the only member of the genus
Xanthomonas that is pathogenic to humans. This species rests
uneasily within this genus, however, and a recent report has
proposed that it be placed in a new genus, which includes a
single species, Stenotrophomonas maltophilia (24). They are
glucose-nonfermenting, gram-negative bacilli and are increas¬
ingly recognized as an important opportunistic pathogen, often
affecting patients with lowered defense mechanisms (12, 21, 22,
29). The species is commonly resistant to a wide range of
P-lactams as well as other classes of antimicrobial agents (11,
15, 22). This resistance has been attributed to the interplay
between outer membrane impermeability (20) and the produc¬
tion of two potent p-lactamases. LI, a metallo-p-lactamase
(31), and L2, described as an unusual cephalosporinase (30),
hydrolyze virtually the entire spectrum of p-lactams. It has
been assumed that all strains produced the LI and L2 enzymes.
However, recent studies have shown an unexpected heteroge-
nicily among p-lactamases produced by this species (9, 19).
Both studies reported several p-lactamases differentiated by
their isoelectric points. In the study by Cullmann and Dick (9),
none of the strains examined produced more than one p-lac-
tamase. In this study, we report the biochemical properties of
p-lactamases produced by seven strains of X. maltophilia
isolated from blood cultures at the Edinburgh Royal Infirmary
during 1984 to 1991.
(Part of this work was presented at the 33rd Interscience
Conference on Antimicrobial Agents and Chemotherapy [25).)
MATERIALS AND METHODS
Bacterial strains. Seven strains of X. maltophilia were
examined. All strains were isolated from blood cultures taken
at the Edinburgh Royal Infirmary during 1984 to 1991. They
were stored as lyophilized cultures until required. All strains
were identified by the API 20NE identification strip.
* Corresponding author.
Antimicrobial agents. The following antibiotics were tested
and obtained from the following companies: penicillin and
ampicillin from Sigma Chemical Co. (Dorset, England), BRL
42715 and potassium clavulanate from SmithKline Beecham
(Welwyn Garden City, England), piperacillin from Lederle
Laboratories (Gosport, England), imipenem from Merck
Sharp & Dohme (Hoddesdon, England), ceftazidime and
cefuroxime from Glaxo Laboratories Ltd. (Uxbridge, En¬
gland), cefotaxime and gentamicin from Roussel Laboratories
Ltd. (Uxbridge, England), azloeillin and ciprofloxacin from
Bayer (Newbury, England), and aztreonam from Bristol-Myers
Squibb (Houiislow, England).
Antimicrobial susceptibility tests. MICs were determined by
the agar dilution method. All assays were performed on
Mueller-Hinton agar (Oxoid Ltd., Basingstoke, England). The
inoculum used, approximately 104 CFU/ml, was applied with a
Denley multipoint inoculator (Billinghurst, England). Plates
were incubated overnight at 37°C. Each MIC was determined
as the lowest concentration of antibiotic that inhibited visible
growth.
IEE. Samples were applied to a polyacrylamide gel contain¬
ing ampholines with a pH range of 3.5 to 10.6 or a 1:1 mixture
of pH 3.5 to 10.6 and pH 4 to 6 as previously described (18).
Isoelectric focusing (IEF) was carried out at 4°C at 1 W
(constant), 500 V (limiting), and 20 niA (limiting) for 18 h.
Gels were quantified with pi standard markers (BDfl Ltd.,
Poole, England) and stained by overlaying the gels with filter
paper soaked in nitrocefin (I mM) either directly or after a
30-s overlay with various inhibitors (I mM potassium clavu¬
lanate, I mM aztreonam, 1 niM cloxacillin, 1 mM EDTA, and
100 pM BRL 42715) soaked in filter paper as previously
described (2).
Assessment of inducibility of (3-lactamase. Ten-milliliter
volumes of Mueller-Hinton broth were grown overnight at
37°C with continuous shaking. One milliliter of overnight
culture was added to 9 ml of prewarmed Mueller-Hinton broth
and incubated for a further 90 min. Either cefotaxime or
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TABLE I. Susceptibilities of X. maltophilia isolates to various antibiotics
MIC (|jLg/ml)"
amt Pit' AZI. GXM CTX CAZ IMP AZM CIP GEN
5B105 1084 >256 >256 >256 >256 128 >256 256 >256 4 64
6B52 1985 >256 128 16 >256 128 256 128 >256 8 128
6B 1.33 1985 >256 >256 >256 >256 128 >256 >256 >256 8 128
6B295 1985 >256 >256 >256 >256 128 >256 256 >256 4 64
7B78 1986 >256 64 16 >256 64 128 256 256 4 4
12B286 1991 >256 128 .32 >256 128 128 64 >256 4 256
12B.346 1991 >256 256 256 >256 256 >256 128 >256 2 32
" Abbreviations: AMP. ampicillin; PIP. piperacillin; azl, azlocillin; CXM. ccfuroximc: CTX, cefotaxime; CAZ, ceftazidime; IMP, imipcnem; AZM, aztreonam; CIP,
ciprofloxacin; GEN, gentamicin.
imipenem was then added at one-fourth the MIC. Control
flasks with no added inducer were established. After incuba¬
tion for a further 2 h. cells were harvested and washed and the
P-lactamase was released by sonication; the procedure was
repeated after 4 h. Enzyme activity was measured by UV
spectrophotometry. Nitrocefin (100 p,M) was used as the test
substrate. Protein estimation was measured as previously de¬
scribed (34).
Large-scale preparation of (5-lactamases. Mueller-Hinton
broths (100 ml) were inoculated with the strain under study
and grown overnight with shaking at 37°C. Cultures were then
added to 900 ml of the same prewarmed broth, and incubation
continued under the same conditions for 90 min. For induc¬
tion, imipenem was then added at one-fourth the MIC. Incu¬
bation was continued for a further 3 h. After 3 h, bacterial cells
were harvested by centrifugation at 4°C. The pellet was washed
in 50 mM Tris HCI buffer (pi I 8.0) and recentrifuged. The
pellet was resuspended in 4 ml of the same buffer and
disrupted by ultrasonication (8 pm for I min, three times)
(MSESoniprep 150; MSE Instruments, Crawley, United King¬
dom) with constant cooling in an ice water bath. The prepa¬
ration was partially purified by passing it through a Sephadex
G-150 column (2 cm" by 90 cm) (Pharmacia, Uppsala, Sweden)
previously equilibrated with 50 mM Tris UC1 buffer (pH 8.0)
containing 0.1 mM zinc sulfate. Samples were eluted with the
same buffer with a llcnv rate of 12 nil/h. p-I.actamase activity
was detected with the chromogenic cephalosporin nitrocefin.
The molecular mass on this column was determined as previ¬
ously described (I). The molecular weight standards were alco¬
hol dehydrogenase (150,000), bovine serum albumin (66,000),
and cytochrome c (12.384).
Purification of P-lactamase by electrodialysis. Five hundred
microliters of the partially purified p-lactamase solution pre¬
pared from X. maltophilia 5BI05 was applied to a preparative
IEF gel containing pFI 3.5 to 10.6 and pH 4 to 6 ampholines
in a 1:1 ratio. After focusing as described above, a 1-cm-wide
strip of filter paper soaked in nitrocefin solution was placed
along either side of the gel from the anode to the cathode
to determine the position of the focused p-lactamases. The
P-lactamase bands were then excised from the gel and placed
into a dialysis sack with a minimal amount of 50 mM sodium
phosphate buffer (pH 7.0). The dialysis sack was placed in the
cathode reservoir of a Mini Sub Cell (Bio-Rad Laboratories
Ltd., Hemel Hempstead, England) previously filled with 50
mM sodium phosphate buffer (pH 7.0). A charge of 150 V was
applied to the sack for 10 min. The dialysis sack was then
removed, and the polyacrylamide gel discarded (28). The
remaining purified p-lactamase preparation was reapplied to
an IEF as described above.
iSDS-free (native) PAGE. Sodium dodccyl sulfate (SDS)-free
(native) polyacrylamide gel electrophoresis (PAGE) was per¬
formed on the Phastsystem (Pharmacia). The buffer system
used on the strips was 0.88 M l-alanine-0.25 M Tris (pll 8.8).
Buffer strips were made of 2% agarose 1EF. Fractions eluted
from the G-150 column that contained all p-lactamase bands
(as determined by IEF) were pooled and concentrated to 5 ml
in a centriprep 10 concentrator (Amicon, Danvers, Mass.).
Four microliters of this solution was applied to a Phastge!
homogenous 12.5 minigel. The separations were run as recom¬
mended by the manufacturer. p-Lactamase activity was visu¬
alized with nitrocefin as described above.
Determination of subunit size. The mass of the p-lactamase
subunit was also estimated by SDS-PAGE (14). p-Lactamase
extracts were treated with 5.0% p-mercaptoethanol and 2.5%
SDS at 100°C for 5 min before electrophoresis on a Phastgel
gradient 10 to 15 minigel according to the manufacturer's
instructions. After electrophoresis, gels were incubated for 4 h
in 50 mM Tris HCI buffer (pH 8.0) containing 1% Triton X-100
and 0.1 ntM zinc sulfate to obtain a renaturation of enzymatic
activity as described previously (17). After renaturation was
complete, visualization of p-lactamase activity was obtained by
staining with. ,|jitrocefin as described above. Low-molecular-
weight protein standards (Bio-Rad Laboratories) were run














FIG. 1. Kinetics of fi-lactamase induction for X. maltophilia 5B105.
fi-Lactamase activity is expressed as login nanomoles of nitrocefin
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FIG. 2. IEF patterns of (3-lactamases from seven strains of X.
maltophilia isolated from blood cultures during 1984 to 1991. Lane 1,
5B105; lane 2, 6B52; lane 3, 6B133; lane 4, 6B295; lane 5, 7B78; lane









FIG. 3. IEF patterns of X. inullopliilia (3-lactamases overlaid with
various inhibitors. Lane 1, control; lanes 2 to 6, overlaid with 100 p.M
BRL 42715, 1 mM aztreonam, 1 mM cloxacillin, I mM clavulanate,
and 1 mM EDTA, respectively.
Coomassie brilliant blue R250. The molecular weight stan¬
dards were transposed over the gel with the renatured pi-lac-
tamases for the molecular masses to be ascertained.
(^-Lactamase assays. Assays of [3-lactamase activity were
performed at 37°C on a Perkin-Elmer X 2 spectrophotometer
with freshly prepared antibiotic solutions in either 50 mM Tris
HQ buffer (pH 8.0) or 50 ntM sodium phosphate buffer (pH
7.0) at the wavelength of maximal absorbance for the (3-lactam
ring of each drug over a 5-min period. The following wave¬
lengths were used; 238 nm for penicillin and ampieillin, 236 nnr
for carbenieillin, 260 nm for cefuroxime and ceftazidime, 265
nm for cefotaxime, 240 nm for azlocillin, 255 nm for cephalo-
ridine, and 299 nm for imipenem. Maximum rate of hydrolysis
(Kmax) and Km values were derived by linear regression analysis
of Lineweaver-Burk plots of initial velocity data at different
substrate concentrations.
Inhibition studies. A solution of enzyme was preincubated
with inhibitor for 5 min at 37°C in either 50 mM Tris HCI
buffer (pH 8.0) or 50 mM sodium phosphate buffer (pH 7.0).
The remaining enzymatic activity was assayed spectrophoto-
metrically with cephaloridine (100 p-M), imipenem (100 p.M),
or nitrocefin (100 p.M) as the test substrate.
RESULTS
Antimicrobial susceptibilities. Table 1 shows the results of
antimicrobial susceptibilities. All seven strains examined were
resistant to almost all of the (3-lactams tested, including
imipenem. Only two strains (6B52 and 7B78) were susceptible
to azlocillin (MIC, 16.0 pg/ml). All isolates were also resistant
to gentamicin (breakpoint, 1.0 p-g/ml [4]). Ciprofloxacin was
the most effective agent of all compounds tested, with MICs for
five of the seven strains tested either at or below the recom¬
mended breakpoint level (4 p-g/ntl) (4).
Inducibility of (3-lactaniase production. The kinetics of
(3-lactamase induction for strain 5B105 are shown in Fig. 1.
The test substrate was nitrocefin. When imipenem or cefo¬
taxime was added as an inducer, (3-lactamase activity increased
sharply after less than 1 h. Imipenem was a more potent
inducer of (3-laclamase than cefotaxime was. No discernible
(3-lactamase activity was detected in disrupted cells without the
prior addition of an inducer. This result demonstrated that all
[3-lactamase activity was inducible. No enzyme activity was
detected in the culture filtrate, indicating that the (3-lactamase
was intracellular.
IEE. (3-Lactamase preparations from all seven strains exhib¬
ited identical IEF patterns and revealed the presence of at
least four main bands of (3-lactamase activity (pi 6.8, 6.2, 5.55,
and 5.3) and two minor bands (pi 5.2 and 6.6) (Fig. 2). X.
maltophilia 5B105 was selected its representative and examined
in more detail.
Polyacrylamide gels were overlaid with various inhibitors to
further elucidate the nature of these (3-lactamases (Fig. 3). The
(3-lactamase band of pi 6.8 was inhibited by overlaying the gel
with 1.0 mM EDTA prior to staining, whereas all other bands
were unaffected. Conversely, the other (3-lactamase bands were
completely eliminated by the overlay of BRL 42715 and
partially inhibited by potassium clavulanate. Aztreonam and
cloxacillin overlays appeared to have no significant effect on
any of the [3-lactamase bands.
Gel tiltrat ion of crude |3-lactaniase. Spectropholometrie
analysis of the fractions eluled from the Sephadex G-150
column and subsequent IEF (Fig. 4) revealed the presence of
at least two distinct enzymes, 't he (3-lactamase with a pi of 6.8
eluted first from the column and hydrolyzed imipenem as well
us nitrocefin; the other (3-lactamase bands eluted from the
column at the same rate and hydrolyzed nitrocefin but not
imipenem. The molecular masses of the enzymes were calcu-
F1G. 4. 1I F patterns of (3-lactamases from X. maltophilia 5B105
eluted from a Sephadex G-150 column. Lanes 1 to 19, 15 pi of every
second fraction eluted from a Sephadex G-150 column (fractions 52 to
88) applied to the gel; lane 20, concentrated (3-laetamase preparation
of A. inaltopliilut 5BI05.
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FIG. 5. IEF of p-lactamases from X. maltophilia 5BI05 purified by
electrodialysis. Lane I, original p-lactamase preparation from 5B105:
lanes 2 to 4, P-lactamase bands (pi 5.3, 5.55, and 6.2, respectively)
purified by electrodialysis.
lated as 96 and 48 kDa, respectively, by comparing peak
activity with the standard proteins.
In preliminary experiments, the P-lactamase of pi 6.8 was
found to be unstable in 5(1 mM sodium phosphate buffer (pi I
7.0) at 37°C and 80% of the activity was lost after 5 min of
incubation in the buffer. The enzyme was stable in 50 mM Tris
HO with an optimum pi I of 8.0. Therefore, all assays on the
p-lactama.se of pi 6.8 were performed with this buffer. The
other 3-lactamases were stable in phosphate buffer, and assays
of these enzymes were performed with 50 mM sodium phos¬
phate buffer (pH 7.0).
Purification of p-lactamase by electrodialysis. Purification
of the three main p-lactamase bands (pi 5.3, 5.55, and 6.2) that
were eliminated by BRL 42715 was performed by electrodial¬
ysis. Each band was excised from the gel, repurifted, applied to
an IEF gel, and reseparated (Fig. 5). Each preparation focused
as a single band at exactly the same pi to which it had originally
migrated, indicating that each p-lactamase was a discrete
p-lactamase rather than a satellite band.
Native PAGE. Native PAGE of the concentrated p-lacta¬
mase preparation from the Sephadex G-150 gel column re¬
vealed the presence of four distinct bands of activity, compat¬
ible with the concept of four p-lactamases (Fig. 6).
SDS-PAGE. Two-milliliter fractions from the Sephadex
G-150 column which contained either the p-lactamase of pi 6.8
or the p-lactamases which were inhibited by BRL 42715 were
pooled and concentrated to 200 pi. SDS-PAGE analysis of the
partially purified extracts followed by gel renaturation treat¬
ment (Fig. 7) showed in each case the presence of a single band
of p-lactamase activity, with an apparent molecular mass of 26
kDa for the enzyme of pi 6.8, while the other p-lactamase
bands showed the presence of a single protein with an apparent
molecular mass of 24 kDa. Data suggest that the enzyme of pi
6.8 is a tetramer of four subunits which are very similar in
molecular mass. Between them, the other p-lactamases exhib¬
ited a single band of p-lactamase activity by SDS-PAGE,







FIG. 6. Native PAGE of P-lactamases from X. maltophilia 5B105.
Four microliters of the p-lactamase preparation was applied at the
cathode. +VE, anode; ~VE, cathode.
Hydrolysis of P-lactam antibiotics. Assays of p-lactamase
hydrolysis of various p-lactams were performed with partially
purified extracts from the G-150 column on the p-lactamase of
pi 6.8. It was clearly evident at this stage that the p-lactamases
of lower pi (<6.8) could not be separated, and they were
subsequently pooled. For convenience, these P-lactamases are
hereafter designated XM-A and XM-B, respectively (Table 2).
XM-A was primarily a penicillinase and also readily hydro-
lyzed imipenem. It was much less active against all classes of
cephalosporins, although its affinities (low Km values) for
cephalosporins were higher than those for penicillins and
imipenem. Aztreonam was not hydrolyzed. The XM-B en¬
zymes exhibited a broad substrate profile, hydrolyzing an
extensive range of p-lactams but not imipenem, ceftazidime, or
aztreonam. Their affinities were higher for cephalosporins than
for penicillins.
Inhibitors. Table 3 shows the effect of inhibitors on the
activities of enzymes. The treatment of XM-A with EDTA
resulted in the a^frnplete inhibition of enzymatic activity. This
inhibition was completely reversed after dialysis against 50 mM
Tris HC1 (pH 8.0) for 30 min and the addition of 0.1 mM zinc
sulfate to the reaction mixture. Enzymatic activity was partially
inhibited by mercuric chloride and p-chloromercuribenzoate
(PCMB) but not by either potassium clavulanate or BRL
42715 (50% inhibitory doses of >50 and >10 p,M, respective-
kDa
1 2 3
FIG. 7. SDS-PAGE of the p-lactamases from X. maltophilia 5B105.
Lane 1, molecular mass standards; lane 2, p-lactamase bands of XM-B;
lane 3, p-lactamase band of XM-A.
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TABLE 2. Hydrolysis of (3-lactam antibiotics by XM-A and XM-B
fl-lactamases from X. maltophilia 5B105
XM-A XM-B
Substrate Relative K,„ Relative K„vmax V br inax (mM) v '•r max (mM)
Penicillin 14.3 100 0.6 1.2 100 0.108
Ampicillin 5.71 39.9 0.34 2.3 191.6 0.22
Carbenicillin 2.0 13.9 0.67 0.45 37.5 0.55
Azlocillin 5.5 38.4 0.24 1.25 104 0.22
Cephaloridine 0.09 0.6 0.22 1.8 150 0.05
Cefuroxime 0.66 4.6 0.133 0.28 23.3 0.076
Cefotaxime 0.303 2.1 0.05 0.19 15.8 0.08
Ceftazidime 0.03 0.2 0.09 NMH'
Imipenem 3.33 23.3 0.25 NMH
Aztreonam NMH NMH
" Expressed as micromoies of substrate hydrolyzed per minute per milliliter of
enzyme solution.
6 Relative to the Fnlax of penicillin set at 100%.
' NM11, no measurable hydrolysis.
ly). The XM-B enzymes were not affected by the addition of 0.1
mM EDTA but were inhibited by both 1 ntM potassium
clavulanate and 100 p.M BRL 42715 (50% inhibitory doses of
0.16 and <0.001, respectively). The enzymatic activity of XM-B
was completely inhibited by the addition of 0.5 mM PCMB and
0.5 mM mercuric chloride (Table 3). ,
DISCUSSION
There have been few reports that have characterized the
(3-lactamases encoded by X. maltophilia in detail; it has been
generally assumed that all isolates produce two (3-lactamases,
LI and L2. Recent work, however, has revealed the heteroge-
nicity of (3-lactamase production by strains of X. maltophilia.
These enzymes have not been characterized in full but have
been differentiated only by virtue of their isoelectric points (9,
19).
All enzymatic activity observed was inducible. The produc¬
tion of two inducible (3-lactamases is unusual, although it has
previously been reported for strains of Aeromonas spp. (13),
Bacillus cereus (10), and Yersinia enterocolitica (8). Some
Aeromonas spp. have been reported to produce up to three
different (3-lactamases (32).
The multiple bands of (3-lactamase activity observed with the
strains examined in this report were difficult to purify to
homogeneity. Repeated attempts to purify each band of (3-lac-
tamase activity were unsuccessful despite the utilization of
ion-exchange chromatography with different pH buffers (i.e.,
above and below the pi of the (3-lactamase bands). Not only
did the distinct bands of (3-lactamase fail to separate but the
resulting enzymatic activity of the eluate was very poor. This
technique was especially detrimental to the activity of the
TABLE 3. Effect of various inhibitors and ions on the activity of




PCMB 0.5 69 100
Mercuric chloride 0.5 70 100
EDTA 0.1 100 0
" Nitrocelin (100 (iM) was used as the test substrate.
b Cephaloridine (100 jiM) was used as the test substrate.
XM-A enzyme. However, the (3-lactamase activity could be
separated by gel filtration into two fractions, XM-A and
XM-B.
Polyacrylamide gel overlays with various inhibitors demon¬
strated that XM-A was inhibited by EDTA but not by BRL
42715 (a powerful inhibitor of scrine-active-site (3-lactamases
[7]), indicating that this enzyme was distinct from the other
bands of activity. Inhibitor overlays also demonstrated that the
XM-B enzymes were inhibited by both BRL 42715 and potas¬
sium clavulanate.
The differences in the pis of the XM-B bands suggest that
they may have undergone amino acid substitution or addition
away from the active site of the enzyme and may physically
differ in their primary structure. Purification by electrodialysis
and subsequent 1EF demonstrated that each preparation fo¬
cused as a single band of activity at exactly the same pi to
which it had originally migrated. Its small yield of enzyme
made this technique unsuitable for the purification of enzyme
for further studies. Native PAGE of the concentrated partially
purified (3 lactamase preparation revealed the presence of four
distinct bands of activity. Separated by gel filtration, ail the
bands that were inhibited by BRL 42715 were eluted at the
same rate, with an apparent molecular mass of 48 kDa. When
the molecular mass was estimated by SDS-PAGE and subse¬
quent renaturation of (3-lactamase activity, only one band with
a molecular mass of 24 kDa was observed, suggesting a dimeric
enzyme. Il is improbable that an organism would encode three
or more (3-lactamases with identical molecular masses and
subunit conformation unless they were closely related, like the
TEM enzymes, and in parallel with the TEM (3-lactamases, the
differences in pis arise from a few amino acid substitutions.
These results indicated that the (3-lactamase activity of XM-B
was the result of at least three distinct enzymes and not of
satellite bands. Unfortunately, the identical molecular masses
of these enzymes and the similarities of their pis made
separation of these enzymes impossible, despite employing
cation- anil anion-exchange chromatography.
The XM-A enzyme was very similar in physical and bio¬
chemical profile to the LI enzyme. It was unstable in sodium
phosphate buffer. The plasmid-mediated metallo-(3-lactamase
from Pscudomonas aeruginosa is also unstable in phosphate
buffer (35). The catalytic activity of the XM-A enzyme was
dependent on Zn2' for activity. Although the restoration of
activity with other metal ions was not attempted in this study,
results suggest that the enzyme is a metallo-p-lactamase. Both
enzymes share similar pis (LI, pi 6.9). In parallel with the LI
enzyme, the XM-A enzyme also exists as a tetramer in the
active stale (molecular mass, 96 kDa), with a subunit molecular
mass of 2(i kDa. The inhibitory profiles of both enzymes are
very similar. Both are insusceptible to potassium clavulanate
but susceptible to mercuric chloride, laconis and Sanders (13)
reported that the Ll-producing strain they examined was
inhibited by PCMB (20%), whereas in 1982, Saino et ai. (31)
reported no inhibition by this compound. Under our test
conditions, PCMB inhibited the enzymatic activity of the
XM-A enzyme by 69%. The zinc-active sites of metallo-(3-
lactamases are thought to include a conserved cysteine residue
(3); therefore, inhibition by PCMB would be expected. As with
other melnllo-|3-laclamases (16), XM-A, although exhibiting
predominantly penicillinase activity, also hydrolyzed a broad
range of (3-lactams including imipenem but not the ntonobac-
tam aztreonam.
The other enzymes described in this report, XM-B, although
differing particularly in their isoelectric points from that of the
L2 enzyme described by Saino el al. (30) (pi 8.4), shared some
similarities with this enzyme. However, it should be noted that
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the results obtained witli these combined enzymes should be
treated minimally. We have shown that these enzymes have
distinct physically properties (pis); nevertheless, it has not
been unequivocally shown that all these enzymes react in the
same manner. The inhibitor profile of XM-B was similar to
that reported for the L2 enzyme. All of these enzymes were
inhibited by clavulanate, PCMB, and mercuric chloride. EDTA
had no effect on the enzymatic activity of XM-B. indicating
that XM-B does not require a divalent metal ion for catalytic
activity. The inhibition by BRL 42715 suggests these enzymes
are serine-active-site p-lactamases. The molecular mass of
these enzymes was 48 kDa by gel filtration, whereas that of
their subunit form was estimated to be 24 kDa by SDS-PAGE.
The results show they are dimers in the native state, similar to
the L2 enzyme (active-form molecular mass, 56 kDa; subunit
molecular mass, 27 kDa). Together, the XM-B group of
enzymes hydrolyzed a broad spectrum of antibiotics, including
penicillins and cephalosporins, but not imipenem or aztreo-
nam, whereas the L2 enzyme was primarily a eephalosporinase,
with poor hydrolytic activity against penicillins.
Neither XM-A nor the XM-B group of enzymes was shown
to hydrolyze aztreonam, although all the strains examined
exhibited high levels of resistance to this drug. Another
explanation of the high level of resistance to aztreonam may be
the low permeability of the outer membrane of X. maltophilia
to the influx of antibiotics (20).
Although the exact genetic locations of the genes which
encode these p-lactamases have not been precisely deter¬
mined, the inducibility of the enzymes would suggest that they
are chromosomally mediated. Indeed, from this study and
others (9, 27), there appears to be a paucity of plasmid-
mediated p-lactamases in strains of X. maltophilia.
All p-lactamases are produced with a single inducer; this
might iniply that the enzymes share a common regulatory gene,
although it is known that imipenem is an effective inducer for
more than one p-lactamase (33).
We have shown that the XM-A enzyme shares biological and
physiological properties with the El enzyme and clearly be¬
longs in group 3 (metallo-p-lactamases |MET-N|) in the
classification scheme of Bush (6); however, full sequencing is
necessary for an absolute determination. The XM-B group of
enzymes appears to be well placed in the Bush class 2b'
(extended-broad-spectrum P-lactamases inhibited by clavu-
lanic acid [EBS-Y]) (5); however, without cloning the individ¬
ual genes into a suitable host and subsequently sequencing the
enzymes, it is not possible to determine whether these enzymes
have diverse biochemical profiles. The XM-A and XM-B
enzymes may be common among strains of X. maltophilia.
Cullmann and Dick (9) reported the presence of six distinct
P-lactamases in 19 strains of X. maltophilia. On close scrutiny
of the IEF polyacrylamide gel, there appear to be p-lactamases
from strain 858 that are similar to those described in this
report, although Cullmann and Dick do not describe these
enzymes in their text. Recently, Payne et al. (27) reported the
presence of enzymes with similar pis in two strains of X.
maltophilia. It appears that within the species A', maltophilia, a
number of different p-lactamases which differ from the p-lac¬
tamases of most other genera are produced.
Livermore (16) has classified carbapenemases as efficient or
inefficient, depending on whether they confer high or low levels
of carbapenem resistance on the host organism. High levels of
carbapenem resistance have been found only in those organ¬
isms that are known to commonly produce a chromosomal
metallo-p-lactamase. The metallo-p-lactamase of X. malto¬
philia is an example. There is also a frightening possibility that
the chromosomal genes that encode the p-lactamases of this
species may be transposed onto conjugative plasmids. There
have been recent reports of inefficient carbapenemases, al¬
though not transferable, from Acinetobacter baumannii (26),
Enterobacter cloacae (23), and Senatia marcescens (36), which
are not of the normal p-lactamase complement for the host
species. The increased use of p-lactam drugs, particularly the
newer carbapenem compounds, may facilitate the emergence
of this organism as an important pathogen. If the genes
encoding these enzymes acquire the capability to disseminate
among the more common pathogens, it will further diminish
the range of antibiotics available for use in cases of serious
sepsis.
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